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Abbreviations 
µF  µ-Faraday 
ACT adoptive cell transfer 
ACD anticoagulant citrate dextrose 
allo-MLR allogeneic mixed leukocyte reaction 
APAAP alkaline phosphatase-anti alkaline phosphatase 
APC  antigen presenting cell 
APC (fluorochrome) allophycocyanin 
AWED alive with evidence of disease 
BORIS brother of the regulator of imprinted sites 
CA125 cancer antigen 125 
CAR chimeric antigen receptor 
CD cluster of differentiation 
cDNA  copy DNA 
CMV cytomegalovirus 
CR complete remission 
CRP C-reactive protein 
CS&T beads cytometer setup and tracking beads 
CTCAE common terminology criteria for adverse events 
CTL  cytotoxic T lymphocyte 
CTLA-4 cytotoxic T lymphocyte antigen 4 
CY (fluorochrome) cyanin 
CY cyclophosphamide 
DAB 3,3-diaminobenzidine 
DAMP damage-associated molecular pattern molecule 
DC dendritic cell 
DC-LAMP dendritic cell - lysosomal-associated membrane protein 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
EBV epstein-barr virus 
EDTA ethylenediaminetetra-acetic acid 
ELISA enzyme-linked immunosorbent assay 
EMA European medicines agency 
EMCAR endometrial carcinoma 
FDA food and drug administration 
FIGO international federation of gynecology and obstretics (fédération 
 internationale de gynécologie et d'obstétrique) 
FITC fluorescein isothiocyanate 
FMO fluorescence minus one 
FSC forward scatter 
GM-CSF granulocyte monocyte colony-stimulating factor 
HE hematoxylin-eosin 
HIER heat-induced epitope retrieval 
HLA human leukocyte antigen 
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HRP horse radish peroxidase 
hsCRP high sensitive C-reactive protein 
hTERT  human telomerase reverse transcriptase 
iDC  immature dendritic cells 
IDO indoleamine 2,3-dioxygenase 
IFN interferon 
IgG immunoglobulin G 
IHC immunohistochemistry 
IL interleukin 
IMDM Iscove's modified Eagle's medium 
irRC immune-related response criteria 
IU international units 
MAGE-A3 melanoma-associated antigen 3 
mDC (DCm)  mature dendritic cells 
MDSC myeloid-derived suppressor cells 
meta EMCAR metastasis endometrial carcinoma 
meta US metastasis uterine sarcoma 
MFI mean fluorescence intensity 
MHC major histocompatibility complex 
MMP matrix metallo proteinase 
MMR mismatch repair 
MNE mean normalized expression 
moDC monocyte-derived dendritic cells 
MR mixed response 
mRNA  messenger RNA 
MUC1 mucin-1 
NBT nitro blue tetrazolium chloride 
nl EM normal endometrium 
nm nanometer 
OD optical density 
p.o. per os 
PBMC peripheral blood mononuclear cells 
PD progressive disease 
PD-1 programmed death 1 
PD-L1 Programmed death ligand 1 
PD-L2 Programmed death ligand 2 
PE phyco-erythrin 
PerCP peridinin chlorophyll 
PGE2 prostaglanding E2 
PMA phorbol 12-myristate 13-acetate 
PR partial remission 
pr EMCAR primary endometrial carcinoma 
pr US primary uterine sarcoma 
qRT-PCR quantitative real-time PCR 
rec EMCAR recurrent endometrial carcinoma 
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rec US recurrent uterine sarcoma 
RECIST response evaluation criteria in solid tumors 
rh recombinant human 
RNA ribonucleic acid 
ROS reactive oxygen species 
RT room temperature 
Sp17 sperm protein 17 
SSC side scatter 
TAA tumor-associated antigen 
TAM tumor-associated macrophage 
TCR T cell receptor 
Teff effector T cells 
TGF tumor growth factor 
Th2 T helper 2 
TIL tumor-infiltrating lymphocytes 
TLR toll-like receptor 
TMA tissue microarray 
TNF tumor necrosis factor 
Treg regulatory T cells 
US uterine sarcoma 
VNTR variable nucleotide tandem repeat 
WHO world health organization 
WT1 Wilms' tumor 1
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Project situation 
The most common type of gynecological malignancies is endometrial cancers [1]. Worldwide 
approximately 142 000 women are diagnosed with endometrial cancer each year, making this 
affliction the seventh most common malignant disorder. in 2008, 26.6/100 000 women were 
diagnosed, the highest incidence occurring in the Flemish region (29.1/100 000) [2]  
There are two distinct types of endometrial cancer, designated type I and type II. Type I cancers, or 
endometrioid cancers, comprise approximately 80% of all endometrial cancers. This type bears a 
more benign phenotype and is usually associated with a favorable prognosis. In contrast, type II 
endometrial cancer has a stronger malignant phenotype and poor prognosis. The current first-line 
treatment for endometrial cancer is hysterectomy with or without lymphadenectomy [3, 4], often 
accompanied by (neo)adjuvant chemotherapy or radiotherapy [1, 4, 5]. An uncommon type of 
gynecological malignancies are the uterine sarcomas, representing only 3% of all uterine tumors [6]. 
Similar to endometrial cancer, surgery is the cornerstone of their treatment. However, with this type 
of tumor, little to no clinical benefit has been proven for adjuvant chemotherapy, radiotherapy or 
hormonal therapy. 
Despite a fair cure rate for uterine tumors when diagnosed in an early stage, late stage disease has a 
much worse prognosis and is more prone to metastasis and relapse, which in the majority of cases 
leads to fatality even with robust treatment regimens. The 5-year survival rate for type II endometrial 
cancers is a mere 30% with a recurrence rate of 50% to 80% due to widespread metastatic disease [7, 
8]. The mean overall survival for recurrent endometrial cancer is approximately 12 months. 
Consequently, there is an urgent need for better treatment modalities in uterine cancer, with as little 
as possible toxic side-effects or physical discomfort. The latter is especially important since in the 
majority of cases postmenopausal and older women are treated. 
Immunotherapy, designated as breakthrough of the year in 2013 [9], is one possible treatment 
approach. During tumor growth, the immune system interacts with and attempts to eradicate the 
tumor. Immune therapy is based on the recognition of so-called tumor-associated antigens (TAA) by 
the immune system. TAA enable the immune system to discriminate malignant cells from their 
benign counterparts and raise a specific anti-tumor response without harming healthy surrounding 
tissue.[10]. 
One of the many possible immunotherapeutic treatment modalities is that of dendritic cell (DC) 
therapy. Altogether, DC vaccination has been reported to be nontoxic and encouraging clinical and 
immunological responses have been observed. However, further research is needed to obtain 
optimally activated DC capable of mediating tumor regression that correlates with the induction of 
an anti-tumor immune response. Moreover, the absence of toxicity argues for the inclusion of less 
advanced cancer patients and patients who have had prior tumor debulking surgery, in order to limit 
the effect of tumor-induced immunosuppression on DC, in DC vaccination trials. 
The current project finds its main focus in the development of an immunotherapeutic treatment for 
uterine cancer, in which both the development of a DC vaccine and the validation of suitable target 
antigens to include in the vaccine are included. In addition, possibilities to modulate 
immunosuppressive mechanisms involved in uterine cancer are explored. 
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General introduction 
Although described in the late 1950’s, research focusing on the role of the immune system in cancer 
has long been sidetracked. However, in the last decades, the topic has come back into focus. The 
complexity of the immune system is reflected in its role in cancer. The immune system plays both a 
tumor promoting and tumor suppressing role, depending on the intratumoral composition of the 
immune system as well as immune evasion mechanism exploited by tumor cells. 
The complex role the immune system plays in cancer is explained by the so-called immuno-editing 
theory, by Schreiber et al., describing tumor formation in three separate stages, all of which involve 
the immune system [1]. Although as research progresses, the complexity of the interplay still 
increases due to newly discovered players and their exact role in carcinogenesis, the theory describes 
three basic steps in the process of carcinogenesis. These steps may, but to do not necessarily involve, 
tumor formation: elimination, equilibrium and escape (Fig. 1). During the elimination phase, both the 
innate and the adaptive arm of the immune system cooperate in the process of tumor eradication. 
The exact signals that attract the immune system to the tumor are not fully elucidated but likely 
involve the release of so-called “danger signals” and stress ligands which are also involved in the 
initiation of an immune response to clear a pathogenic host or to initialize tissue repair. In case of 
tumor elimination, cancer cells are destroyed before they become clinically relevant. However, 
cancer cells cannot be eradicated in all cases. Cells that are not eradicated by the immune system can 
be kept under control in the equilibrium state. In this stage of carcinogenesis, tumor cells are kept in 
a state of dormancy, preventing the outgrowth of these tumor cells into established tumors. 
However, the way in which the immune system functions to control latent tumor cells, or a change in 
the controlling capacity of the immune system may in fact change the characteristics of the tumor 
cells, which may enable them to escape from immune control. In this stage of tumor immune escape, 
the immune system is no longer capable of tumor control, causing clinically apparent established 
tumors [1]. 
As exemplified in Fig. 1, many immune-related factors play an important role in tumor formation. 
Consequently, therapeutic intervention increasing the immune system’s capacity to attack the tumor 
or circumventing the immunosuppressive mediators can be of importance in cancer treatment. 
Many different forms of anticancer immunotherapy have already been investigated to date, 
comprising both active and passive forms of immunotherapy. 
Passive immunotherapy consists of the administration of active immune components for direct 
antitumor effects.  
Passive immunotherapy collectively includes: 
• Immunization using antibodies 
• Adoptive transfer of in vitro activated cells, e.g. T cells or NK cells 
• Inhibition of immunosuppression 
• (low-dose) chemotherapy 
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Active immunotherapy is aimed at stimulating the patients’ immune response. Active 
immunotherapy regimens comprise: 
• DNA vaccines 
• Peptide vaccines 
• Immunostimulatory cytokines 
• Oncolytic viruses 
• Dendritic cell-based vaccines 
 
 
Figure 1: The cancer immuno-editing theory (adopted from Schreiber et al. [1]). 
These different modalities and their disadvantages will briefly be discussed below, with a more 
elaborate analysis of different modalities of dendritic cell vaccination. 
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Passive immunotherapy 
MONOCLONAL ANTIBODIES 
Many different types of monoclonal antibodies have been developed, such as humanized antibodies, 
human antibodies using phage display and chimeric antibodies [2]. Nowadays, 15 different  
FDA-approved monoclonal antibodies are used in the clinic for the treatment of several cancer types 
(Table 1). 
Table 1: FDA-approved monoclonal antibodies used in cancer therapy. (adapted from Vachelli et al. 
[3]). 
mAb Target Approved Type Indications 
Alemtuzumab CD52 2001 Hzed IgG1 Chronic lymphocytic 
leukemia 
Bevacizumab VEGF 2004 Hzed IgG1 Glioblastoma 
multiforme, 
colorectal, renal and 
lung cancer 
Brentuximab 
Vedotin 
CD30 2011 C IgG1 Hodgkin’s and 
anaplastic large cell 
lymphoma (coupled 
to MMAE) 
Catumaxomab CD3 
EPCAM 
2009 M-R hybrid Malignant ascites in 
patients with EPCAM
+
 
cancer 
Cetuximab EGFR 2004 C IgG1 HNC and colorectal 
carcinoma 
Denosumab RANKL 2011 H IgG2 Breast cancer, 
prostate carcinoma, 
and giant cell tumors 
of the bone 
Gemtuzumab 
Ozogamicin 
CD33 2000 Hzed IgG4 Acute myeloid 
leukemia (coupled 
with calicheamicin) 
Ibritumomab tiuxetan CD20 2002 M IgG1 Non-Hodgkin 
lymphoma (coupled 
with 
90
Y or 
131
I) 
Panitumumab EGFR 2006 H IgG2 Colorectal carcinoma 
Pertuzumab HER2 2012 Hzed IgG1 Breast carcinoma 
Ofatumumab CD20 2009 H IgG1 Chronic lymphocytic 
leukemia 
Rituximab CD20 1997 C IgG1 Chronic lymphocytic 
leukemia and non-
Hodgkin lymphoma 
Tositumomab CD20 2003 H IgG1 Non-Hodgkin 
lymphoma (naked or 
coupled with 
131
I) 
Trastuzumab 
(emtansine) 
HER2 1998 Hzed IgG1 Breast carcinoma 
(naked or coupled to 
mertansine) and 
gastric or 
gastroesophageal 
junction cancer 
Ipilimumab CTLA-4 2011 H IgG1 Melanoma 
HNC: head and neck carcinoma, Hzed: humanized, M: murine, C: chimeric, H: human, Ig: immunoglobulin. 
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Antibodies used in cancer therapy have several antitumor functions [2]. They can be used for 
inhibition of pro-survival cascades, interference with tumor-stroma interactions, which inhibits 
tumor cell growth, direct binding of tumor-associated antigens (TAA) and consequently, activation of 
immune mechanisms, and for targeting the crosstalk between the immune system and the tumor, for 
example by facilitating antigen presentation by DC. 
ADOPTIVE CELL TRANSFER 
Adoptive cell transfer (ACT) consists of the transfer of ex vivo activated effector cells in order to 
achieve direct antitumor effects. Cells most commonly used for transfer consist of antitumor T cells 
and NK cells. However, γδ T cells as well as NKT cells, mast cells, eosinophils and macrophages are 
valid candidates [4]. The source from which these cells can be retrieved or generated are either 
tumor tissue or peripheral blood. The source of the cells may be related to the objective response 
rate of the treatment, as exemplified in melanoma [5], where the use of the entire TIL population 
resulted in the highest objective response rate, whereas the use of selected individual clones 
resulted in the lowest response rate. Although generating substantial response rates, the use of 
tumor-infiltrating lymphocytes (TIL) for ACT requires the availability of tumor material and involves a 
cumbersome isolation procedure which is often not equally successful at generating tumor-reactive 
TIL [5]. In addition, the functional capacities of TIL are highly dependent on the culturing period and 
thus the “age” of the TIL used for transfer. The use of so-called “young” TIL, which have only had a 
brief culturing period has been shown to be result in comparable clinical responses as conventionally 
cultured TIL [6]. Alternative to the use of TIL, peripheral blood T cells can be used for the cloning of 
high avidity T cell receptors (TCR). These T cell receptors can be generated in large quantities and 
transfected into lymphocytes, thereby generating large quantities of antigen-specific T cells [7]. 
An important limitation of the use of TCR genes is the major histocompatibility complex (MHC) 
restriction [7]. T cells transfected with certain TCR genes can only be used in patients with a certain 
human leukocyte antigen (HLA) type. This limitation can be avoided by the use of chimeric antigens 
receptors (CAR). CAR consist of the antibody binding portion of an antibody, which does not comply 
to MHC restriction and the intracellular signaling domain of the TCR, which activates T cells. An 
additional advantage of the use of CAR is that it does not only recognize antigen peptides, as does 
the conventional TCR, but also other surface molecules, such as carbohydrates and glycolipids, which 
may be associated with tumors [7]. CAR technology has been used successfully in clinical trials in 
several cancer types, such as neuroblastoma, lymphoma, melanoma and colorectal cancer, 
summarized in [7]. 
ANTIBODY BLOCKADE OF IMMUNE CHECKPOINTS 
In clinical trials using immunotherapy, there is an evident lack of a consistent correlation between 
the induction of an immune response and a clinical response. One of the reasons which are believed 
to be at the base of this discrepancy is the presence of several immune suppressive mechanisms in 
tumors. Consequently, strategies to suppress or circumvent these immunosuppressive mediators 
would preferentially be incorporated in clinical trials. Nowadays, such inhibitors are being evaluated 
(pre)clinically [8] (Table 2). 
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Table 2: Immune modulating antibodies currently in clinical development (adapted from Blank et al. 
[8]). 
Target Biological function Antibody or fusion protein State of clinical development 
CTLA-4 Inhibitory receptor Ipilimumab, fully human IgG4 EMA and FDA approved for melanoma, 
phase II and III trial in RCC, SCLC/NSCLC, 
prostate, pancreatic, ovarian, and Merkel 
cell carcinoma 
  Tremelimumab, fully human IgG2 Failed in phase III for melanoma, phase II in 
mesothelioma 
PD-1 Inhibitory receptor Nivolumab, fully human IgG4 Phase III for melanoma and NSCLC 
recruiting, phase II in RCC 
  Lambrolizumab (MK-3475), 
humanized IgG4 
Phase III for melanoma and NSCLC 
recruiting, phase II in CRC 
  Pidilizumab, CT-011, humanized 
IgG 
Phase II in follicular lymphoma, DLBCL, 
multiple myeloma, AML, RCC, CRC, 
pancreatic cancer 
  AMP-224 PD-L1 and human IgG1 
fusion protein 
No active study 
PD-L1 Inhibitory ligand BMS-936559 (MDX-1105), human 
IgG4 
No recruiting study 
  MEDI4736, engineered human 
IgG1 
Phase I recruiting 
  MPDL3280A, engineered IgG1 Phase II in melanoma, NSCLC 
  MSB0010718C 
(Merck---Serono) 
Phase I in solid tumors, recruiting 
ICOS Co-stimulatory 
receptor 
MEDI570, fully human IgG1 Phase I terminated 
  AMG557, fully human IgG2 Phase Ib in SLE and psoriasis 
B7-H3 Inhibitory ligand MGA271, humanized igG1 Phase Ib in melanoma 
B7-H4 Inhibitory ligand  Preclinical development 
LAG3 Inhibitory receptor IMP321, recombinant soluble 
LAG3-Ig fusion protein 
Phase II in melanoma 
TIM3 Inhibitory receptor  Preclinical development 
TNF(R) family    
CD40 Co-stimulatory 
receptor 
CP-870,893, fully human IgG2 Phase Ib in melanoma (+ tremelimumab) 
and pancreatic cancer (+ gemcitabine) 
  Lucatumumab, fully human IgG1 Phase II in lymphoma 
  Dacetuzumab, (SGN040), 
humanized IgG1 
 
CD137 Co-stimulatory 
receptor 
Urelumab (BMS-663513), fully 
human IgG4 
Phase II in melanoma, phase Ib in NSCLC 
and B-NHL 
  PF-05082566, fully human IgG2 Phase Ib in NHL (+ rituximab 
CD27 Co-stimulatory 
receptor 
CDX-1127, fully human IgG1 Phase I 
OX40 Co-stimulatory 
receptor 
Anti-CD40 mouse IgG Phase I 
OX40L Co-stimulatory 
ligand 
RO4989991, fully human IgG1 Phase II in allergic asthma 
GITR Co-stimulation TRX518, engineered human IgG1 Phase Ib in melanoma 
EMA: European medicines agency, FDA: food and drug administration, RCC: renal cell carcinoma, SCLC: small cell lung 
carcinoma, NSCLC: non-small cell lung carcinoma, CRC: colorectal cancer, DLBCL: diffuse large B cell lymphoma, AML: acute 
myeloid leukemia, SLE: systemic lupus erythematosus, B-NHL: B cell non-Hodgkin lymphoma, NHL: non-Hodgkin lymphoma. 
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(LOW DOSE ) CHEMOTHERAPY 
Chemotherapy is known to have immunosuppressive effects resulting from direct toxic effects on 
immune cells and bone marrow suppression. Nonetheless, chemotherapy can also have 
immunostimulating or immunomodulating effects, providing opportunities for immunotherapy. 
Chemotherapy has for example been shown to have an indirect activation effect on DC, and can 
result in depletion or functional suppression of regulatory T cells (Treg). The latter has been shown 
when using very low doses of cytotoxic chemotherapy. These low doses may also have a beneficial 
stimulatory effect on effector cells [9]. The immune stimulatory effects that are known for the 
different chemotherapeutic agents that are currently used in the clinic are summarized in Table 3. 
Table 3: Immune stimulating effects of chemotherapy (adopted from Shurin et al. [9]). 
 
Active immunotherapy 
DNA VACCINES 
DNA can be administered as naked DNA or implemented in vectors [10]. Uptake of DNA by antigen 
presenting cells (APC) will result in presentation in MHC I context, resulting in the induction of a Th1 
response and thus the activation of cytotoxic T lymphocytes (CTL). 
A major advantage of the use of DNA vaccines with respect to cellular therapies is that DNA vaccines 
are not patient-specific and can be generated in large amounts with high purity and they can be 
generated as off the shelf vaccines. In addition, the generated DNA sequence can be altered to 
change the intracellular processing of TAA into MHC I or MHC II context. If supplemented with 
bacterial sequences, these sequences can serve as adjuvants to the vaccine [10]. This type of 
anticancer vaccines is currently being tested in several clinical trials, but no FDA approved DNA 
vaccine for use in humans is available. 
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PEPTIDE VACCINES 
Vaccination with peptides offers several advantages. Like DNA vaccines, peptide vaccines can be 
generated as off the shelf vaccines. In addition, vaccination can be done against well-defined 
peptides, which offers the possibility of avoiding vaccination with peptides that might result in 
undesired side-effects [11]. In addition, both CD8 T cells and CD4 T cells can theoretically be 
activated. However, an important limitation of the use of peptides in cancer treatment is their MHC 
restriction. Peptides are only suitable for patients with a certain HLA type. Moreover, most currently 
known peptides are MHC class I restricted. Much less information is available for peptides that are 
MHC II restricted. This will result in the activation of mainly CD8
+
 T cells. Peptides binding MHC 
molecules of non-professional antigen presenting cells (e.g. fibroblasts) is another important 
drawback. On these cells, the costimulatory signals required for adequate T cell activation will not be 
available, rendering T cells tolerogenic. 
IMMUNOSTIMULATORY CYTOKINES 
Stimulating cytokines are often used prior to or following cancer treatment. They are often used in 
order to reconstitute the immune system after treatments with detrimental effects on the immune 
system, such as chemotherapy. They may also be used prior to chemotherapy in order to prevent 
lymphodepletion or chemotherapy-induced neutropenia. In addition, in case of leukemia, cytokines 
are used to mobilize latent leukemic cells prior to chemotherapy or to stimulate hematopoietic stem 
cells for autologous stem cell transplantation [12]. 
Cancer often develops in a background of chronic inflammation, which is related to the presence of 
high levels of pro-inflammatory cytokines. Additional cytokine treatment may thus in fact exacerbate 
the oncogenic potential. To date, the regulatory authorities have only approved three cytokine 
treatments [12]; interferon (IFN)-α2a for hairy cell leukemia and chronic myeloid leukemia, IFN-α2b  
in follicular lymphoma, hairy cell leukemia, AIDS-related Kaposi’s sarcoma, multiple myeloma, 
melanoma, condyloma acuminata and cervical intraepithelial neoplasms, and  
interleukin (IL)-2 for metastatic melanoma and metastatic renal cell carcinoma. 
ONCOLYTIC VIRUSES 
Oncolytic viruses are viruses which have the capacity to directly infect and kill tumor cells. Some 
examples that can be used in cancer therapy are measles virus, herpes simplex virus, adenovirus and 
myxoma virus [13]. Like for DNA-based vaccines, described above, oncolytic viruses can be 
genetically engineered to obtain specific antitumor effects, such as the addition of pro-apoptotic 
factors. The tumor cell lysis induced by the viral particle in itself may also contribute further to the 
antitumor effects. The virus can cause immunogenic cell death and the release of additional TAA 
against which additional antitumor effects can be mounted. In addition, immunogenic factors of the 
viral particle, such as damage-associated molecular pattern molecules (DAMP) serve as so-called 
“danger signals” to alert the immune system to the presence of a virus, which could fortify the 
mounted immune response and result in an increased antitumor immune response [13]. Although 
not routinely used as anticancer treatment, several oncolytic viruses are currently being tested in 
advanced stages of clinical trials [13, 14]. 
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DENDRITIC CELL-BASED VACCINES 
One of the most potent cell types in the induction of an immune response is that of dendritic cells. 
DC-based vaccines have been used in several different setups in different cancer types. Of vital 
importance in DC-based vaccines is the generation of fully mature and fully functional DC with the 
appropriate antigens which are presented stably in MHC context. The method of generation of DC as 
well as the antigen loading procedure present as major challenges to this type of cancer vaccine, 
along with the appropriate route of administration [15]. Different methods of DC generation and 
antigen loading will briefly be elaborated on below. 
Naturally occurring DC types 
The naturally occurring DC population exists of two separate types, both originating from a different 
hematopoietic lineage; the conventional DC or myeloid DC, derived from the myeloid cell lineage and 
the plasmacytoid DC, derived from the lymphoid lineage [16]. Conventional DC consist of resident 
DC, which reside in the lymphoid organs and the migratory DC which reside in the peripheral organs 
[16]. 
DC generation methods 
Three sources of DC have been used in clinical trials [15]. CD34
+
 precursors, derived from blood or 
bone marrow, peripheral blood DC or monocyte-derived DC (moDC). The most routinely used source 
is that of the moDC, most importantly due to the low numbers and difficult isolation methods of 
CD34
+
 precursors and peripheral blood DC. Peripheral blood monocytes can be isolated from a 
leukapheresis product through magnetic selection, elutriation or plastic adherence. By addition of IL-
4 and granulocyte macrophage colony-stimulating factor (GM-CSF), monocytes can be differentiated 
into cells phenotypically and functionally resembling immature DC [17]. 
Antigen loading 
Immature DC are capable of antigen-uptake, after which they fully mature and present the processed 
antigen. Once mature, DC lose the function of antigen-uptake. Consequently, in vitro antigen loading 
needs to be performed simultaneously to DC maturation. Possible antigen sources are similar to the 
non-DC-based immunotherapeutic options, described above. Selected, defined TAA can be used or a 
pool of all TAA present in the tumor [17]. 
Selected antigens can be loaded into DC using peptides or mRNA. When comparing these two 
methods, electroporation using mRNA offers several advantages over peptides. Using mRNA, the 
entire TAA is translated into the corresponding protein by the cytoplasmic machinery present in DC. 
This offers firstly the advantage that all of the peptides of the protein can be presented in MHC 
context, instead of selected peptides that are loaded separately. In addition, electroporation with the 
entire mRNA of a TAA circumvents the issue of single peptide HLA-restriction. This is an important 
advantage with regard to the patient population that can be targeted. 
As described above for DNA vaccines, mRNA can be adapted and constructed to obtain improved 
results. An important modification is the addition of the DC-LAMP sequence to the mRNA sequence 
encoding for the TAA. The DC-LAMP signal is responsible for the shuttling of antigens that are being 
processed by DC to the endosomal pathway, which results in antigen presentation in MHC II context. 
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Consequently, coupling of DC-LAMP to mRNA will result in antigen presentation in both MHC I and 
MHC II context [24]. 
Whole tumor TAA can be introduced into DC by the use of total tumor mRNA, whole tumor cell 
lysates or tumor cell-DC hybrids [17]. Although quite cumbersome, the advantage of this antigen 
loading technique is that the whole TAA spectrum is presented to the immune system. However, this 
may lead to an increased possibility of autoimmune reactions. 
Maturation protocols 
Maturation of dendritic cells is vital to obtain fully capable DC to be used for vaccination purposes. 
Mature DC can be generated by adding stimuli to immature DC, such as a cytokine mixture consisting 
of IL-1β, tumor necrosis factor (TNF) α, currently most commonly used, or by the addition of toll-like 
receptor (TLR) ligands, such as LPS, poly (I:C), resiquimod and imiquimod [17, 18]. Addition of the 
cytokine cocktail has been shown to induce a stable, mature phenotype of DC with adequate 
immunostimulatory capacity [19]. Maturation using TLR ligands results in increased DC trafficking 
and increased priming of CD8 T cells [20-22]. 
These methods have been in use for many years in DC-based vaccination studies. However, a more 
recently developed procedure for DC maturation is the use of TriMix electroporation. TriMix is a 
cocktail of mRNA encoding for CD40L, constitutively active (ca)TLR4 and CD70. The combination of 
CD40L and caTLR4 results in CD40 ligation, providing an activation signal for immature DC. Using this 
protocol, like with other maturation protocols, fully mature and functional DC can be generated. In 
addition, through the presence of CD70, a substantial increase in T cell stimulatory capacity can be 
achieved [23]. This type of maturation stimulus is particularly interesting for vaccines wherein 
antigen loading is also performed by electroporation because antigen loading and maturation can be 
performed in one step. 
HURDLES IN CANCER VACCINATION 
As stated above, there is a lack of a consistent correlation between immunological responses and 
clinical responses in immunotherapy trials. The presence of immune inhibitory molecules is one of 
the possible reasons for this discrepancy. In order for cancer immunotherapy to be successful, a 
series of steps must occur successfully, recently described as the cancer immunity cycle (Fig. 2) [25]. 
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Figure 2: The cancer immunity cycle (adopted from Chen et al. [25]). 
As exemplified in Fig. 2, a successful antitumor response is subject to several factors. T cells must first 
of all be sufficiently primed, and be capable of infiltrating the tumor and receive all necessary 
activation signals to become active, functional CTL. However, DC in cancer often show impaired 
function, which may in fact already jeopardize sufficient antigen presentation and T cell priming. 
Additionally, if T cell priming and infiltration are successful, tumors exploit several mechanisms to 
hamper T cell functioning. 
The complex interplay between immunostimulatory and immune inhibitory molecules and mediators 
advocate for a combinatorial approach to optimize the activation of the immune system as well to 
intervene with immunosuppressive mechanisms and to apply these therapeutic modalities in 
combination with currently used standard treatments in order to improve anticancer treatment. 
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Project aims 
The primary aim of the project is to explore and develop an mRNA based DC vaccine for uterine 
tumors. 
 
The preclinical work is subdivided in the following secondary aims: 
1. Exploration of available data on the immune system in uterine cancer 
2. Selection and experimental validation of existing tumor-associated antigens (TAA) to define 
appropriate targets for the dendritic cell vaccine. 
3. Analysis of the immunosuppressive environment in uterine tumors to identify possible 
therapeutic targets 
 
In addition, work was performed within the framework of 2 separate clinical studies: 
1. Immune monitoring of uterine cancer patients vaccinated with a WT1 dendritic cell vaccine 
2. Synchronization of treatment with low-dose cyclophosphamide treatment to CRP immune 
cycles in patients with ovarian or uterine cancer
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The immune system in the normal endometrium and its implication 
in endometrial cancer development 
ABSTRACT 
Although described for the first time already some decades ago, the contribution of the immune 
system to the establishment of tumors has long not been extensively pursued. Over the last decade, 
however, more and more evidence is accumulating concerning the role the immune system plays in 
tumor development and progression and its possible role in patient prognosis. In addition, interest is 
growing for preclinical and clinical research concerning the use of the immune system in the 
treatment of cancer. 
Immunotherapy for gynecological cancers in general, and especially for endometrial cancer is still in 
its early days. Only a small number of studies, with varying success rates, have been published. 
We currently provide a concise overview of the available literature on the role of the immune system 
in the normal endometrium and in endometrial cancer as well as the possible implication for future 
immunotherapeutic studies. 
INTRODUCTION 
Many risk factors involved in the etiology of endometrial cancer have been described. Obesity and 
physical inactivity are two important risk factors for the development of uterine tumors, along with 
elevated blood pressure, high energy intake, high serum glucose levels and increased exposure to 
estrogens [1]. For some of these risk factors, effects on and interactions with the immune system are 
described. Hormonal fluctuations during the menstrual cycle have been described to modulate 
immune functions, reviewed by Wira et al. [2]. Hormonal fluctuations and interactions with immune 
cells result in a protective environment against invading pathogens while creating a favorable 
environment for embryonal implantation and fetal development. Obesity, which is related to an 
increased risk of developing endometrial cancer, is considered a chronic inflammatory state, causing 
increased release of pro-inflammatory cytokines such as IL-6 and CRP [3].  
In addition to the effect of the described risk factors on the immune system, the vast majority of 
endometrial cancer cases is diagnosed in post-menopausal women and often in elderly patients. Age 
has an important influence on the immune system, the so-called immunosenescence, which parallels 
hormonal changes which occur with increasing age [4]. Aging causes an overall decrease in immune-
related functions and results in a latent pro-inflammatory state.  
Taken together, these data indicate that risk factors associated with the occurrence of endometrial 
cancer have an important influence on the immune system. In the current review, we provide an 
overview of the role the immune system plays in the normal non-pregnant uterus and how changes 
in the immune system may play a role in the development of uterine tumors and possible clinical 
outcome. This knowledge is important for successful further development of immunotherapeutic 
strategies for uterine cancer. 
1. The uterine immune system under physiological conditions and in cancer 
The immune system in the normal uterus serves a dual purpose. On the one hand, it plays a role in 
the protection against pathogens, while on the other hand, it has the ability to adapt to an 
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immunosuppressive state in order to create feto-maternal tolerance towards a semi-allogeneic fetus. 
These separate functions involve the complex interplay of the hormonal fluctuations of the 
menstrual cycle and the immune system. Normal endometrium is naturally under strict hormonal 
control. It is under constant control of the variations of estradiol and progesterone during the 
menstrual cycle. Both the innate and adaptive arm of the immune system are influenced by these 
hormonal changes. Several risk factors have been described for endometrial cancer, which may be 
linked with increased inflammation of the endometrial tissue, reviewed by Modugno et al. [5]. 
Increased exposure to estrogens has been shown to be associated with endometrial cancer 
development, due to the mitogenic effect of estrogens [6-8]. Consequently, the estrogen-related 
carcinogenesis may be related to inflammatory events. Chronic inflammation has been linked to 
cancer development [9]. Several inflammation pathways are involved in carcinogenesis. Many of 
these pathways are initialized by, among others, activation of STAT 3 or NF-κB [10]. The detailed role 
these pathways and their downstream mediators play in carcinogenesis is beyond the scope of this 
review and briefly summarized in Fig. 1. This interplay is discussed and further elaborated on by 
Elinav et al. [10]. 
 
Figure 1: Inflammatory signaling and carcinogenesis.  
Pro-inflammatory cytokines induce signal transducer and activator of transcription 3 (STAT3) and nuclear factor-κB (NF‑κB) 
signalling in cancer cells, which leads to the suppression of apoptosis and the promotion of cell cycle progression. 
Inflammasome-dependent interleukin‑22 binding protein (IL‑22BP) secretion inhibits IL‑22‑driven STAT3 induction. 
Genomic destabilization can be promoted by cytokine-mediated ectopic expression of activation-induced cytidine 
deaminase (AID) and by hypoxia-dependent suppression of DNA repair mechanisms. In addition, STAT3 and NF‑κB 
signalling also induces epithelial–mesenchymal transition (EMT) by downregulating the expression of epithelial 
differentiation markers. ASC, apoptosis-associated speck-like protein containing a CARD; HIF1α, hypoxia-inducible factor 
1α; IL‑1R, IL‑1 receptor; MYD88, myeloid differentiation primary response 88; NLR, NOD-like receptor; ROS, reactive 
oxygen species; TGFβ, transforming growth factor‑β; TNF, tumor necrosis factor; TNFR, TNF receptor. (reproduced with 
permission from Elinav et al. [10]). 
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1.1 Immune functions of normal and malignant endometrial cells 
The endometrial epithelium serves as the primary line of defense against viruses and other 
pathogens entering the uterus. The epithelial cells form an integral part of the mucosal immune 
system. Next to forming a physical barrier, the epithelial cells have several direct immune-related 
functions, one of which is the secretion of defensins [11]. Defensins form a part of the innate 
immune system, considering their immediate antimicrobial function and their ability to activate the 
adaptive immune system. Defensins have for example been shown to attract T cells and immature 
dendritic cells (DC) in response to binding to the C-C chemokine receptor type 6 (CCR6) [12]. Other 
secreted molecules include macrophage inflammatory protein (MIP) 3α, also a ligand for CCR6, and 
secretory leukocyte protease inhibitor (SLPI) [13, 14]. Contradictory, uterine epithelial cells secrete 
unidentified, soluble immune mediators that confer a tolerogenic phenotype to DC [15]. 
Obesity and diabetes have also been shown to be associated with increased release of pro-
inflammatory molecules, such as IL-6, TNF-α, CRP, leptin and macrophage migration inhibitory factor 
[3, 16]. Two studies evaluating the serum levels of IL-6, TNF-α and CRP and the risk of developing 
endometrial cancer, have shown that elevated levels of CRP are associated with endometrial cancer 
risk [17, 18]. Wang et al. found this correlation after correcting for BMI and age [18]. Friedenreich et 
al., in addition, found CRP and endometrial cancer risk were associated with high BMI and serum IL-6 
and endometrial cancer risk to be associated with low BMI [17]. 
Indoleamine 2,3-dioxygenase (IDO), which is responsible for T cell suppression through the 
deprivation of the for T cells crucial nutrient tryptophan, is up-regulated in secretory versus 
proliferative endometrium. The presence of the enzyme may serve a dual protective role: it functions 
as an anti-bacterial agent, while on the other hand it induces suppression of T cells. The latter will 
create an immunosuppressive state to allow embryonal implantation [19]. IDO is also expressed by 
endometrial carcinoma cells [20-22], and was proven to be associated with myometrial invasion, 
lymph node metastases and lymphovascular space involvement [21]. In addition, high IDO expression 
correlated with decreased CD8
+
 TIL and NK cell involvement and was associated with poor survival 
[20]. Thus, both in normal and malignant endometrium, IDO’s primary function seems to be 
induction of immunosuppression in order to allow embryonal implantation or tumor growth. 
Endometrial epithelial cells are also potent antigen-presenting cells. Ferguson et al. found expression 
of MHC class I in endometrial glands as well as stromal cells and endothelial cells. MHC class II, on the 
contrary, was found to be expressed in the endometrial glands in approximately 50% of normal 
endometrium samples [23]. Fahey et al. have shown that cultured epithelial cells express CD40 and 
CD1d and that epithelial cells as well as stromal endometrial cells can elicit tetanus toxoid specific T 
cell responses [24, 25]. In endometrial tumors, classical MHC class I was down-regulated in 48.5% of 
520 tumors, which is associated with worse disease prognosis [26]. In addition, the non-classical MHC 
class I molecule, HLA-G, was up-regulated in 39.8% of samples, corroborating results of Barrier et al., 
who found expression of HLA-G in 55% of samples [27]. Although requiring further investigation, the 
up-regulation of HLA-G molecules in endometrial tumors may be a protective mechanism to avoid NK 
cell lysis in case of down-regulation of MHC class I molecules, as shown in other tumors [28, 29]. 
MHC class II was found to be present in only a small portion of malignant endometrial cells. Low 
presence of both the classical MHC I and II molecules as well as the up-regulation of the non-classical 
HLA-G point to a poor antigen-presenting capacity of endometrial tumor cells [30, 31]. Cells in the 
underlying stroma, however, do show MHC II positivity [30]. Taken together, normal endometrial 
cells can present antigens in the context of MHC molecules, probably as a defense mechanism to 
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pathogens. Endometrial tumor cells however, down-regulate expression of MHC molecules to 
mediate immune escape. 
Lastly, several members of the B7-H family have been described. We recently described the presence 
of these molecules both in normal endometrium and uterine tumors [22]. We found expression of 
PD-L1 (B7-H1), and B7-H4 in the vast majority of normal endometria, while PD-L2 (B7-DC) was 
present in approximately half of normal endometria, albeit at low levels. All of these molecules were 
also present in endometrial cancer [22]. When comparing the expression levels of all molecules, we 
did not find an up-regulation in endometrial tumors. Although the investigated population was fairly 
small for sound analysis, a trend towards decreased survival was found in PD-L1
+ 
tumors [22]. Our 
results on B7-H4 are contradictory a previously published study, in which B7-H4 was reported to be 
significantly up-regulated in endometrial tumors [32, 33]. The expression pattern of this molecule 
was mainly cytoplasmic in conjunction with strong membrane staining and has been shown to 
negatively correlate with the number of TIL, both the T cell population as a whole (CD3
+
) and the 
separate CTL population (CD8
+
) [32]. For the latter, this correlation was also found for B7-H3 
[34].These data indicate that, since for most of these mediators no up-regulation was found in 
endometrial tumors, these molecules may also exert their immunosuppressive functions in both the 
normal and cancerous situation, as described above for IDO. 
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Table 1: Overview of immunological mediators in uterine tumors. 
Molecule/cell 
type 
Normal 
endometrium 
Uterine tumors 
  Available data Correlation to clinicopathology Relation to 
prognosis 
MHC class I Expressed Down-regulated Down-regulated in advanced 
and undifferentiated tumors 
Worse 
prognosis 
MHC class II Expressed in ~ 
50% of cases 
Present in minority of tumor 
cells 
  
HLA-G Conflicting 
data 
Up-regulated   
IDO Up-regulated 
in secretory 
phase 
Up-regulated Associated with myometrial 
invasion, lymph node 
metastases and 
lymphovascular space 
involvement 
Associated 
with poor 
survival 
NK cells Increase 
during 
menstrual 
cycle 
Low levels, increased upon 
progestin treatment 
Activity decreased in advanced 
disease 
 
Macrophages Increase 
during 
menstrual 
cycle 
Location-dependent pro- or 
anti-tumor effects 
Location-dependent Location-
dependent 
Neutrophils Increase 
during 
menstrual 
cycle 
Increased Increased NLR associated with 
lymph node metastasis 
 
DC Low levels Increased Negatively correlated with the 
clinical stage and lymph node 
metastasis 
 
B cells Present in 
aggregates 
   
T cells Present in 
aggregates 
Conflicting data  Dependent 
on 
location 
and 
phenotype 
Treg Increase 
during 
menstrual 
cycle 
Increased compared to 
blood 
Increased in advanced disease Worse 
prognosis 
MDSC Unknown Present with higher 
frequency of granulocytic 
subtype 
 Unknown 
NLR: neutrophil to lymphocyte ratio. 
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1.2 Infiltration by immune cells 
Next to the mediators just discussed, which can attract immune cells, immune cells themselves are 
present as part of endometrial tissue. The exact nature of the immune cells present in endometrial 
tissue/tumors and their function will be elaborated on below. A schematic representation of the 
presence of immune cells in normal endometrium is given in Fig. 2a and the main players in the 
tumor microenvironment are depicted in Fig. 2b. Table 1 gives a concise overview of the 
immunological players in endometrium and endometrial tumors and their implication in tumor 
biology. 
1.2.1 Innate immune cells 
Macrophages represent approximately 10% of the total cellular population of the endometrium. 
They are mostly present in the endometrial stroma and myometrial connective tissue [35]. Their 
frequency is the highest prior to menstruation, along with the frequency of neutrophils. The latter 
play a role in the breakdown of the endometrial tissue at menstruation as well as in the elevation of 
immune protection during the disruption of the protective barrier of the endometrial epithelium 
[36]. Macrophages play a paradoxical role in cancer, in a sense that they can have both a pro- and 
anti-tumorigenic function [37]. Tumor-associated macrophages (TAM) located in the focal necrotic 
center of the tumor and TAM at the tumor margin correlated with disease progression and with 
clinicopathological features of the tumor [37, 38]. TAM at the tumor margin were associated with the 
formation of lymph node metastases, indicating tumor progression, whereas macrophages in the 
tumor nest, the bulky area of the tumor surrounding the tumor center, were associated with a better 
relapse-free survival. This may be explained by local factors within the tumor, exerting different 
functions on macrophages. The tumor center, for example, is known to be hypoxic. This is suggested 
to trigger the angiogenic capacities of macrophages, leading to renewed oxygen supply and tumor 
progression [37]. Another cell type, like macrophages derived from the myeloid lineage, are myeloid-
derived suppressor cells (MDSC). To date, to our knowledge, MDSC have only been described in 
endometrial cancer by our own group [22]. MDSC analysis was subdivided into the presence of 
monocytic MDSC (lin
-
HLA-DR
-/lo
CD11b
+
CD14
+
) and granulocytic MDSC (lin
-
HLA-DR
-/lo
CD11b
+
CD14
-
).  
Both MDSC of the monocytic and granulocytic type were found, although the majority of the 
identified population was of the granulocytic type. This subtype has been described to have the 
strongest suppressive capacity compared to the monocytic subtype [39], providing evidence of 
increased immunosuppression in endometrial tumors. 
The largest representative of the innate immune system however, is that of natural killer cells  
(NK cells). Like for the cells described above, their numbers in normal endometrium vary depending 
on the phase in the cycle. The highest number of NK cells is found in the secretory phase of the cycle. 
At this point NK cells represent about 70% of the total leukocyte population [35]. This is likely the 
result of both increased IL-15 levels in the endometrium in the secretory phase and of an increased  
NK cell influx from peripheral blood [19]. However, research by Manaster et al. showed that the 
percentage of NK cells remains relatively constant at approximately 30% of the total lymphocyte 
population [40]. Male et al found the presence of precursor NK cells, so-called stage 3 NK cells in 
uterine mucosa as well as mature, stage 4, NK cells. [41]. The authors postulate that stage 3 NK cells 
(CD34
-
CD117
+
CD94
+
) migrate into the uterus where they mature to obtain their distinct phenotype 
(CD34
-
CD117
-/+
CD94
+
) [41]. Uterine NK cells are different from their counterparts in blood [42]. Like 
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NK cells in blood they express CD94, CD56 and CD9, but do not express CD16, CD8 or CD57. In 
addition, CD56 is expressed at about ten-fold higher levels in uterine NK cells than in blood NK cells 
[42]. Little has been described concerning the functional differences of peripheral blood NK cells and 
uterine NK cells. NK cells in both proliferative and secretory phase endometrium have been shown to 
be inert cells which lack both their cytotoxic capacity and their ability to secrete cytokines. However 
this can be reverted when the cells are cultured in the presence of IL-15 [40]. Stimulation with IL-15 
resulted in the up-regulation of the activating NK cell receptors NKp30 and NKp44, but no difference 
was found in expression of NKp46 and NKG2D. In addition, IL-15 activated endometrial NK cells 
showed increased in vitro cytotoxic capability and secreted IP-10 (CXCL-10) and IFN-γ [40]. Uterine 
NK cells are thus suggested to be inert lymphocytes without the cytotoxic capabilities of peripheral 
NK cells. These NK cells are inactive during the normal menstrual cycle and are suggested to mature 
to fully functional NK cells during pregnancy [40]. There are only few studies focusing on NK cells in 
endometrial carcinoma patients. NK cell activity in peripheral blood against K562 cells was found to 
decrease with an increase in histological differentiation grade and myometrial invasion in early stage 
(stage I) endometrial carcinoma [43]. A study already published in 1987 by Timonen et al. in 8 
endometrial cancer patients and 1 endometrial stromal sarcoma patient showed that unstimulated 
peripheral blood lymphocytes show cytotoxic responses against autologous tumor and against HeLa 
cells in 7/9 patients [44]. This activity was increased upon addition of recombinant IL-2. The IL-2 
activated lytic precursor cells belonging to the subpopulation of lymphocytes which includes NK cells 
[44]. Ferguson et al. found that NK cells were virtually absent in endometrial tumors [23]. 
Intratumoral NK cells were analyzed immunohistochemically in endometrial carcinoma patients 
following progestin treatment [45]. After treatment with progestin, the total cytotoxic (granzyme B
+
) 
lymphocyte population in the tumors increased 6.5-fold. While CD56
+
 NK cells were low or absent 
pre-treatment, the NK cell frequency rose to 76% of the total cytotoxic (granzyme B
+
) cell population 
in endometrial lesions which showed signs of regression. On the contrary, in lesions of stable or 
progressive nature, no increase in NK cells was noted. CD8
+
 CTL showed a mild increase in regressing 
lesions, while they remained approximately constant in stable or progressive lesions. Thus, progestin 
treatment can attract NK cells into uterine tumors which is associated with disease improvement. In 
addition, these findings can explain the increased level of NK cells in the secretory phase of normal 
endometrium, when progesterone levels are highest. 
Dendritic cells (DC) were also described in the human endometrium, at relatively low levels 
compared to other immune cells [46]. Throughout the cycle, these cells reside both in the functional 
and basal layers. The frequency of immature CD1a
+
 DC increases during the cycle, while the mature 
CD83
+
 DC population remains relatively constant. This indicates that, in accordance with their natural 
function, mature dendritic cells migrate from their resident tissue. In uterine tumors, HLA-DR
+
 DC 
have been shown to be present in both the glandular cells and in interstitial tissue [47]. The 
functional capacity of tumor-infiltrating DC, however, has been shown to be compromised in uterine 
tumors, due to significantly reduced expression of the costimulatory molecules CD86, CD80 and 
CD40 compared to DC in normal endometrium [48]. 
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Figure 2: The immune system in the normal uterus and in uterine cancer.  
A. Fluctuations in the immune system in the normal menstrual cycle. During the proliferative phase up until the secretory 
phase, NK cells and macrophages proliferate and the lymphoid aggregates increase in size. The increased frequencies 
corroborate their function in the breakdown of the endometrium. CD1d
+
 DC increase in frequency, while CD83
+ 
DC remain 
constant, possibly indicating DC migration. During the secretory phase, both IDO and the frequency of Treg are increased in 
order to create an immunosuppressive environment for possible embyonal implantation. Dashed rectangles indicate the 
location of the endometrium the cells reside in.  
B. The immune system in endometrial cancer.  
In contrast to in normal endometrium, MHC class I/II molecules are down-regulated, facilitating immune escape, while HLA-
G is up-regulated. In addition, MDSC infiltrates are described in uterine tumors and DC have been shown to downregulate 
costimulatory molecules. 
For T cells (incl Treg), as well as macrophages, their exact function and the resulting effect on outcome is dependent on the 
location within the tumor/ at the tumor margin. 
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1.2.2 Adaptive immune cells  
T and B cells, both members of the adaptive immune system, can also be found in the normal 
endometrium. They are present in uterine mucosa as unique aggregates consisting of a B cell core 
surrounded by T cells. Additionally, these structures are surrounded by a capsule of macrophages 
and monocytes [49]. These structures have been suggested to be similar to the mucosa-associated 
lymphoid tissue (MALT), which can be found in the gastrointestinal system [50]. The T cells present in 
these aggregates are almost exclusively CD8
+ 
CD45RO
+
, indicating that they are memory type effector 
cells [51]. These aggregates have been shown to increase in size from the proliferative phase, at this 
point without the B cell core, until the secretory phase of the menstrual cycle. In addition, they are 
absent in the menopause, indicating that their expansion is hormone-driven [49]. This is further 
exemplified by the observation that T cells within the aggregate express estrogen receptors [52]. 
Additionally, Yeaman et al. have shown that the accumulation of T cells is the result of T cell 
migration towards the endometrium, rather than a proliferation of single resident T cell clones [51]. 
The function of these aggregates is largely unknown. However, they may serve a purpose in both the 
creation of an immunosuppressive environment to allow feto-maternal tolerance on the one hand 
and on the other hand to create a protective environment against pathogens during menstruation, 
when the epithelial barrier is disrupted. The former is exemplified by the observation that the 
cytotoxic T lymphocytes in the proliferative phase of the cycle have cytotoxic capacity, while this 
function is severely dampened in the secretory phase, during which conception can occur [53]. In 
addition, CD8
+
 T cells are still capable of exerting their full cytotoxic function, further indicating that 
during the secretory phase of the menstrual cycle, a temporary state of immunosuppression occurs, 
in order to allow possible embryonal implantation. The difference in cytotoxic capacity of T cells 
during the different phases of the menstrual cycle is subject to hormonal control in order to maintain 
the balance between immune protection and tolerance [53]. The latter function of the lymphoid 
aggregates is supported by the location from which they originate. During the proliferative phase, 
the aggregates expand from within the basalis stroma, the inner third of the endometrium that is not 
shed during menstruation. Consequently, the lymphoid aggregates may provide immune protection 
against pathogens during menstruation. Alternatively, the presence of these aggregates in the basalis 
stroma may be a means to prevent loss of T and B cells during menstruation [49]. This type of 
lymphoid structures, recently termed tertiary lymphoid structures, resemble the MALT found in the 
gastrointestinal system, as mentioned above. These structures have been described in several tumor 
types, such as colorectal cancer, lung cancer, melanoma, ovarian cancer, renal cell cancer and breast 
cancer [54]. The co-localization of both T and B lymphocytes in these aggregates has been shown to 
correlate with improved patient survival [55]. In uterine tumors, MALT-like structures have not been 
described to date, but tumor infiltrating lymphocytes (TIL) have been shown in different studies. 
Chang et al. found that CD8
+
 (TIL) showed less expression of granzyme B and perforin than their 
blood counterparts, indicating possible functional defects or tumor-induced suppression [56]. 
However, in vitro activation of TIL resulted in adequate activation of TIL and induction to the same 
polarization profile as found in peripheral blood (i.e. main polarization to Th1 type cells). TIL have 
been associated with prognosis in endometrial cancer, with contradictory reports. The prognostic 
value of this infiltrate depends on the location within the tumor. Increased numbers of TIL, of 
unspecified composition, at the invasive margin of the tumor (i.e. the tumor-myometrial junction) 
did not have a beneficial effect on patient survival according to a study by Silverberg et al. [57]. These 
results were contradicted by Kondratiev et al., who found that, although confirming the presence of 
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CD8
+
 TIL at the tumor invasive margin, the presence of these TIL was associated with improved 
prognosis [58]. However, the latter study only considered CD8
+ 
TIL at the invasive border while 
Silverberg et al. considered the total lymphocyte population, which may clarify these different 
findings. Two additional studies studied the total lymphocyte population at the invasive margin [59, 
60]. Deligdisch et al observed that the presence of an infiltrate consisting of lymphocytes and plasma 
cells, potentially indicating the described tertiary lymphoid structures, appeared to be related to low-
grade endometrial tumors, and suggested that TIL are associated with a favorable prognosis [60]. A 
later study by Ambros et al. refuted this suggested association [59]. Intratumoral CD8
+
 TIL have been 
associated with improved disease-free survival in both type I and type II endometrial cancer [61]. 
These intratumoral TIL were found more frequently in low grade tumors than in high grade tumors. 
The presence of CD45RO
+ 
T cells, indicating memory T cells, was also shown. Moreover, the presence 
of memory T cells was associated with increased overall survival and with reduced events of 
recurrence [61]. Chang et al. described that the majority of tumor infiltrating CD8
+
 T cells are  
CD28
-
CD45RA
-
CD45RO
+
, defining terminally differentiated T cells. In addition, the T cells appeared to 
be in an activated state, exemplified by the expression of CD69, CD103 and CD152 [56]. In the 
proximal tumor draining lymph nodes (TDLN), the CD4/CD8 ratio is increased [62]. In addition, 
Yamamoto et al. found that clonally expanded T cells are absent from TDLN in patients with local 
endometrial tumors, while clonally expanded T cells could be retrieved from TDLN and peripheral 
blood in patients suffering from metastatic cancer, supporting the role of immune responses to solid 
tumors [63]. This specific appearance of T cell clones in TDLN of metastatic tumors may be a 
consequence of direct T cell priming by (metastasized) tumor cells present in the TDLN in metastatic 
tumors. This results in the expansion of T cell clones in affected lymph nodes. This direct priming 
does not occur in unaffected lymph nodes, as is the case in early-stage disease [64]. The results of 
Yamamoto et al. expand earlier findings of Garzetti et al. [65], who did not find any clinical 
significance in the lymphocyte distribution in lymph nodes in patients with early stage disease. In 
addition, Garzetti et al. showed that myometrial invasion with or without lymphovascular space 
involvement was associated with increased CD16
+
 and CD56
+
 cells, defining NK cells, in pelvic nodes 
[65]. 
Regulatory T cells (Treg) have a natural function to suppress ongoing immune responses when they 
are no longer necessary. However, this suppressive property of these cells may also cause 
suppression of an antitumor immune response. Treg have been shown to be increased in peripheral 
blood of normal controls in the late follicular phase [66]. Analysis of the Treg frequency in the 
endometrium showed that Treg are present in only low frequencies in the endometrium and that the 
frequency is higher in the proliferative phase compared to the secretory phase [67]. Collectively, 
these data indicate that the frequency of Treg cells appears to increase during the proliferative phase 
and is reduced after ovulation. 
Several studies have reported the presence of regulatory T cells (Treg) in endometrial carcinoma. 
Intratumoral CD4
+
CD25
+
 Treg, expressing higher levels of FoxP3, CD103 and GITR, are increased 
compared to peripheral blood [56]. In this particular study, it was also shown that, like CTL, 
intratumoral Treg also express granzyme B, indicating the capacity to lyse effector cells. However, 
Treg in stromal tissue were found to be significantly lower in tumor samples compared to normal 
endometrium [68]. Although lower, high Treg counts in tumor samples were shown to correlate with 
increased vascularity [68], tumor grade, stage, the extent of lymph node metastases and myometrial 
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invasion [56] as well as worse disease-free survival [69]. The latter has also been shown to result 
from the presence of high Treg/CD8 and Treg/CD4 ratios [69]. In distal TDLN, the proportion of 
functional regulatory T cells is increased [62]. 
Taken together, the fluctuations of the different cell types during the normal menstrual cycle are a 
further indication of the dual role the immune system plays in the uterus, described earlier. The 
immunosuppressive capacity that certain cell types, such as Treg, have in the framework of  
feto-maternal tolerance, also contributes to immune escape. Some cell types, such as macrophages 
and T cells appear to have a different effect on the outcome of a tumor, depending on the location at 
which they reside. This likely indicates that at different sites within the tumor or the tumor 
microenvironment the immune system may be differentially influenced in such a way that the 
functional capacities of the immune cells are influenced towards either an anti-tumor or a pro-tumor 
profile. 
2. Clinical implications 
The currently reviewed data provide some insight into several immune mechanisms in uterine 
tumors and indicate possible options for therapeutic modalities. The composition of the intratumoral 
immune infiltrate may have an important influence on treatment outcome. This phenomenon has 
recently been described in ovarian cancer [70]. It was shown that the 5-year survival rate of ovarian 
cancer patients who underwent debulking surgery and received adjuvant chemotherapy was at least 
6 times higher in patients with an intratumoral T cell infiltrate in the tumor islet, compared to 
patients without T cell infiltrate [70]. Several negative immune regulators are present and possibly 
active in endometrial cancer. Of the currently reviewed regulators, several could present as valuable 
targets for therapeutic intervention. Firstly, IDO and PD-L2 are useful targets, although only in a 
limited percentage of tumors [22]. Several trials are currently ongoing to evaluate the use of IDO 
inhibitor 1-methyltryptophan (registered at www.clinicaltrials.gov). No studies were listed to 
evaluate the use of an IDO inhibitor in endometrial cancer. Several trials are currently ongoing to 
evaluate its use, whether or not in combination with other treatments in ovarian cancer and 
peritoneal tumors. Both PD-L1 and B7-H4 could represent targets in EMCAR, considering their high 
expression levels. Antibodies directed against PD-L1 or the receptor PD-1 are being used in trials for 
several solid tumors. Anti PD-L1 treatment resulted in objective response rates ranging from 6 to 
17% in patients with solid tumors, among which melanoma, renal cell carcinoma and non-small cell 
lung cancer, while anti-PD-1 led to objective response rates up to 27% [71, 72]. MDSC also represent 
a valuable target in endometrial cancer. Preliminary data of a clinical trial evaluating MDSC targeting 
with the use of all trans retinoic acid (ATRA) showed promising results. In small cell lung cancer 
patients, co-treatment with a DC vaccine and ATRA resulted in a substantial increase in immune 
response after vaccination, as exemplified by an increase in IFN-γ-secreting antigen-specific T cells 
[73]. 
Lastly, the presence of NK cells in uterine tumors is correlated with a beneficial treatment outcome 
in uterine tumors. This provides motivation for the use of adoptive NK cell therapy in uterine tumors. 
This type of therapy still remains to be explored for these tumors. 
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CONCLUSION 
The currently outlined data clearly show that the immune system is present and active both in 
normal endometrium as well as in endometrial tumors. In the normal endometrium, the immune 
system plays a central role in the protection against pathogens and in safeguarding feto-maternal 
tolerance. Like this dual role in the healthy situation, it also has both a pro- and anti-tumorigenic 
function. In our opinion, the interplay between positive and negative players and mechanisms in 
tumor development and progression, provides possible intervention options in the treatment of 
endometrial cancer, which deserves further attention in future research. 
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Preclinical evaluation of survivin as target tumor-associated antigen 
for immunotherapy in uterine cancer 
ABSTRACT 
Survivin is an anti-apoptotic protein, not expressed in terminally differentiated adult tissues, yet 
overexpressed in several tumors. Therefore, it is an interesting target for immunotherapeutic 
strategies. In addition to specific overexpression in tumors, tumor survival is mediated by survivin 
and hence tumor survival can be tackled by targeting survivin. Survivin expression in uterine cancer 
was validated by qRT-PCR and IHC. In addition, we evaluated survivin immunogenicity by analyzing 
spontaneous B cell and T cell responses in patients. 
Survivin as a protein was expressed in only a minority of normal tissues, while being expressed in all 
of the currently analyzed uterine cancers, both endometrial carcinoma (n= 52) and uterine sarcoma 
(n=52). Survivin RNA transcripts were overexpressed in more aggressive tumors and survivin protein 
was overexpressed in recurrent endometrial tumors compared to primary tumors. These results 
further indicate the role of survivin in tumor cell survival. 
Spontaneous T cell responses were seen in 5/24 endometrial cancer patients and 1/10 uterine 
sarcoma patients. No T cell responses were found in normal controls (n=17). Although increased 
antibody titers were found in more aggressive and far-advanced tumors, no differences in B cell 
responses were seen. Overall, when compared to normal controls, a B cell response was only 
measured in 1/35 uterine sarcoma patients. 
In conclusion, we currently validated the presence of survivin in uterine cancer. In addition, 
spontaneous T cell responses were found in 17.6% of the total patient population. These data 
indicate that a survivin-specific tumor response may be induced spontaneously in patients, further 
fortifying the eligibility of survivin as an immunotherapeutic target. 
INTRODUCTION 
Several tumor-associated antigens have been described in cancer, one of which is survivin, a member 
of the inhibitor of apoptosis protein family. The exact function of survivin in the cell cycle and its role 
in the prevention of apoptosis in not yet fully understood, but it has become clear that survivin is 
involved in the control of several stages of the cell cycle [1]. Survivin is absent in fully developed 
adult tissues, except in proliferating cells. It has been shown to be expressed, for example, by 
thymocytes and bone marrow-derived stem cells [2]. In cancer however, survivin is up-regulated, 
among which in endometrial cancer and was associated with advanced disease and increased 
aggressiveness of tumors [3, 4]. Survivin expression has been linked to resistance to apoptosis, the 
formation of metastasis, bypass of cell cycle checkpoints and resistance to therapy [5]. Its presence 
has been shown to be a prognostic factor in several types of cancer and to have predictive value with 
regard to disease recurrence, summarized by Rödel et al. [6]. The location of survivin within cancer 
cells is of importance for its function, although data are inconsistent across several tumor types. 
Knauer et al. described that cytoplasmically located survivin is essential for its anti-apoptotic function 
[7]. These results were corroborated in colorectal cancer, where cytoplasmic survivin was associated 
with poor prognosis [8]. In contrast, nuclear localization of survivin has been associated with poor 
prognosis in lung cancer [9] and Merkel cell carcinoma [10], while it was inversely correlated with the 
occurrence of lymph node metastasis in esophageal cancer [11]. Additionally, a combination of 
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nuclear as well as cytoplasmic staining is a negative prognostic marker in high-grade astrocytomas 
[12]. 
This selective up-regulation in tumor cells, while being absent in normal tissue, in conjunction with its 
multiple roles in cancer, makes survivin a qualified antigenic target for cancer therapy [13]. Cancer 
immunotherapy targeting survivin has focused on different approaches in several cancer types, 
briefly reviewed by Altieri et al [5] and Andersen et al. [14]. 
In many types of cancer, spontaneous immune responses have been shown towards auto-antigens. 
A possible reason for the appearance of these responses is the presence of neo-antigens in tumors 
due to modifications of auto-antigens in tumors, differences in cellular localization, causing 
intracytoplasmic antigens to appear at the cellular surface as well as the release of cryptic epitopes 
and microvesicles from tumor cells [15]. This results in an increase of the immunogenicity of 
auto-antigens. These responses can be found both with regard to reactive T cells as well as auto-
antibody responses. Auto-antibodies against several types of antigens, such as cancer testis antigens, 
mutation antigens, differentiation antigens and embryonal proteins have been shown in several 
types of tumors, reviewed by Reuschenbach, with varying outcomes concerning the presence of 
auto-antibodies and tumor stage as well as any correlation with prognosis [15, 16]. The most widely 
studied auto-antigen is p53, due to a high percentage of tumors bearing p53 mutations [17]. Quite 
some data are available on the presence of auto-antibodies for colorectal carcinoma and lung cancer 
[18-22]. 
Immune responses to survivin have been described in several types of tumors. Survivin-specific T 
cells were reported in lung tumors, multiple myeloma, breast cancer, leukemia and melanoma [14, 
23, 24]. Auto-antibody responses were shown among others in colorectal cancer, lung cancer, 
gastrointestinal tumors, brain tumors and ovarian cancer [20, 22, 25-28]. 
In the current research we aim to validate the presence of survivin in uterine cancer and to evaluate 
the induction of spontaneous anti-survivin B and T cell responses. We hereby aim to gain insight into 
the possible eligibility of survivin for future use in immunotherapeutic strategies for uterine cancer 
patients. 
MATERIALS AND METHODS 
Patient samples and reagents 
Biopsy material (tumor or normal endometrium) from uterine cancer patients and healthy controls 
was collected from the tissue biobank of the gynecologic oncology department at the University 
Hospital Leuven, either as snap-frozen biopsies for qRT-PCR or as paraffin-embedded tissue for 
immunohistochemistry (IHC). 
For healthy donors, buffy coats were obtained from the Belgian Red Cross in ACD bags.  
A panel of RNA isolated from normal tissues was purchased from Ambion (Life Technologies, Ghent, 
Belgium).  
Peptide pools consisting of 15-mer peptides with an 11 aa overlap were obtained from Miltenyi 
Biotec (Leiden, the Netherlands) (survivin, CMVpp65, EBV BZLF1 and Influenza MP1). 
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Serum/plasma and PBMC isolation 
Venous peripheral blood was collected in uncoated tubes or SST tubes (Vacutainer®, BD Bioscience, 
Erembodegem, Belgium) for serum samples and in EDTA-coated tubes for plasma samples (N = 8) 
and PBMC. Serum or plasma was separated from whole blood by centrifugation (10’, 3000 rpm, 4°C). 
The resulting supernatant was aliquoted and stored at -80°C until use. 
For healthy donor PBMC, buffy coats were diluted 1/3 in PBS and PBMC were isolated using 
Lymphoprep™ (AXIS-SHIELD, Dundee, Scotland) density gradient centrifugation and counted with 
Türck’s solution. For patient samples, peripheral blood was diluted 1/2 in PBS and PBMC were 
isolated by the same procedure as above. PBMC were cryopreserved in 90% human AB serum (Sera 
Laboratories International, West Sussex, UK) containing 10% DMSO at 5-10 x 10
6
 cells per vial using 
CoolCell freezing containers (BioCision, Larkspur, California, USA), and stored in liquid nitrogen until 
further use. 
Quantitative real-time PCR 
Total RNA was isolated from snap-frozen material using Trizol (Life Technologies, Ghent, Belgium), 
according to manufacturer’s instructions. 0.2 µg RNA was reverse-transcribed in a total volume of  
20 µl in a mixture containing 10X RT buffer, 5.5 mM MgCl2, 10 mM dNTP’s, 2.4 µM random 
hexamers, 0.5 U/µl RNase inhibitor and 50 U/µl Multiscribe reverse transcriptase (all from Life 
Technologies). The reaction was performed using ABI prism® 7000 Sequence Detection System (Life 
Technologies) as follows: 10 minutes at 25°C, 30 minutes at 48°C and 5 minutes at 95°C. 
Quantitative real-time PCR (qRT-PCR) was performed by using ABI prism® 7000 Sequence Detection 
System (Life Technologies, Ghent, Belgium) and the data were analyzed with 7000 system software. 
All samples were analyzed in triplicate and testis cDNA was used as positive control. Survivin 
transcripts were detected using the human BIRC5 Taqman gene expression assay (Life Technologies, 
Ghent, Belgium). The following cycling program was used: 2 min at 50°C, 10 min at 95°C and 40 
cycles of 15 s at 95°C and 1 min at 60°C. Samples with housekeeping gene (β-actin and β-
glucuronidase) cycle threshold (Ct) values above 30 were considered non-evaluable and omitted 
from analysis. Survivin expression levels were normalized to the geometric mean of β-actin and β-
glucuronidase and the mean normalized expression (MNE) was calculated with Q-Gene software. 
Samples in which no Ct value could be measured were considered undetectable (i.e. no expression). 
Data are expressed as fold expression compared to the mean MNE value of normal endometrial 
samples. An increase of > 2-fold was considered as overexpression. 
Immunohistochemistry 
4.0 µm formol-fixed, paraffin-embedded tissue slides were deparaffinized and rehydrated using 
toluene and ethanol. Blocking of endogenous peroxidase was done for 30’ using 0.5 % H2O2 in 
methanol. Heat-induced epitope retrieval (HIER) was performed for 2 h at 90°C in 0.01M Tris-HCl (pH 
9.0) containing 1mM EDTA, after which aspecific antibody binding was blocked using a mixture of 
2 % BSA and 1% non-fat milk powder in TBS. Primary antibody (Rb anti human survivin, 1.5 µg/ml 
(R&D Systems, Minneapolis, Minesota, USA)) was incubated overnight at 4°C. Visualization was 
performed using the EnVision+ system HRP-labelled polymers (DAKO, Leuven, Belgium) followed by 
DAB (Sigma-Aldrich, Diegem, Belgium) precipitation and hematoxylin counterstaining. All steps, 
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except the rehydration and blocking step, were followed by the appropriate washing step. The 
validation on normal tissues was done using a tissue microarray (TMA) (MTU951; Pantomics, Inc., 
Richmond, California, USA), following the same protocol. 
Slide scoring 
For evaluation of antigen expression, a scoring system was developed based on 2 different 
parameters; percentage of tumor cells staining positive for the antigen and the staining intensity. For 
each parameter, 3 different levels were determined. The percentage of tumor cells staining positive 
was divided in 1-25%, 25-50% and > 50%. The staining intensity was evaluated as weak (score 1), 
moderate (score 2) and strong (score 3). Based on these parameters a total score was assigned to 
each slide (Table 1). All slides were analyzed for the presence of tumor using a conventionally stained 
HE slide. 
Table 1: scoring system for evaluation of TAA expression by IHC. 
% positive tumor cells Staining intensity Assigned score 
1-25 1 0 
1-25 2 0 
1-25 3 0 
25-50 1 0 
25-50 2 1+ 
25-50 3 2+ 
>50 1 0 
>50 2 3+ 
>50 3 4+ 
 
Survivin antibody ELISA 
Survivin auto-antibodies were analyzed in duplicate and determined using the commercially available 
Human anti-survivin (Surv) antibody ELISA Kit (CUSABIO, Wuhan, China), according to manufacturer’s 
instructions. In brief, the provided recombinant calibrator was diluted to obtain a calibration curve 
ranging from 40 ng/ml – 0.625 ng/ml. Calibration curve and samples, diluted when appropriate, were 
incubated in the provided plate for 2 hours at 37°C. After incubation, antibody detection was done 
using a biotin-conjugated secondary antibody coupled to HRP-avidin, both of which incubated for 
1 hour at 37°C. After incubation ranging from 10 to 30’ with TMB substrate at 37°C, reaction was 
stopped and OD was measured at 450 nm, followed by subtraction of the OD of the blank sample or 
by subtracting the OD at a reference wavelength of 540 nm, following company protocol 
optimization. The two methods were compared and did not lead to significant differences in results. 
For titer analysis, absolute values as calculated from the standard curve are used. Antibody 
responses are defined as the mean titers of the normal controls + 2 SD. 
Detection of TAA-specific T cells 
The CD137 assay was carried out in T cell medium (IMDM supplemented with 5% human AB serum, 
penicillin-streptomycin (Life Technologies, Ghent, Belgium) and L-glutamin (Life Technologies, Ghent, 
Belgium)) and the serum lot was pretested for assay performance. On day 1, 1-2 vials of PBMC were 
thawed in a 37°C water bath until only small ice crystals were visible. The cell suspension was 
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transferred to ice-cold RPMI1640 and centrifuged at 1500 rpm for 5 minutes at 4°C. The PBMC pellet 
was re-suspended in T cell medium, containing 10 U/ml DNase1 and left to recover at RT for 1 h. 
After 1 h, cells were counted with trypan blue and re-suspended in T cell medium at a concentration 
of 10
7
 cells/ml. Cells were plated at 20-100 µl per well in half-well 96 well plates (Greiner Bio-One, 
Wemmel, Belgium) and cultured in the absence or presence of the indicated overlapping peptide 
pools at 0.6 nmol/ml for 16-20 h at 37°C / 5% CO2. After the incubation period, the cells were used 
for flow cytometric analysis. 
Flow cytometry staining and analysis 
Plates were centrifuged during 5 min at 1800 rpm and 4°C. After aspiration of the supernatant, cells 
were first washed with cold PBS (Life Technologies, Ghent, Belgium), centrifuged again and 
subsequently incubated for 30 min with 150 µl per well of a fixable viability dye (Fixable Viability Dye 
eFluor 506, eBioscience, Vienna, Austria) diluted at 1 µl/ml in PBS for discrimination of live and dead 
cells. After incubation, plates were centrifuged and cells were washed with PBS. Next, Fc receptor 
blocking was performed by adding 25 µl per well of a 10% normal goat serum (Sigma-Aldrich, 
Diegem, Belgium) solution in PBS/0.5% BSA. To identify antigen-specific T cells, the cells were stained 
with the following antibodies: CD4-FITC (BD Pharmingen, San Jose, California, USA), CD137-PE (BD 
Pharmingen, San Jose, California, USA), CD3-PerCp-Cy5.5 (BioLegend, San Diego, California, USA), 
CD19-PE-Cy7 (BioLegend, San Diego, California, USA) and CD8-APC-H7 (BD Pharmingen, San Jose, 
California, USA). All antibodies were titrated to optimal dilution before use. Acquisition was 
performed with a FACSCanto II flow cytometer using BD FACSDIVA software and 2.5-5 x 10
5
 cells 
were acquired per sample. Photo Multiplier Tube (PMT) voltages were set using CS&T beads and 
compensation was calculated using single-stained samples. Data analysis was done using FACSDIVA.  
The following gating strategy was used: first, dead cells were gated out using the viability dye and 
cells were gated on the lymphocyte population based on FSC/SSC properties. Within the lymphocyte 
population, a gate was set around CD3
+
 CD19
-
 cells and subsequently, the CD4
+
 and CD8
+
 population 
was gated in the CD3
+
 population with exclusion of double-positive T cells. Finally, CD137 expression 
within the CD4
+
 or CD8
+
 population was evaluated. Background expression of CD137 by the T cells 
was determined on T cells from cultures without peptides. Positive reactivity to an antigen was 
defined as a minimum 2-fold increase in CD137 positivity compared to the unstimulated control. The 
gating of a representative sample is shown in Fig. 1. 
These studies were conducted in a laboratory that operates under exploratory research principles 
using investigative protocols and assays. 
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Figure 1: Gating strategy for detection of CD137
+
 T cells in a representative patient sample. 
Statistics 
Statistical analysis was performed using the GraphPad Prism 5.0 software. All sample groups were 
checked for Gaussian distribution using the D’Agostino and Pearson omnibus normality test followed 
by the appropriate (non)-parametric test when comparing 2 or more groups. 
RESULTS 
Survivin expression in normal tissues 
Survivin expression levels were assessed in normal tissues and tumor samples. The presence of 
survivin was evaluated both at mRNA and at protein level. 
Survivin mRNA expression was analyzed in a panel of normal tissues and showed the expected 
expression in thymus, testis and spleen. However, background levels of expression were also found 
in other tissues (Fig. 2A). Survivin was found to be expressed as a protein in only 25.4% of samples. 
Expression was found in the digestive tract (stomach, small intestine and colon); the male 
reproductive tract (testis, prostate) and in liver, kidney and the urinary bladder (Fig. 2B). 
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Figure 2: Survivin expression in normal tissues. A. Survivin mRNA expression, expressed as mean normalized expression.  
B. Survivin protein expression levels, expressed as evaluated expression score. 
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Survivin expression in uterine tumors 
Analysis in normal endometrial samples and uterine tumors showed that survivin transcripts were 
detectable in 89 % of controls and in all EMCAR and US samples. Survivin mRNA was overexpressed 
in 71 % of EMCAR samples and 94 % of US samples compared to controls. Expression in US was 
significantly higher compared with EMCAR (p = 0.0108, Fig. 3A). With regard to clinicopathological 
tumor characteristics, survivin was found to be up-regulated in FIGO stage II versus FIGO stage I 
EMCAR (p < 0.05; Fig. 3B), as well as in grade 3 EMCAR versus grade 1 EMCAR (p < 0.01). Additionally, 
survivin was up-regulated in type II tumors, defined as grade 3 endometrioid and all serous and clear 
cell tumors, versus type I tumors, defined as grade 1 and 2 endometrioid tumors (p = 0.0025). 
 
Figure 3: Survivin expression in uterine tumors. A. mRNA levels in EMCAR vs US (data expressed as fold increase compared 
to normal controls). B. left panel: survivin mRNA in EMCAR according to FIGO stage. Middle panel: survivin mRNA in EMCAR 
according to histological grade. Right panel: survivin mRNA in type I vs type II EMCAR. Data are expressed as fold increase 
compared to normal endometrium. C. left panel: percentage of samples positive for survivin protein. Numbers indicate the 
percentage of positive samples in each group. Right panel: survivin expresssion score in different tumor groups. 
nl EM: normal endometrium, pr EMCAR: primary endometrial carcinoma, rec EMCAR: recurrent endometrial carcinoma, 
meta EMCAR: metastatic location endometrial carcinoma, pr US, primary uterine sarcoma, rec US: recurrent uterine 
sarcoma, meta US: metastatic location uterine sarcoma.  
Normal distribution was verified in all groups before all other statistical analyses. Differences in expression between the 
tumor groups (A) was analyzed using the Mann Whitney test. Differences in expression in type I versus type II tumors was 
analyzed using an unpaired t test. All other groups were compared using the non-parametrical Kruskal-Wallis test followed 
by the Dunn’s Multiple Comparison Test. 
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Table 2: clinical characteristics of IHC/qRT-PCR samples. 
Tumor type IHC qRT-PCR 
Tumor type EMCAR US EMCAR US 
Characteristics     
Total number of patients 48 47 70 34 
Total number of tumors 52 52 70 34 
Number of patients     
Primary 27 24 N/A N/A 
Recurrence 11 10 N/A N/A 
Metastasis 7 10 N/A N/A 
Primary + recurrence 0 1 N/A N/A 
Primary + metastasis 3 1 N/A N/A 
Metastasis+ recurrence 0 1 N/A N/A 
FIGO stage pr EMCAR
1
 
(number of tumors) 
I 10 N/A 35 N/A 
II 4 N/A 10 N/A 
III 7 N/A 14 N/A 
IV 9 N/A 11 N/A 
Histological grade EMCAR2 (number of tumors) 
1 7 N/A 24 N/A 
2 3 N/A 14 N/A 
3 32 N/A 22 N/A 
Unknown 9 N/A 10 N/A 
Histological subtype
3
 
(number of tumors) 
Endometrioid 17 N/A 48 N/A 
Serous 21 N/A 11 N/A 
Clear cell 9 N/A 3 N/A 
Mixed 2 N/A 8 N/A 
Carcinosarcoma
4 
2 18 N/A 11 
Leiomyosarcoma N/A 13 N/A 11 
Rhabdomyosarcoma N/A 7 N/A 2 
Endometrial stromal 
sarcoma 
N/A 10 N/A 7 
Adenosarcoma N/A 4 N/A 1 
Mixed N/A - N/A 1 
unknown N/A - N/A 1 
1
 Only for IHC. Only primary tumors included; 
2
 Only for IHC. All tumors included; 
3
 Only for IHC. All tumors included, 
4
 Only 
for IHC. Only carinomatous tumor part included. 
EMCAR samples expressed survivin protein in 85.3 % of pooled cases, with a significant up-regulation 
in recurrent tumors compared with the primary tumors (p < 0.01, Fig. 3C). In the US group, the 
pooled tumor population showed expression in only 52 % of the currently analyzed samples. For 
protein levels, no analysis was performed with regard to clinicopathological characteristics, due the 
small number of samples in each group. Clinical characteristics of all patient samples used for 
qRT-PCR analysis and IHC analysis are summarized in Table 2. 
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Both nuclear and cytoplasmic survivin expression was found in the majority of tumor samples. In the 
pooled population of all analyzed samples, combined expression was found in 38/52 EMCAR samples 
(73%) and in 33/52 (63%) US samples. On the contrary, 16/17 normal endometria (94%) showed only 
cytoplasmic expression. 
Endogenous anti-survivin immunity 
An important characteristic of an immunogenic TAA, is the ability to induce immune responses in 
patients. Therefore, we analyzed endogenous T and B cell responses against survivin in patients as 
well as healthy controls. 
Survivin-specific T cells were assessed by culturing PBMC with overlapping peptides covering the 
whole antigen. Antigen-reactivity was assessed by analyzing CD137 up-regulation on both the CD4
+
 
and CD8
+
 T cell subpopulations. Recall responses to viral antigens CMVpp65, EBV BZLF1 and Influenza 
Matrix Protein 1 were used as positive controls to assess immunocompetence. Reactivity with at 
least 1 of the 3 viral antigens was observed in 7/9 (78%) of benign controls, 21/24 (88%) of EMCAR 
patients and 8/10 (80%) of US patients (data not shown). In patients that did not mount a viral 
response, survivin-specific T cells could be measured in 14.2% of patients, while survivin-specific T 
cells were noted in 13.8% of patients with an anti-viral response (data not shown). 
 
Figure 4: Spontaneous anti-survivin immune responses. A. CD4
+
 and CD8
+
 T cell responses in peripheral blood. Results are 
expressed as fold increase compared to unstimulated T cells. The minimal threshold of a 2-fold increase is indicated by the 
dashed line. B. B cell responses in peripheral blood. Left panel: comparison of titers at diagnosis. Middle panel: titers at 
diagnosis in type I versus type II endometrial tumors. Right panel: titers at diagnosis in low-grade versus high-grade 
endometrial tumors. Results are expressed as absolute titers. Antibody titers were analyzed separately compared to normal 
controls using the Mann Whitney test or an unpaired t test, depending on normal distribution. Type I versus type II tumors 
and low grade versus high grade tumors were analyzed using the Mann Whitney test. 
  
controls EMCAR US
0
1
2
3
4
CD4
CD8
ra
tio
 
CD
13
7+
 
T 
ce
lls
to
 
u
n
st
im
u
la
te
d
Co
ntr
ols
Be
nig
n
No
rm
al
EM
CA
R US
0
2
4
6
8
10
*
An
tib
o
dy
 
tit
er
s 
(in
 
n
g/
m
l)
Ty
pe
 
I
Ty
pe
 
II
0
2
4
6 *
An
tib
o
dy
 
tit
er
s 
(in
 
n
g/
m
l)
Lo
w
 
gra
de
Hig
h g
ra
de
0
2
4
6
**
An
tib
o
dy
 
tit
er
s 
(in
 
n
g/
m
l)
A
B
Part III Validation of TAA 
Chapter 3 
 65 
Survivin-specific T cells could not be detected in control patients. However, survivin reactivity in 
EMCAR was noted in 5/24 patients for CD4
+
 T cells and in 2/24 patients for CD8
+
 T cells. In US, 
survivin responsiveness could be measured in 1/10 patients for CD4
+
 T cells and in 1/10 patients for 
CD8
+
 T cells (Fig. 4A). For some of the tested patients, we investigated whether levels of  
survivin-specific T cells correlate with survivin expression levels in the tumor, but we could not note a 
correlation (data not shown). Due to the limited number of available samples no analysis with regard 
to clinicopathological features could be performed (Table 3). 
Table 3: Clinical characteristics of samples for spontaneous immune response. 
 T cell response B cell response 
Characteristics Controls EMCAR US Controls EMCAR US 
Number of patients 17 24 10 34 39 35 
Histology 
Benign 8 N/A N/A 20 N/A N/A 
Normal 9 N/A N/A 14 N/A N/A 
Endometrioid N/A 16 N/A N/A 24 N/A 
Clear cell N/A 1 N/A N/A 2 N/A 
Serous N/A 4 N/A N/A 10 N/A 
Mixed N/A 3 N/A N/A 3 N/A 
Carcinosarcoma N/A N/A 2 N/A N/A 16 
Leiomyosarcoma N/A N/A 3 N/A N/A 10 
Endometrial stromal 
sarcoma 
N/A N/A 2 N/A N/A 6 
Rhabdomyosarcoma N/A N/A 1 N/A N/A N/A 
Adenosarcoma N/A N/A N/A N/A N/A 2 
Other N/A N/A 1 N/A N/A N/A 
Unknown N/A N/A 1 N/A N/A 1 
Histological grade 
1 N/A 8 2 N/A 18 5 
2 N/A 2 0 N/A 4 1 
3 N/A 13 5 N/A 17 19 
Unknown N/A 1 3 N/A N/A 10 
Stage 
I N/A 10 2 N/A 23 4 
II N/A 2 0 N/A 1 3 
III N/A 8 0 N/A 7 3 
IV N/A 3 6 N/A 8 8 
recurrence N/A N/A  N/A N/A 2 
Unknown N/A 1 2 N/A N/A 15 
 
B cell responses, defined by survivin-specific auto-antibodies were analyzed in plasma/serum. The 
total sample population of uterine tumor patients contains both samples that were taken prior to 
treatment and samples taken during treatment. In order to determine if there is an initial difference 
in titer at tumor diagnosis, all samples taken prior to surgery were analyzed separately. 
Unexpectedly, we found a significant decrease in antibody levels in EMCAR patients, compared to 
normal controls (p = 0.0330) as well as a trend towards decreased levels at diagnosis of US  
(p = 0.0663). No differences were found when comparing either tumor type compared to the total 
control group or the benign group separately (Fig. 4B). 
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Further analysis of the antibody titers in the patient groups, showed an increase in antibody titers at 
diagnosis in type II EMCAR, comprising serous and clear cell tumors as well as mixed and grade 3 
endometrioid tumors compared to type I EMCAR, comprising grade 1 and grade 2 endometrioid 
tumors (p = 0.0088; Fig. 4B). In addition, we found a significant increase in titers in high grade tumors 
(grade 2 and 3) versus low grade tumors (grade 1; p < 0,0102; Fig. 4B). No difference in antibody 
titers was found when comparing locally advanced (FIGO I and II) and far-advanced tumors (FIGO III 
and IV) at diagnosis. In the US group, no differences were found between any of the histological 
types (data not shown). With the current data set of US patients, we were not able to perform  
in-depth analysis of histological grade nor FIGO stage, due to a fairly large number of unknown 
parameters (Table 3). 
Although these significant differences in titers were seen, the vast majority of the measured titers 
did not reach the threshold for response, described in the material and methods section. A B cell 
response was measured in only 1/35 US patients and remarkably, in 1/8 patients with a benign 
gynecological affliction. 
As described above for T cells, the correlation between antibody titers and the expression of survivin 
in the tumor was evaluated. For 9 EMCAR patients and 13 US patients tumor biopsies were stained 
and evaluated for survivin expression. In the EMCAR group 3/9 biopsies (33.3%) had a high score 
(total score 3 or 4) and 6/9 (66.7%) a low score (total score 0-2). In the US group 6/13 (46.1%) had a 
high score and 7/13 (53.9%) a low score. Next, we analyzed if the antibody titers in these patients 
correlated with the survivin expression level in the tumor. In the US group, samples from 2 patients 
were taken during chemotherapy following surgery. All other samples were taken preoperatively. No 
significant difference in the pooled EMCAR and US sample population was found concerning 
antibody titers when comparing the presence of tumors with a low survivin expression level 
compared to a high survivin level (data not shown). 
DISCUSSION 
We have currently validated the anti-apoptotic protein survivin as a possible target for 
immunotherapy in uterine cancer. To this end, both the presence of the antigen, as well as the 
immunogenicity were analyzed. Survivin was found to be present both in its RNA form and the 
translated protein. The currently obtained data in normal tissue were similar to previously published 
results, when comparing the same method of analysis, reviewed by Fukuda et al., except for the 
expression levels in skin and uterine cervix[29]. Several studies have already described the presence 
of survivin in EMCAR. Takai et al. showed that expression of survivin protein is correlated with 
histological grade, tumor stage and patient survival [30]. These results were, however, not 
corroborated in a later study by Pallares et al. [31]. In our study, survivin mRNA was found to be  
up-regulated in type II compared with type I EMCAR. Type II EMCAR comprises differentiation grade 
3 endometrioid samples as well as serous and clear cell EMCAR, which are classified as high grade. 
The current RNA results thus corroborate the results of Takai et al [30]. We also found an  
up-regulation of survivin protein expression in recurrent carcinoma with respect to primary 
carcinoma, suggesting a survival advantage of the tumor cells leading to the development of the 
recurrent tumor. 
The immunogenicity of an antigen, i.e. the ability to elicit an immune response is a key characteristic 
in order for the antigen to be eligible as a target for immunotherapy. Spontaneous T cell responses 
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against several TAA, mainly melanoma-associated antigens, have been described in several tumor 
types, both solid tumors and hematological tumors [32]. 
Spontaneous survivin-specific T cells have been described before in 9/23 multiple myeloma patients 
and 1/21 healthy donors [23]. In addition, Turksma et al. also described survivin-specific CD8
+
 T cells 
in 3/5 patients with head and neck cancer [33]. 
To our knowledge, survivin-specific T cell have not been described in uterine cancer. We currently 
found specific T cell responses in 6/34 patients. Five EMCAR patients out of 24 and 1/10 US patients 
showed spontaneous survivin-specific T cells. 
To date, little information is available concerning spontaneous auto-antibody levels, i.e. not induced 
by immunotherapy, in uterine tumors. In 2001, Bosscher et al. described the presence of anti-
cathepsin D auto-antibodies in patients with endometrial cancer [34]. In 29/31 patients, antibodies 
against pro-cathepsin D were detected, whereas none of the controls showed responses [34]. To our 
knowledge, one other publication reports on survivin auto-antibodies in uterine tumors [21]. Among 
11 different tumor types, ovarian and uterine tumors were included as gynecological malignancies. 
The authors report that from the total population that was analyzed, both gynecological tumor types 
and thyroid cancer showed very little immune response compared to other analyzed tumor types. 
Although not specified whether the uterine tumor population consisted of a combination of EMCAR 
and US samples or either, a survivin antibody response was found in 4/27 (14.8%) of analyzed uterine 
tumor samples, whereas in ovarian cancer only 1/39 (2.6%) tumor samples showed positivity [21]. In 
our sample group, out of a pooled tumor population of 74 tumor samples, only 1 sample was 
considered positive (1.3%). Our results corroborate the finding that survivin auto-antibody responses 
are low in uterine tumors. However, the responses detected by Megliorino et al. are still considerably 
higher than the current data [21]. We believe the difference can be explained by the threshold 
criteria that define an immune response. Like for many other publications on detection of  
auto-antibodies that use a threshold of the mean OD measured for the control group + 2 or 3 SD, the 
latter was also used by Megliorino et al [21]. In our analysis, however, a cut-off value based on the 
extrapolated titer + 2 SD rather than on the raw OD value was used. This method is likely more 
stringent, since standard deviations of extrapolated values may be larger. In addition, in the current 
sample population, actual titers compared to a standard curve with known concentrations of survivin 
antibodies were analyzed, instead of a comparison of OD values between different groups. In the 
current data set, with application of these threshold criteria, none of the normal control samples 
were above threshold. In one patient with a benign gynecological affliction, an auto-antibody 
response was measured, which may in fact be explained by the presence of the benign condition, 
which may elicit anti-survivin responses as well. 
Data on a correlation between the presence of an antigen in the tumor and a corresponding immune 
response are not always consistent, as reviewed by Reuschenbach et al. [16]. A link between the 
presence of anti-survivin antibody responses and the expression of survivin mRNA was found in 
patients with head and neck tumors [35]. In our results, we did not find any correlation between 
increased titers, below response threshold, and the presence of low or high survivin expression 
levels. In addition, no correlation was found between the presence of survivin in the tumor and the 
presence of survivin-reactive T cells in peripheral blood. 
When analyzing antibody titers according to histopathological characteristics, we showed that 
patients suffering from EMCAR with a more aggressive phenotype (type II EMCAR) or high-grade 
EMCAR showed increased anti-survivin antibody titers, indicating some reaction of the immune 
system although it does not reach the threshold of a definite immune response. This increase in 
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titers corroborates results found in head and neck tumors by Chang et al. [36] and Eto et al. [37], who 
showed increased responses in patients with far-advanced tumors and Li et al. and Taylor et al, who 
showed increased survivin auto-antibody levels in advanced ovarian cancer [25, 26]. 
In conclusion, we currently validated the presence of the anti-apoptotic protein survivin in uterine 
tumors. To our knowledge, this is the first paper to describe its presence in uterine sarcoma. 
To further evaluate the validity of survivin as an immunotherapeutic target, we investigated the 
occurrence of spontaneous T and B cell responses directed against survivin. We found a B cell 
response in only 1 patient, while T cell responses could be detected in 6/34 patients. 
These data collectively indicate that survivin poses as a valid candidate for future immunotherapeutic 
strategies in the treatment uterine cancer. 
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Validation of tumor antigens as immunotherapeutic targets in 
uterine cancer 
ABSTRACT 
Immunotherapy for uterine cancers is still in its early days. Although quite some information is 
known about the presence of TAA in uterine cancer, its implementation into immunotherapeutic 
regimens has so far not been pursued to large extent. We currently validate TAA in uterine cancer 
patients in order to ascertain future applicability in dendritic cell based immunotherapy. 
The presence of 5 different TAA; BORIS, MUC1, hTERT, MAGE-A3 and Sp17 was validated in human 
tumor samples of endometrial carcinoma as well as uterine sarcoma by IHC and/or qRT-PCR. In 
addition, we have analyzed the immunogenicity of these antigens by determining the spontaneous 
TAA-specific T cell responses in patient blood. 
All the currently analyzed TAA were found to be present in the majority of both endometrial 
carcinoma and uterine sarcoma, with MUC1 being preferentially expressed in uterine sarcomas 
containing an epithelial component. 
Spontaneous T cell responses against the analyzed TAA were detected in only a minority of patients. 
In addition, we found spontaneous T cell responses in patients with benign gynecological afflictions. 
Taken together, the currently obtained data provide further indications of the immunogenicity of 
TAA in uterine cancer, fortifying their validity as targets in immunotherapeutic regimens. 
INTRODUCTION 
Cancer vaccination, based on the recognition of the so-called tumor-associated antigens (TAA), is a 
valid therapeutic option for many types of cancer. Numerous different TAA have already been 
described to date. In 2009, Cheever et al. ranked a list of known TAA according to a whole array of 
characteristics, such as tissue expression, presentation in MHC context, and immunogenicity [1]. 
Several TAA have already been described in various tumor types and tested in (pre)clinical 
immunotherapeutic settings with varying success [2]. Most data have been gathered in among others 
melanoma [3-6], glioblastoma [7, 8], renal cell carcinoma (RCC) [9], prostate cancer [8] and 
hematological malignancies [10].  
Some of these known antigens have already been described in uterine cancer. However, even though 
TAA have been described in uterine tumors, only few studies were done to verify their potential use 
in immunotherapeutic strategies. Uterine tumors have been shown to be immunogenic which is 
exemplified by the presence of tumor-infiltrating lymphocytes and macrophages [11, 12]. Some 
immunotherapy studies have already been done in uterine tumors using WT1 as target antigen [5, 
13, 14]. Other (pre)clinical studies in uterine tumors based on the targeting of antigens have mainly 
focused on the use of whole tumor lysate [15, 16]. The current research is focused on the validation 
of some of the described TAA in uterine tumors. In specific, we have analyzed the following antigens: 
brother of the regulator of imprinted sites (BORIS), mucin-1 (MUC1), human telomerase reverse 
transcriptase (hTERT), sperm protein 17 (Sp17) and melanoma-associated antigen A3 (MAGE-A3). 
BORIS, Sp17 and MAGE-A3 are members of the cancer-testis antigen family. In normal tissues, their 
expression is restricted to male germ cells, fetal ovary, placenta and immature gametes [17], while 
they are expressed in several types of cancer, among which breast cancer [18, 19], making them 
attractive targets for immunotherapeutic purposes. hTERT is considered a universal TAA. This antigen 
Part III Validation of TAA 
Chapter 4 
 74 
plays a role in the survival of tumor cells. It is absent in adult tissues, with the exception of 
proliferating tissues, while being up-regulated in dividing tumor cells, which fortifies its suitability as 
target TAA [20, 21]. MUC1 is an epithelial antigen, constitutively expressed on normal epithelium in 
its wild-type form. The TAA MUC1, however, discriminates itself from the wild-type form by a 
hypoglycosylation pattern, exposing new epitopes, which can attract antigen-specific T cells [22]. 
These antigens were arbitrarily selected based on an analysis of the available data of these antigens 
concerning (a) their presence in uterine tumors, (b) their ranking in the prioritization list described 
above, (c) available data on their application in immunotherapeutic regimens in other tumor types, 
and (d) their specific expression/function in tumorigenesis. 
We currently aim to validate the presence of these TAA in endometrial carcinomas and evaluate their 
expression in uterine sarcoma, which has, to our knowledge, not been described before. In addition, 
we evaluate their immunogenicity by analyzing the naturally-occurring in vivo TAA-specific T cell 
responses. The combined data will give a view on the applicability of the currently investigated TAA 
for immunotherapy in uterine cancer patients. 
MATERIALS & METHODS 
Patient samples, cell lines and reagents 
Biopsy material from uterine cancer patients and healthy controls was collected from the tissue 
biobank of the gynecologic oncology department at the University Hospital Leuven. Whole blood was 
collected from uterine cancer patients or patients with benign gynecological diseases through 
venipuncture using EDTA-coated BD vacutainer tubes (BD Diagnostics, Erembodegem, Belgium); 
buffy coats of healthy controls, collected in ACD bags, were purchased from the Belgian Red Cross. 
Freshly collected blood was stored at room temperature and processed within 24 hours.  
Informed consent was obtained from all patients donating blood and/or tumor tissue prior to 
inclusion in the study.  
Expression levels in normal tissues were analyzed using RNA isolated from normal tissues, purchased 
from Ambion (Life Technologies, Ghent, Belgium) and/or a tissue microarray (TMA) (MTU951; 
Pantomics, Inc., Richmond, California, United States). 
The commercial cell lines SKOV-3, OVCAR-3, RL-95-2, HEC-1 and SK-UT-1 were obtained from ATCC. 
Peptide pools consisting of 15-mer peptides with an 11 aa overlap were obtained from Miltenyi 
Biotec (Leiden, the Netherlands) (MAGE-A3, CMVpp65, EBV BZLF1 and Influenza MP1), JPT Peptide 
Technologies GmbH (Berlin, Germany) (MUC1, VNTR repeat region) or Thermo Scientific (Beersel, 
Belgium) (Sp17). 
RNA isolation and reverse transcription reaction 
Total RNA was isolated from snap-frozen material using Trizol (Life Technologies, Ghent, Belgium), 
according to manufacturer’s instructions. 0.2 µg RNA was reverse-transcribed in a total volume of 
20 µl in a mixture containing 10X RT buffer, 5.5 mM MgCl2, 10 mM dNTP’s, 2.4 µM random 
hexamers, 0.5 U/µl RNase inhibitor and 50 U/µl Multiscribe reverse transcriptase (all from Life 
Technologies). The reaction was performed using ABI prism® 7000 Sequence Detection System (Life 
Technologies) as follows: 10 minutes at 25°C, 30 minutes at 48°C and 5 minutes at 95°C. 
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Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) was performed by using ABI prism® 7000 Sequence Detection 
System (Life Technologies) and the data were analyzed with 7000 system software. Tumor cDNA was 
analyzed together with testis cDNA as positive control. qRT-PCR reactions were performed in 
triplicate for all samples. Thermal cycling conditions were as follows: 2 min at 50°C, 10 min at 95°C 
and 40 cycles of 15 s at 95°C and 1 min at 60°C. Primers used for the different genes are indicated in 
Table 1. TAA gene expression levels were normalized to the geometric mean of β-actin and β-
glucuronidase and the mean normalized expression (MNE) was calculated with Q-Gene software. 
Samples in which cycle threshold (Ct) values of housekeeping genes (β-actin and β-glucuronidase) 
were above 30 were considered to be of insufficient quality and omitted from analysis. Samples in 
which no Ct value for a gene of interest could be measured, were considered undetectable (i.e. no 
expression). All PCR data were expressed as fold change compared to the mean MNE of normal 
endometrium samples. TAA were considered to be overexpressed in case of ≥ two-fold increase. 
Statistical analysis to calculate differences in expression levels between groups were performed with 
GraphPad Prism software, using the appropriate (non)-parametric test following initial analyses to 
determine normal distribution of results using the D’Agostino and Pearson omnibus normality test. 
Table 1: Primers used for qRT-PCR 
TAA Primers and probe 
BORIS Human CTCFL Taqman gene expression assay from Applied Biosystems (Life 
Technologies) 
MAGE-A3 Sense primer, 5’-GTCGTCGGAAATTGGCAGTAT-3’ 
Antisense primer, 5’-GCAGGTGGCAAAGATGTACAA-3’ 
Probe, 5’-6FAM-AAAGCTTCCAGTTCCTT-MGB-3’ 
Sp17 Human SPA17 Taqman gene expression assay from Applied Biosystems (Life 
Technologies) 
hTERT Human TERT Taqman gene expression assay from Applied Biosystems (Life 
Technologies) 
β-actin Human ACTB (beta actin) Endogenous Control from Applied Biosystems (Life 
Technologies) 
β-glucuronidase Human GUSB (beta glucuronidase) Endogenous Control from Applied Biosystems (Life 
Technologies) 
 
Immunohistochemistry 
For all stainings, 4.0 µm phormol-fixed, paraffin-embedded tissue sections were stained. Sections 
were first deparaffinized and rehydrated in ethanol. Next, endogenous peroxidase was blocked in 
0.5% (MUC1) or 3% H2O2 (hTERT) in methanol for 30 minutes. For hTERT, heat-induced epitope 
retrieval (HIER) was performed at 85°C. For MUC1, the same step was performed for 1h at 90°C in 
citrate (pH 6.0), after which the slides were cooled down and primary antibody incubation was 
performed. Ms α Hu MUC1 (DAKO (Leuven, Belgium; 1.15 µg/ml) incubated for 2 h at room 
temperature (RT). Rb anti Hu TERT (Rockland (Gilbertsville, Pensylvania, United States; 2.5 µg/ml) 
incubated overnight at 4°C. For all antigens, EnVision+ system HRP-labelled polymers (DAKO) were 
used as secondary antibodies and incubated for 30 minutes at RT. Visualization was performed using 
3,3'-Diaminobenzidine (DAB) and hematoxylin counterstaining. 
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The validation of the tumor associated antigens on normal tissues was done using a tissue microarray 
(TMA) (MTU951; Pantomics, Inc. Richmond, California, United States), following the same protocols. 
Slide scoring 
For evaluation of antigen expression, a scoring system was developed based on 2 different 
parameters; percentage of tumor cells staining positive for the antigen and the staining intensity. For 
each parameter, 3 different levels were determined. The percentage of tumor cells staining positive 
was divided in 1-25%, 25-50% and > 50%. The staining intensity was evaluated as weak (score 1), 
moderate (score 2) and strong (score 3). Based on these parameters a total score was assigned to 
each slide (Table 2). All slides were analyzed for the presence of tumor using a conventionally stained 
HE slide. 
Table 2: scoring system for evaluation of TAA expression by IHC 
% positive tumor cells Staining intensity Assigned score 
1-25 1 0 
1-25 2 0 
1-25 3 0 
25-50 1 0 
25-50 2 1+ 
25-50 3 2+ 
>50 1 0 
>50 2 3+ 
>50 3 4+ 
 
PBMC isolation 
For healthy donors, buffy coats were diluted 1/3 in PBS and PBMC were isolated using Lymphoprep™ 
(AXIS-SHIELD, Dundee, Scotland) density gradient centrifugation according to manufacturer’s 
instructions and counted with Türck’s solution. For patient samples, peripheral blood was diluted 1/2 
in PBS and isolated following the same protocol. The median PBMC number obtained was 8.5x10
6
 
cells per 10 ml of whole patient blood. PBMC were cryopreserved in 90% human AB serum (Sera 
Laboratories International, West Sussex, United Kingdom) containing 10% DMSO at 5-10 x 10
6
 cells 
per vial using CoolCell freezing containers (BioCision, Larkspur, California, United States). The 
freezing container was placed at -80°C  and vials were transported to liquid nitrogen after 16-48 h 
and stored until further use. 
Detection of TAA-specific T cells 
The CD137 assay was carried out in T cell medium (IMDM supplemented with 5% human AB serum, 
penicillin-streptomycin (Life Technologies) and L-glutamin (Life Technologies)) and the serum lot was 
pretested for assay performance. On day 1, 1-2 vials of PBMC were thawed in a 37°C water bath until 
only small ice crystals were visible. The cell suspension was transferred to ice cold RPMI1640 and 
centrifuged at 1500 rpm for 5 minutes at 4°C. The PBMC pellet was re-suspended in T cell medium, 
containing 10 U/ml DNase1 and left to recover at RT for 1 h. After 1 h, cells were counted with trypan 
blue and re-suspended in T cell medium at a concentration of 10
7
 cells/ml. Cells were plated at  
20-100 µl per well in half-well 96 well plates (Greiner Bio-One, Wemmel, Belgium) and cultured in 
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the absence or presence of the indicated overlapping peptide pools at 0.6 nmol/ml for 16-20 h at 
37°C / 5% CO2. After the incubation period, the cells were used for flow cytometric analysis. 
Flow cytometry staining and analysis 
Plates were centrifuged during 5 min at 1800 rpm and 4°C. After aspiration of the supernatant, cells 
were first washed with cold PBS (Life Technologies, Ghent, Belgium), centrifuged again and 
subsequently incubated for 30 min with 150 µl per well of a fixable viability dye (Fixable Viability Dye 
eFluor 506, eBioscience, Vienna, Austria) diluted at 1 µl/ml in PBS for discrimination of live and dead 
cells. After incubation, plates were centrifuged and cells were washed with PBS. Next, Fc receptor 
blocking was performed by adding 25 µl per well of a 10% normal goat serum (Sigma-Aldrich) 
solution in PBS/0.5% BSA. To identify antigen-specific T cells, the cells were stained with the 
following antibodies: CD4-FITC (BD Pharmingen, San Jose, California, United States), CD137-PE (BD 
Pharmingen, San Jose, California, United States), CD3-PerCp-Cy5.5 (BioLegend, San Diego, California, 
United States), CD19-PE-CY7 (Biolegend, San Diego, California, United States) and CD8-APC-H7 (BD 
Pharmingen, San Jose, California, United States). All antibodies were titrated to optimal dilution 
before use. Acquisition was performed with a FACSCanto II flow cytometer using BD FACSDIVA 
software v6.1.3 and 2.5-5 x 10
5
 cells were acquired per sample. Photo Multiplier Tube (PMT) voltages 
were set using CS&T beads and compensation was calculated using single-stained samples. Data 
analysis was done using FACSDIVA v6.1.3.  
The following gating strategy was used: first, dead cells were gated out using the viability dye and 
cells were gated on the lymphocyte population based on FSC/SSC properties. Within the lymphocyte 
population, a gate was set around CD3
+
 CD19
-
 cells and subsequently, the CD4
+
 and CD8
+
 population 
was gated in the CD3
+
 population with exclusion of double-positive T cells. Finally, CD137 expression 
within the CD4
+
 or CD8
+
 population was evaluated. Background expression of CD137 by the T cells 
was determined on T cells from cultures without peptides. Positive reactivity to an antigen was 
predefined as a minimum 2-fold increase in CD137 positivity compared to the unstimulated control. 
The gating of a representative sample is shown in Fig. 1. 
These studies were conducted in a laboratory that operates under exploratory research principles 
using investigative protocols and assays. 
Part III Validation of TAA 
Chapter 4 
 78 
 
Figure 1: Gating strategy for detection of  CD137
+
 T cells in a representative patient sample. 
RESULTS 
TAA expression in normal human tissues and tumor cell lines at mRNA level 
Prior to testing primary patient material, mRNA expression levels of the different TAA were assessed 
on a panel of normal human tissues. For the currently selected antigens, PCR analysis was performed 
for all antigens, except for MUC1. The difference between the wild-type and tumor antigen MUC1 is 
a difference in glycosylation pattern. This is a post-translational modification and can thus not be 
detected at the level of RNA. As expected, the cancer-testis antigens BORIS, MAGE-A3 and Sp17 were 
expressed at the highest levels in testis, but for BORIS and Sp17 a fairly high level of background 
expression could also be observed in other tissues. MAGE-A3 expression was more restricted to testis 
(Fig. 2A). With regard to the universal TAA hTERT, the highest expression levels were found, as 
expected, in tissues with a lot of proliferative cells, such as spleen, testis, and thymus (Fig. 2A). 
TAA expression was also assessed on a small selection of commercially available gynecological tumor 
cell lines. All TAA were expressed at medium to high levels in these cell lines, except for MAGE-A3 
which showed lower expression levels (Fig. 2B). 
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A 
 
B 
Figure 2: TAA expression in normal tissues. 
A panel of normal human tissues was assayed for expression of BORIS, MAGE-A3, Sp17 and hTERT by quantitative RT-PCR. 
Values represent the mean normalized expression of the TAA normalized to β-actin and β-glucuronidase. Cells are  
color-coded from low expression (green) to high expression (red).B. TAA analysis in commercially available cell lines. 
TAA expression in uterine cancer at mRNA level 
When looking at the mRNA expression levels of BORIS in our sample collection, we noted that BORIS 
was detectable in 60 % of healthy controls, 50 % of endometrial carcinomas and 92 % of uterine 
sarcomas. Furthermore, we observed BORIS overexpression (calculated as > 2-fold increase 
compared with the mean expression in healthy controls) in 26 % of endometrial carcinomas and 62 % 
of uterine sarcomas (Table 3). The expression seems slightly, yet not significantly increased in uterine 
sarcoma (US) compared with endometrial carcinoma (EMCAR; Fig. 3A). Due to a fairly small amount 
of samples tested for this antigen, no analysis concerning clinicopathological features was 
performed. All clinicopathological features of the samples that were currently analyzed are 
summarized in Table 4. 
  
MNE Level MNE Level MNE Level MNE Level
SKOV-3 6,90E-04 ++ 1,49E-05 + 3,03E-02 ++++ 5,66E-04 ++
OVCAR-3 7,45E-03 +++ 8,98E-06 +/- 2,50E-02 ++++ 1,82E+00 ++++++
RL-95-2 3,72E-04 ++ 3,56E-05 + 1,40E-02 ++++ 1,92E-03 +++
HEC-1 2,04E-03 +++ 3,33E-05 + 2,68E-02 ++++ 4,90E-04 ++
SK-UT-1 ND ND 5,23E-04 ++ 6,28E-02 ++++ 2,97E-04 ++
Cancer-testis antigens
BORIS MAGE-A3 Sp17 hTERT
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Table 3: Evaluation of TAA expression in patient biopsies by qRT-PCR 
TAA Samples Healthy 
controls 
Endometrial 
carcinoma 
Uterine 
sarcoma 
BORIS # samples tested (%) 9 (100) 49 (100) 15 (100) 
# evaluable samples (%)
1
 5 (56) 43 (88) 13 (87) 
# undetectable samples (%)
2
 2 (40) 21 (50) 1 (8) 
% > 2-fold change
3
 (%)  11 (50) 8 (67) 
MAGE-A3 # samples tested (%) 12 (100) 71 (100) 35 (100) 
# evaluable samples (%)
1
 10 (83) 70 (99) 34 (97) 
# undetectable samples (%)
2
 0 (0) 7 (10) 3 (9) 
% > 2-fold change
3
  7 (11) 3 (9) 
Sp17 # samples tested (%) 12 (100) 71 (100) 34 (100) 
# evaluable samples (%)
1
 10 (83) 70 (99) 34 (100) 
# undetectable samples (%)
2
 0 (0) 0 (0) 0 (0) 
% > 2-fold change
3
  14 (20) 1 (3) 
hTERT # samples tested (%) 9 (100) 70 (100) 34 (100) 
# evaluable samples (%)
1
 9 (100) 70 (100) 33 (97) 
# undetectable samples (%)
2
 6 (67) 0 (0) 26 (79) 
% > 2-fold change
3
  50 (71) 16 (59) 
1
 A sample is considered evaluable if the Ct of the reference genes is below 30. 
2
 A sample is considered undetectable when 
no Ct value could be measured (i.e. Ct > 40). 
3
 Numbers are expressed as > 2-fold change compared to the mean expression 
of normal endometrium. 
 
 
Figure 3: mRNA expression of TAA in uterine tumors. A. BORIS expression. B. MAGE-A3. C. Sp17. D. hTERT. Results are 
expressed as fold change compared to the mean normalized expression of normal endometrium. Overexpression is defined 
as at least two-fold increase compared to normal endometrium (dashed line). After verifying normal distribution, all 
comparisons were analyzed using the Mann Whitney test or an unpaired t test, depending on distribution outcome. 
  
EM
CA
R US
0
20
40
60
80
100
100
200
300
fo
ld
 
in
cr
ea
se
 
in
 
ex
pr
es
si
o
n
EM
CA
R US
0
2
4
6
8
10
12
14
16
18
20
fo
ld
 
in
cr
ea
se
 
in
 
ex
pr
es
si
o
n
A B
D
EM
CA
R US
0
10
20
30
40
fo
ld
 
in
cr
ea
se
 
in
 
ex
pr
es
si
o
n
EM
CA
R US
0
2
4
6
8
10
12
14 *
fo
ld
 
in
cr
ea
se
 
in
 
ex
pr
es
si
o
n
C
Part III Validation of TAA 
Chapter 4 
 81 
MAGE-A3 could be detected in almost all samples (100 % of controls, 90 % EMCAR and 91 % US) and 
was overexpressed at mRNA level in 10 % of EMCAR samples and 9 % of US samples  
(Table 3, Fig. 3B). No differences in MAGE-A3 expression were observed among the different FIGO 
stages of EMCAR, nor between the different histological subtypes or grade of differentiation of 
EMCAR or histological subtypes of US (data not shown). 
Sp17 transcripts could be detected in all samples. Overexpression of Sp17 mRNA was found in 20 % 
of samples of the EMCAR population and in 3 % of uterine sarcomas (Table 3). It was significantly  
up-regulated in EMCAR compared with US (p = 0.0273, Fig. 3C). In addition, a significant  
down-regulation in type II EMCAR compared with type I EMCAR was found (p = 0.0206), indicating 
potential down-regulation of Sp17 with increased aggressiveness of tumors (data not shown). 
We noted that hTERT was detectable in 33 % of control samples, 100 % of EMCAR and 21 % of US 
samples. hTERT mRNA was overexpressed in 71 % and 48 % of EMCAR and US, respectively  
(Table 3, Fig. 3D). When comparing hTERT expression in EMCAR according to FIGO stage, hTERT was 
up-regulated in stages II (p < 0.01), III (p < 0.01) and IV (p < 0.05) compared to stage I (data not 
shown). 
Table 4: Clinical characteristics samples qRT-PCR analysis 
Tumor type EMCAR US 
Tumor-associated antigen BORIS Sp17/ 
MAGE-A3 
hTERT BORIS Sp17/hTERT MAGE-A3 
Characteristics 
Total number of selected 
patients  
49 71 70 15 34 35 
FIGO stage EMCAR 
(number of tumors) 
I 24 34 35    
II 8 11 10    
III 11 14 14    
IV 6 11 11    
Histological grade EMCAR  
1 17 24 24    
2 5 14 14    
3 14 22 22    
Unknown 13 11 10    
Histological subtype 
(number of tumors) 
Endometrioid 34 48 48    
Serous 8 12 11    
Clear cell 3 3 3    
Mixed 4 8 8    
Carcinosarcoma    6 11 11 
Leiomyosarcoma    4 11 11 
Rhabdomyosarcoma    1 2 2 
Endometrial stromal 
sarcoma 
   4 7 8 
Adenosarcoma    0 1 1 
Mixed    0 1 1 
Unknown    0 1 1 
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TAA expression in normal human tissues at protein level 
Protein analysis was done only for hTERT and MUC1. For the other antigens, no optimal specific 
antibody was available. For MAGE-A3, there is no commercially available antibody that is specific for 
the detection of MAGE-A3. TAA expression in normal tissues was evaluated using a TMA containing 
22 different normal tissues. We found that 42.9 % expressed MUC1. As expected, expression was 
predominantly found in epithelial cells. In addition, 57.6 % of tissues expressed hTERT. The tissues 
that express each of the investigated antigens and the respective scores are summarized in Table 5. 
Table 5: TAA protein expression in normal tissues. Numbers indicate given scores according to the 
IHC scoring system described in Materials and methods section. 
 
 
TAA expression in uterine cancer at protein level 
For protein expression analysis of MUC1 and hTERT, a broad spectrum of paraffin-embedded tissue 
samples were analyzed. All clinicopathological characteristics are summarized in Table 6. In addition, 
in order to obtain an idea on the expression of a certain antigen in the tumor as a whole, specimens 
taken at different locations in the tumor, to a maximum of 3 different sites, were analyzed if 
possible. The total number of tumors that were analyzed for each of the antigens is summarized in 
Table 7. Microscopic analysis of the tissue samples showed that for MUC1, 96.6 % of the pooled 
EMCAR population expressed the antigen. In comparison with normal endometrium, primary tumors 
(p < 0.05) as well as recurrent tumors (p < 0.01) and metastatic lesions (p < 0.01) show a significant 
up-regulation (Fig. 4A) based on slide scoring. In addition, 43 % of the US samples was also positive 
for this tumor antigen. For this type of tumors, the metastatic lesions show a significant  
up-regulation of MUC1 in comparison to the primary and recurrent tumors (p < 0.05; Fig. 4A). This 
difference is most likely due to the high total amount of carcinosarcomas and endometrial stromal 
sarcomas in the total population of metastases (9/13). However, in the recurrent tumor population 
8/13 tumors have either histological subtype, indicating that MUC1 is indeed expressed at the 
highest level in metastatic lesions. 
  
Tissue MUC1 hTERT Tissue MUC1 hTERT 
Adrenal gland 0 0 Liver 0 4
Urinary bladder 4 3 Lung 4 0
Breast 0 1 Ovary N/A N/A
Cerebellum 0 1 Pancreas 3 3
Brain 0 3 Prostate 0 3
Esophagus 3 3 Salivary gland 3 3
Stomach 1 0 Skin 1 0
Small intestine 0 3 Testis 0 0
Colon 1 1 Thyroid 0 1
Rectum 0 0 Cervix 0 1
Kidney 4 3 Endometrium N/A N/A
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Table 6: Clinical characteristics samples IHC analysis. 
Tumor type EMCAR US 
Tumor-asscociated antigen MUC1 hTERT MUC1 hTERT 
Characteristics 
Total number of patients 62 48 60 47 
Total number of tumors 70 52 65 52 
Number of patients 
Primary 40 27 37 24 
Recurrence 8 11 10 10 
Metastasis 6 7 10 10 
Primary + recurrence 4 0 1 1 
Primary + metastasis 4 3 1 1 
Metastasis+ recurrence 0 0 1 1 
FIGO stage pr EMCAR
1
 
(number of tumors) 
I 17 10 N/A N/A 
II 6 4 N/A N/A 
III 11 7 N/A N/A 
IV 14 9 N/A N/A 
Histological grade EMCAR
2
  
(number of tumors) 
1 15 7 N/A N/A 
2 6 3 N/A N/A 
3 39 32 N/A N/A 
Unknown 9 9 N/A N/A 
Histological subtype
3
 
(number of tumors) 
Endometrioid 29 17 N/A N/A 
Serous 24 21 N/A N/A 
Clear cell 11 9 19 18 
Mixed 3 2 17 13 
Carcinosarcoma
4
 2 2 9 7 
Leiomyosarcoma   15 10 
Rhabdomyosarcoma   5 4 
1
 Only primary tumors included; 
2
 All tumors included; 
3
 All tumors included; 
4
 Only carinomatous tumor part included in 
EMCAR evaluation. 
 
Table 7: Evaluation of TAA expression in patient biopsies by IHC. 
Tumor type MUC1 hTERT 
# samples % positive # samples % positive 
Normal tissue 17 82.4 14 92.8 
Primary carcinoma 48 91.6 30 66.7 
Recurrent carcinoma 11 100 10 90 
Metastatic carcinoma 10 90 9 66.7 
Primary sarcoma 39 33.3 22 50 
Recurrent sarcoma 15 26.7 12 41.7 
Metastatic sarcoma 13 69.2 13 76.9 
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The protein data for hTERT showed positivity in 75.6 % of EMCAR samples and in 59.3 % of US 
samples. Remarkably, the antigen was significantly up-regulated in normal endometria in comparison 
to primary EMCAR and metastatic EMCAR locations (p < 0.05) as well as primary and recurrent US  
(p < 0.01, Fig. 5B). 
For all the currently described antigens, no sub-analysis was done to determine differences in 
expression according to clinicopathological characteristics, due to too small sample sizes to perform 
sound analyses. 
 
Figure 4: Expression levels of TAA by IHC. Left panel: overall percentage of positive biopsies. Middle panel: TAA expression 
levels in normal endometrium and EMCAR samples. Right panel: TAA expression levels in normal endometrium and US 
samples. A. MUC1 expression. B. hTERT levels. nl EM: normal endometrium; pr EMCAR: primary endometrial carcinoma; rec 
EMCAR: recurrent endometrial carcinoma; meta EMCAR: metastasis endometrial carcinoma; pr US: primary uterine 
sarcoma; rec US: recurrent uterine sarcoma; meta US: metastasis uterine sarcoma. All data were analyzed using the non-
parametrical Kruskal-Wallis test, followed by the Dunn’s Multiple Comparison Test. 
Endogenous T cell responses to TAA 
MAGE-A3, MUC1 and Sp17 were selected for further assessment of immunogenicity by determining 
the presence of endogenous TAA-specific T cells after stimulation with overlapping peptides covering 
the whole TAA. Stimulation with peptide pools covering the viral antigens CMVpp65, EBV BZLF1 and 
Influenza Matrix Protein 1 were included as a control for assessing immune competence. CD137  
up-regulation on CD4
+
 and CD8
+
 T cells after in vitro culture of PBMC with the indicated peptide pools 
was measured. The clinical characteristics of the patients included in this analysis are shown in  
Table 7. 
Virus-specific immunity as determined by CD137 up-regulation on either CD4
+
 or CD8
+
 T cells upon 
stimulation with at least 1 of the 3 viral antigens was observed in 7/9 (78%) of benign controls, 10/10 
(100%) of EMCAR patients and 8/10 (80%) of US patients (data not shown). In patients that did not 
mount a viral response, no TAA-specific T cells could be measured (data not shown). 
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MAGE-A3 specific T cells could be measured in 1/9 controls for CD4
+
 T cells and 1/9 controls for CD8
+
 
T cells. For EMCAR patients, MAGE-A3 specific CD4
+
 and CD8
+
 T cells were observed in 2/10 and 1/10 
patients respectively, while for US patients MAGE-A3 reactivity could be noted in 4/10 patients for 
CD4
+
 T cells and in 3/10 patients for CD8
+
 T cells (Fig. 5A). 
MUC1 specific CD4
+
 and CD8
+
 T cells were present in 2/9 and 1/9 controls respectively. For EMCAR 
patients, MUC1 responsiveness could only be observed in CD4
+
 T cells in 3/10 patients. In US, MUC1 
specificity was measured in 1/10 patients for CD4
+
 T cells and in 2/10 patients for CD8
+
 T cells  
(Fig. 5B). 
 
Figure 5: Analysis of T cell responses. A. CD4
+
 and CD8
+
 responses against MAGE-A3. B. CD4
+
 and CD8
+
 responses against 
MUC1. C. CD4
+
 and CD8
+
 responses against Sp17. 
For Sp17, control patients only showed reactivity in 1/9 patients for CD8
+
 T cells. In EMCAR, Sp17 
specificity was seen in 2/10 patients for CD4
+
 T cells, while Sp17 specific T cells could be noted in 
2/10 US patients for CD8
+
 T cells (Fig. 5C). 
Altogether, endogenous T cells specific to any of the tested TAA were only detected in a minority of 
patients. For some of the tested patients, we investigated whether levels of TAA specific T cells 
correlate with TAA expression levels in the tumor but we could not note a correlation for any TAA 
(data not shown). 
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Table 7: Clinical characteristics samples T cell responses. 
Tumor type Healthy/ 
benign 
EMCAR US 
Total number of 
selected patients  
9 16 10 
Healthy 0 N/A N/A 
Benign 9 N/A N/A 
FIGO stage 
I N/A 9 2 
II N/A 2 0 
III N/A 1 0 
IV N/A 3 6 
Unknown N/A 1 2 
Histological grade  
1 N/A 6 2 
2 N/A 2 0 
3 N/A 8 5 
Unknown N/A 0 3 
Histological subtype 
Endometrioid N/A 11 N/A 
Serous N/A 3 N/A 
Clear cell N/A 1 N/A 
Mixed N/A 1 N/A 
Carcinosarcoma N/A N/A 2 
Leiomyosarcoma N/A N/A 3 
Rhabdomyosarcoma N/A N/A 1 
Endometrial stromal 
sarcoma 
N/A N/A 2 
Other N/A N/A 1 
Unknown N/A N/A 1 
 
DISCUSSION 
We have currently validated the presence of 5 different antigens in uterine tumors, comprising both 
endometrial carcinoma and uterine sarcoma. To our knowledge, this is the first study to describe the 
presence of these antigens in uterine sarcoma, with the exception of BORIS [23]. This TAA has 
emerged fairly recent and has been investigated in several tumor types [24]. BORIS was described in 
uterine cancer by Risinger et al. [23]. These authors describe BORIS expression in 77 % of analyzed 
EMCAR samples as well as BORIS expression in 77 % uterine mesodermal tumors (carcinosarcomas). 
Analysis of BORIS in the current EMCAR samples showed BORIS mRNA expression in 60% of normal 
endometria and 50% of EMCAR, with an overexpression in 26% of the EMCAR samples in which 
BORIS could be detected. Our results do not correspond to the results of Risinger et al. Using a 
different primer set, they have shown expression in 77% of EMCAR and no expression in normal 
endometrium. A recent study concerning the expression of BORIS and its paralogue CTCF in EMCAR 
showed that BORIS RNA was significantly increased in non-endometrioid tumors compared with 
endometrioid tumors [25]. In addition, BORIS levels increased during cancer progression and were 
associated with aggressive tumors. Importantly, an association between BORIS expression and worse 
5- year disease-free survival was found. 
Part III Validation of TAA 
Chapter 4 
 87 
In contradiction to previously published results by Chitale et al. [26], who found MAGE-A3 to be 
present in 20% of 130 analyzed endometrial cancers, we found MAGE-A3 to be present in 90% of the 
analyzed tumor biopsies, overexpressed compared to normal endometrium in only 10 % of cases. 
Chitale et al. performed their analysis based on a TMA applying a threshold for positivity of protein 
expression in > 50% of tumor cells, while we currently analyzed the presence of mRNA encoding for 
MAGE-A3, which allows for the detection of lower levels of TAA expression. 
Sp17 analysis revealed that the transcript is present in 100% of the currently analyzed EMCAR 
samples. The percentage of tumors expressing Sp17 is higher than found by Li et al. [27]. However, Li 
et al. analyzed Sp17 protein expression, which may explain the discrepancy. It may indicate that, 
even though present as mRNA, it may possibly not be translated into a functional protein in the 
majority of cases. Next to its presence in uterine tumors, Sp17 has also been shown in ovarian 
tumors [28, 29]. Sp17 RNA was detected in 83% of ovarian tumors. In addition, Sp17 has been shown 
to be related to chemoresistance in ovarian cancer. 
MUC1 expression was seen in the vast majority of all analyzed samples of both normal endometrium 
and EMCAR. Our results showed a higher percentage of positive tumors with respect to previously 
published data [30]. We did not expect to find great differences between the percentage of biopsies 
expressing MUC1 when comparing normal endometria to EMCAR samples since wild-type MUC1 is 
expressed in normal epithelium, which was also shown by the TMA analysis of normal tissues. MUC1 
as tumor antigen differs from the wild-type by a hypoglycosylation and the antibody directed against 
MUC1 that was used in the current immunohistochemical staining detects both the wild-type and the 
truncated form of MUC1. MUC1 has been described to play a role in tissue invasion of tumor cells 
and the formation of metastases [31-33]. In our data, we show that there is an increase in MUC1 
expression level when comparing normal endometrial samples to primary carcinoma samples as well 
as to recurrent EMCAR and metastatic lesions, further supporting these data. 
Telomerase was chosen as target to evaluate due to their role in tumor cell proliferation and survival. 
hTERT was found to be present in its RNA form in 100% of analyzed EMCAR samples. These results 
are comparable to previously published results, showing its expression in 78% [34] and 92% [35] of 
EMCAR samples. The current mRNA and protein data for hTERT expression do not correspond 
entirely. Although some of the expression levels we found in normal tissue were similar to previously 
described expression levels [36], we found high hTERT expression in brain, kidney, prostate, pancreas 
and liver, and a negative result for testis tissue. This is quite unexpected and in contradiction to the 
results of Hiyama et al., and Kyo et al. [34, 36]. In addition, we found hTERT protein to be higher in 
normal endometrial samples compared to EMCAR and US. This phenomenon cannot be explained 
solely by hTERT expression in proliferative endometrium, as we also found clear expression in 
atrophic endometrium, contradicting previous results [37]. These results led us to suspect that the 
antibody that was used for the immunohistochemistry is likely not ideal. mRNA data showed that 
hTERT is overexpressed in 71% of tumors compared with normal endometrium and we found an up-
regulation in more advanced tumors, supporting the role of hTERT in immortalization and tumor 
development. 
To our knowledge, none of the currently analyzed TAA has been described in uterine sarcoma before, 
with the exception of BORIS, as described above. 
Like in EMCAR, we found expression of the analyzed cancer testis antigens in US samples. BORIS, 
MAGE-A3 and Sp17 were found to be present in the vast majority to all of the analyzed biopsies. In 
US samples, we found MUC1 expression in 43% of tumors. This is not unexpected since MUC1 is an 
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epithelial antigen and sarcomas are of mesenchymal origin. Our current tumor population, however, 
also contains malignant mixed mesodermal tumors, also known as carcinosarcomas, endometrial 
stromal sarcomas, and adenosarcomas, which all contain an epithelial component where MUC1 is 
present. Although the majority of the positive sarcomas are attributable to these two types of 
tumors, we did find other sarcomatous tumors to be positive for MUC1. 
hTERT was expressed both as mRNA transcript and protein in sarcoma samples. In addition, we found 
a significant down-regulation of hTERT in primary and recurrent US in comparison to normal 
endometrium. 
The immunogenicity of an antigen, i.e. the ability to elicit an immune response is a key characteristic 
in order for the antigen to be eligible as a target for immunotherapy. Spontaneous T cell responses 
against several TAA, mainly melanoma-associated antigens, have been described in several tumor 
types, both solid tumors and hematological tumors [38]. To our knowledge, spontaneous T cell 
responses to any of the tested TAA in this study have not been reported to date in either 
endometrial carcinoma or uterine sarcoma. 
We found endogenous T cells reactive to any of the tested TAA in only a minority of patients. 
Moreover, for MAGE-A3, MUC1 and Sp17, comparable levels of TAA-specific T cells were found in 
patients with benign gynecological afflictions. 
Inokuma et al previously showed low level MAGE-A3 T cell responses in healthy females which were 
increased in breast cancer patients [39], which corroborates our finding of spontaneous MAGE-A3 
specific T cells in patients with benign diseases. Our currently analyzed patient population is however 
too small to evaluate whether these responses are increased in endometrial carcinoma or uterine 
sarcoma. 
The presence of pre-existing MUC1 specific T cell immunity in both healthy donors as well as breast 
cancer patients has been described by Gückel et al, which corroborates our findings of MUC1 
reactive T cells in patients with benign diseases [40]. 
Spontaneous Sp17 specific T cells have, to our knowledge, not been described to date, neither in 
healthy donors, nor in cancer patients. The group of Chiriva-Internati, however, have shown that it is 
possible to generate Sp17 specific T cells after 4 rounds of in vitro stimulations with Sp17-pulsed DC 
in patients with ovarian cancer and multiple myeloma and in healthy donors [41-43]. These data 
suggest the presence of low levels of Sp17 specific T cells in the circulation of both healthy donors 
and cancer patients. 
In conclusion, the current data collectively validate the presence of the selected TAA in endometrial 
cancer and indicate the presence of those antigens in uterine sarcoma. In addition, spontaneous T 
cell responses could be detected in patient blood, indicating the immunogenicity of these antigens. 
Based on the combined analysis of TAA expression data and the occurrence of TAA-specific T cells, 
MUC1 shows the best profile for future application in immunotherapeutic studies, along with the 
previously validated survivin (Vanderstraeten A et al., submitted) These data are a further indication 
of their possible applicability in immunotherapeutic regimens to treat uterine cancer patients. 
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Mapping the immunosuppressive environment in uterine tumors: 
implications for immunotherapy 
The major hurdle for cancer vaccines to be effective is posed by tumor immune evasion. Several 
common immune mechanisms and mediators are exploited by tumors to avoid immune destruction. 
In an attempt to shed more light on the immunosuppressive environment in uterine tumors, we 
analyzed the presence of PD-L1, PD-L2, B7-H4, indoleamine 2,3-dioxygenase (IDO), galectin-1, 
galectin-3, arginase-1 activity and myeloid-derived suppressor cell (MDSC) infiltration.  
IDO, PD-L1, PD-L2 and B7-H4 were analyzed by immunohistochemistry. PD-L2 was mostly expressed 
at low levels in these tumors. We found high IDO expression in21 % of endometrial carcinoma 
samples and in 14 % of uterine sarcoma samples. For PD-L1 and B7-H4 we found high expression in 
92 % and 90 % of endometrial cancers respectively and in 100 % and 92 % of the sarcomas. Galectin-
1 and 3 were analyzed in tissue lysates by ELISA, but we did not find an increase in both molecules in 
tumor lysates compared with benign tissues. We detected expression of galectin-3 by fibroblasts, 
immune cells and tumor cells in single-cell tumor suspensions. In addition, we noted a highly 
significant increase in arginase-1 activity in endometrial carcinomas compared with normal 
endometria, which was not the case for uterine sarcomas. Finally, we could demonstrate MDSC 
infiltration in fresh tumor suspensions from uterine tumors. 
These results indicate that the PD-1/PD-L1 interaction and B7-H4 could be possible targets for 
immune intervention in uterine cancer patients as well as mediation of MDSC function. These 
observations are another step toward the implementation of inhibitors of immunosuppression in the 
treatment of uterine cancer patients. 
INTRODUCTION 
Currently used immunotherapeutic regimens often result in immunological responses, such as 
antigen-specific T cell responses, but are all too often not accompanied by a correlating clinical 
response. One of the reasons for the lack of consistent clinical responses is thought to be attributable 
to immune escape exerted by the tumor. Various mechanisms of immune evasion by tumors have 
been described, but the picture in uterine tumors is still enigmatic. By increasing our knowledge on 
the involvement of these immune escape pathways in uterine tumors, we aim to identify new 
treatment options for this cancer type for which not much progress has been made in recent years. 
One of the possible immune escape mechanisms are the so-called immune checkpoints. Immune 
checkpoints, some of which are briefly outlined below, comprise an array of pathways which the 
immune system occupies to maintain self-tolerance. Besides their natural function in the prevention 
of among others autoimmunity, these molecules also play an important role in antitumor immunity, 
more specifically in the prevention/blockage thereof. The two checkpoints most focused on are 
CTLA-4 and PD-1. Several inhibitors of these molecules are currently in clinical development and 
being analyzed in both the preclinical setting as well as in clinical trials, with the aim of improving 
treatment outcome and survival in cancer patients [1-4]. 
PD-L1 and PD-L2, both members of the B7-CD28 family, are ligands for the death receptor 
Programmed Death Receptor 1 (PD-1), which play an important role in the central T cell tolerance 
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during T cell development [5]. PD-L1 is expressed in a variety of tissues, such as placenta, heart and 
spleen cells as well as islets and leukocytes [5, 6]. In tumors, PD-L1 expression has been abundantly 
detected and is often associated with a poor prognosis [7-9]. The expression pattern of PD-L2 on the 
other hand is much more restricted. It is expressed mainly on dendritic cells and macrophages [6], 
but expression can be induced on several other immune and non-immune cells depending on 
environmental stimuli [10]. PD-L2 expression was shown in different tumor types, although mostly in 
a minority of patients [11-13]. PD-1/PD-L1 interactions have been shown to inhibit antigen-
experienced T cells in the periphery, thereby protecting normal tissues from immune destruction [3]. 
PD-L2 on the other hand is regulated by Th2 cytokines and may itself possibly be involved in the 
modulation of Th2 responses [10]. 
B7-H4 mRNA is abundantly detected in human somatic tissues, but protein expression on tissues is 
limited [14]. On the contrary, B7-H4 protein expression has been found in many different types of 
human tumors [14] and soluble B7-H4 can be detected in the serum of cancer patients [15, 16]. B7-
H4 has been shown to play a role in the inhibition of activation, proliferation and clonal expansion of 
both CD4
+
 and CD8
+
 T cells [14, 17]. 
Indoleamine 2,3-dioxygenase (IDO) is an intracellular enzyme mediating the rate-limiting step of 
tryptophan catabolism along the kynurenine pathway. IDO mediates “metabolic immune regulation” 
by depriving T cells of tryptophan and by the production of toxic metabolites, both leading to 
inhibition of T cell proliferation and induction of T cell death. Furthermore, IDO can convert naïve T 
cells into regulatory T cells (Treg) and enhances their activity [18]. IDO expression has been observed 
in a variety of cancers, and high IDO expression is associated with dismal prognosis [19].  
Another family with important immunoregulatory functions is the galectin family. The current 
manuscript is focused on galectin-1 and galectin-3. Galectin-1 expression by tumors is associated 
with poor prognosis and the formation of metastasis through modulation of among others cell 
migration, adhesion and angiogenesis [20]. Besides its direct effects on tumor progression, galectin-1 
also plays a role in tumor immune regulation by creating a bias toward a Th2 profile and activation of 
tolerogenic DC and IL-10 producing regulatory (Tr1) cells. Galectin-3 is involved in the differentiation 
and proliferation of several immune cells. It activates both lymphoid and myeloid cells, such as T 
cells, mast cells, monocytes and neutrophils [20]. Galectin-3 is also a negative regulator of immune 
cell function by controlling the anergic state of T cells [21]. Galectin-3 is capable of forming lattices 
with the T cell receptor complex, thereby intervening with T cell receptor signaling and subsequent T 
cell activation [20].  
Other key players in tumor immune suppression are certain types of immune cells, such as Treg or 
myeloid-derived suppressor cells (MDSC). The latter are a heterogeneous population of immature 
myeloid cells with monocytic and/or granulocytic features. MDSC exert their suppressive function by 
depleting L-arginine from the tumor micro-environment via the production of arginase-1. The 
depletion of L-arginine subsequently causes a down-regulation of the ζ-chain of the T cell receptor, 
[22, 23] as well as cell cycle arrest of T cells [24]. Furthermore, MDSC produce reactive oxygen 
species (ROS) and nitric oxide (NO) radicals, which also capable of suppressing T cell function [25]. 
MDSC have been implicated in various tumors and are correlated with poor prognosis [26, 27]. MDSC 
levels might serve as a predictive marker for clinical outcome of oncologic treatment [25, 28].  
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We have used an immunohistochemical approach to validate the presence of IDO in uterine tumors, 
as well as to investigate the presence of PD-L1/PD-L2, to our knowledge not described in this type of 
tumor before, and B7-H4. 
In addition, we have analyzed the expression of galectin-1 and 3 in uterine tissue samples by ELISA 
and confirmed galectin-3 expression on cellular subtypes in uterine tumor specimens by flow 
cytometry. The activity of arginase-1 in uterine tissue samples was determined, and we further 
provided evidence of MDSC infiltration in uterine tumor specimens by multi-parametric flow 
cytometry. 
MATERIALS AND METHODS 
Biopsy material 
All biopsies were collected at the University Hospital Leuven, campus Gasthuisberg, from patients 
undergoing surgery at the Department of Gynecologic Oncology. When possible, multiple blocks 
were used from the same tumor to a maximum of three tumor blocks per tumor. The latter was done 
in order to obtain an idea of expression across the entire tumor. Samples of normal endometrium or 
myometrium were collected from patients undergoing surgery for benign afflictions.  
The collection of all human samples was approved by the Institutional Review Board of the University 
Hospitals Leuven and written informed consent was obtained from all patients. 
Immunohistochemical staining 
For all stainings 4.0 µm formalin- or Bouin-fixed paraffin-embedded tissue slides were used. All slides 
were deparaffinized and rehydrated prior to staining. The general steps for each of the staining 
procedures are similar comprising the consecutive steps of endogenous alkaline phosphatase or 
peroxidase inhibition using 0.2N HCl or 0.5% H2O2 in methanol, respectively, followed by heat-
induced epitope retrieval (HIER), blocking of slides to prevent aspecific antibody binding, and 
application of the appropriate antibodies and visualization methods. The specifications of these steps 
for each of the staining procedures are summarized in Table 1. 
Table 1: Experimental conditions of IHC procedures. 
Target IDO PD-L1 PD-L2 B7-H4 
HIER 
Buffer Tris-HCl + 1mM EDTA Tris-HCl + 1mM EDTA Tris-HCl + 1mM EDTA citrate 
Time 2h 1.5h 2h 1h 
Temperature 90°C 90°C 90°C 90°C 
Primary antibody 
Antibody Ms anti Hu IDO 
(Chemicon) 
Rb anti Hu PD-L1 
(Abcam) 
Ms anti Hu PD-L2  
(R&D Systems) 
Rb anti Hu B7-H4 
(Epitomics) 
Final concentration 2 µg/ml Ready to use 0,8 µg/ml 1/600 dilution 
Secondary antibody Go anti Ms IgG-Po + 
APAAP complex 
Envision system anti 
Rb-HRP 
Envision system anti 
Ms-HRP 
Envision system anti 
Rb-HRP 
Visualization NBT DAB DAB DAB 
Counterstaining hematoxylin hematoxylin hematoxylin hematoxylin 
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Scoring system 
Before scoring the tissue slides, tumor tissue was identified using a conventionally stained HE tissue 
slide of the same tumor. All slides were scored with a scoring system, partially adopted from Ino et 
al. [29]. All slides were given two separate scores. One for the percentage of total tumor cells 
showing expression, divided in three different categories: 1-25; 25-50; >50 %. Each of these 
parameters was subsequently given a score of 1, 2 and 3 respectively. The second score was given 
according to the intensity of the expression: 1 (weak), 2 (moderate) and 3 (strong). Depending on the 
sum of the 2 scores, a final value was given. A sum of 0-1 = final score 0; 2-3 = 1; 4-5 = 2 and 6 = 3. 
Based on these scores, a discrimination between biopsies with high and low expression levels was 
made, adopted from De Jong et al. [30]. Biopsies with a total score of 0-1 are classified as low score 
(lo), and biopsies with a total score of 2-3 are classified as high score (hi). The intensity scores which 
match the visual aspect of the staining were determined for each molecule separately. 
Tumor lysate preparation 
150 - 200 mg of snap-frozen tissue samples were lysed by mechanical friction using magnetic stones 
after adding lysis buffer consisting of 250 mM Tris HCl, 750 mM NaCl, 0.5 % SDS, 2.5 % deoxycholic 
acid, 5 % Igepal and 0.01 % protease inhibitor cocktail (Mammalian Cell Lysis Kit; Sigma-Aldrich). 
After incubating the minced tissue material for 30 min at 4 °C, the lysed material was purified from 
debris through centrifugation. Protein content was determined using the Pierce BCA Protein Assay 
(Thermo Scientific) according to manufacturer’s instructions. 
Galectin-1 ELISA 
Ninety-six well plates were coated overnight with goat anti-human galectin-1 (R&D Systems, 2 µg/ml 
in PBS). After blocking the wells with 1% BSA in PBS for 1 h at room temperature (RT), standards 
(recombinant galectin-1; range: 25-0.39 ng/ml) and samples were added for 2 h at RT. Analyses were 
performed on tumor lysates at a concentration of 5 mg/ml. Detection was done using a combination 
of goat anti-human IgG (R&D systems, 200 ng/ml) and HRP-conjugated streptavidin, followed by 
incubation with TMB substrate. The reaction was stopped using 2 M H2SO4 and OD was measured at 
450 nm, with 540 nm as reference wavelength. 
Galectin-3 ELISA 
Galectin-3 detection was performed using a commercially available ELISA (R&D Systems) with minor 
modifications. For coating, mouse anti-human galectin-3(2 µg/ml) was used. The galectin-3 standard 
was used within the range of 4000-62.5 pg/ml. Detection was performed using mouse anti-human 
IgG in combination with HRP-conjugated streptavidin. All other steps are identical to galectin-1 
detection. 
Arginase-1 activity assay 
Measurement of arginase-1 activity, through determination of the urea content in tumor lysates (at a 
concentration of 5 mg/ml) was performed using the QuantiChrom™ Arginase Assay Kit (Bioassay 
Systems) following the manufacturer’s protocol. 
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Preparation of single-cell suspensions from tumor biopsies 
Single-cell suspensions of fresh tumor biopsies were prepared by a combination of mechanical 
dissociation and enzymatic digestion using the Human Tumor Dissociation Kit (Miltenyi Biotec) and 
the GentleMACS dissociator (Miltenyi Biotec). Briefly, the protocol for soft tumors was followed, 
according to manufacturer’s instructions. The cell suspensions were purified on a 40 µm cell strainer 
and counted with Türck’s solution. Single-cell suspensions from tumor biopsies were either used 
fresh or after cryopreservation for subsequent flow cytometric analysis. 
Flow cytometric analysis 
Cell suspensions were first stained with a fixable viability dye (Fixable Viability Dye eFluor 506, 
eBioscience) for discrimination of live and dead cells. After washing with PBS, Fc receptor blocking 
was performed by adding a 10 % normal goat serum (Sigma-Aldrich) solution in PBS/0.5 % BSA. For 
single-cell tumor suspensions, red blood cell lysis was performed after the membrane staining using 
1x PharmLyse (BD Pharmingen), according to manufacturer’s instructions. 
Galectin-3 expression by primary tumor cell lines was evaluated by staining with galectin-3-PE 
(BioLegend) or the appropriate isotype control, either on the membrane or intracellularly after 
fixation/permeabilization using the FoxP3 Staining Buffer Set (eBioscience). Acquisition was 
performed with a FACS Canto II flow cytometer using BD FACS DIVA software, and 3 x 10
4
 cells were 
acquired per sample. Data analysis was done using BD FACS DIVA software. Cells were gated on 
FSC/SSC characteristics, and analyzed for the expression of membranous or intracellular galectin-3. 
For the analysis of galectin-3 expression by different cell types, we used the following antibody 
cocktail: CD90-FITC (BioLegend), galectin-3-PE (BioLegend), EpCAM-PerCP-Cy5.5 (BioLegend) and 
CD45-APC-H7 (BD Pharmingen). Intracellular expression of galectin-3 was assessed after 
fixation/permeabilization with the FoxP3 Staining Buffer Set (eBioscience). Acquisition was 
performed with a FACS Canto II flow cytometer using BD FACS DIVA software, and between 2.5 x 10
4
 
and 1 x 10
6
 cells were acquired in the live gate per sample. Data analysis was done using BD FACS 
DIVA software. Cells were gated as follows: first, dead cells were gated out using the viability dye, 
and cells were gated based on FSC/SSC characteristics. Next, CD90
+
 fibroblasts, CD45
+
 immune cells 
and EpCAM
+
 tumor cells (for EMCAR), or CD45
-
 CD90
-
 tumor cells (for US) were gated and each 
analyzed for the expression of membranous or intracellular galectin-3. Appropriate isotype controls 
were included to set the gates for the positive and negative populations. 
For enumeration of MDSC, the following antibody cocktail was used: CD45-FITC (BioLegend), CD11b-
PE (BioLegend), CD14-PerCP-Cy5.5 (BD Pharmingen), CD3-PE-Cy7 (BioLegend), CD19-PE-Cy7 
(BioLegend), CD56-PE-Cy7 (BioLegend), CD15-APC (BioLegend), HLA-DR-APC-H7 (BD Pharmingen) and 
CD33-V450 (BD Horizon). Analysis of arginase-1 expression was done by replacing CD45-FITC with 
Arginase-1-fluorescein (R&D Systems) in the above-mentioned MDSC cocktail. For assessment of 
arginase-1 expression, cells were first stained for membrane markers, subsequently fixed and 
permeabilized using the FoxP3 Staining Buffer Set (eBioscience) and stained with arginase-1-
fluorescein (R&D Systems). Acquisition was done as mentioned above for assessment of galectin-3 on 
tumor subpopulations. Data analysis was done using BD FACS DIVA software. The following gating 
strategy was used for enumeration of MDSC: first, dead cells were gated out using the viability dye, 
and cells were gated based on FSC/SSC characteristics, followed by CD45 positivity. Next, a gate was 
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defined for lineage-negative (CD3-, CD19- and CD56-negative), HLA-DR
low/-
 cells. Within this 
population, CD11b
+
 CD14
-
 granulocytic MDSC and CD11b
+
 CD14
+
 monocytic MDSC were specified. On 
both cell types, the expression of CD15 and CD33 was documented. Arginase-1 expression by MDSC, 
was analyzed as follows: dead cells were gated out using the viability dye, and cells were gated based 
on FSC/SSC characteristics. Next, the lineage-negative (CD3-, CD19- and CD56-negative), HLA-DR
low/-
 
cell population was identified. Within this population, CD11b
+
 CD14
- 
granulocytic MDSC and CD11b
+
 
CD14
+
 monocytic MDSC were defined, and the expression of arginase-1 on both subtypes was 
analyzed. Proper isotype controls were used to set the gates for the positive and negative 
populations. 
Statistics 
Statistical analyses were done using the GraphPad Prism 5.0 software. All scoring data were analyzed 
using the nonparametric Kruskal-Wallis test, followed by the Dunn’s multiple comparison test. 
Differences in proportion were calculated using the Fischer exact test. Multiple group comparisons 
were performed using either ANOVA or Student’s t-test. Comparison of survival curves was 
performed using the Log-Rank (Mantel-Cox) test. 
RESULTS 
IDO expression in uterine tumors 
Patient characteristics of the IHC analysis of IDO, PD-L1, PD-L2 and B7-H4 are summarized in Table 2. 
IDO is present in 57 % of normal endometria (Table 3). When looking at the carcinomatous tumors, 
we found IDO to be present in only 36 % of the primary endometrial cancers (EMCAR). It is slightly, 
yet not significantly, increased in the metastatic locations (44 %). Sixty percent of the currently 
analyzed recurrent EMCAR samples showed IDO expression. The enzyme is present in only a minority 
of sarcoma samples, and the expression level is generally low in this tumor type (Fig. 1). In 
comparison with normal endometrium, both the percentage of positive tumors (p < 0.01) and the 
expression level is significantly lower in primary US (p < 0.01) and recurrent US (p < 0.05). IDO is 
present in a significantly lower proportion of metastatic US lesions compared to normal 
endometrium (p < 0.05) and at a lower expression level (p < 0.05).  
The expression pattern of IDO was mainly cytoplasmic. In the EMCAR biopsies, in some tumors, clear 
apical expression could be detected (Fig. 2). In addition, IDO expressing infiltrating cells could be 
detected in the tumor periphery of some of the analyzed tumors, both carcinoma and sarcoma. 
Twenty-one percent of primary EMCAR samples were IDO
hi
, while for US, 14 % of primary tumors 
were IDO
hi
, indicating that IDO blockade could be a useful strategy in a minority of patients. 
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Figure 1: IDO expression levels in uterine tumors. A. Percentage of tumors/normal endometrium positive for IDO. B. Overall 
expression levels between groups. Statistical analysis was performed using the Kruskal-Wallis test in combination with the 
Dunn’s Multiple Comparison Test. 
 
 
Figure 2: IDO expression in endometrial biopsies. A. normal endometrium with moderate (intensity score 2) expression 
levels of IDO (40x enlarged). B. normal endometrium with clear apical IDO expression at high expression level (intensity 
score 3, 40x enlarged). C. endometrial carcinoma biopsy with numerous infiltrating cells in the tumor stroma (black arrows, 
10x enlarged). 
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Table 2: Clinical characteristics of biopsies used for IHC detection. 
Patient characteristics EMCAR patients 
Number (%) 
US patients 
Number (%) 
Total  48 47 
Age (years)  
Mean 69.18 60.7 
Range 43-86 26-85 
Type 
Primary 27 (55.1%) 25 (53.2%) 
Recurrence 11 (22.9%) 10 (21.3%) 
Metastasis 7 (14.3%) 10 (21.3%) 
Primary + metastasis 3 (6.1%) 1 (2.1%) 
Metastasis + recurrence 0 (0.0%) 1 (2.1%) 
FIGO stage
1
 
I 10 (33.3%) N/A 
II 4 (13.3%) N/A 
III 7 (23.3%) N/A 
IV 9 (30%) N/A 
Differentiation grade 
Low 7 (14.3%) N/A 
Moderate 3 (6.1%) N/A 
High 29 (59.2%) N/A 
unknown 9 (18,. 5%) N/A 
Histologic subtype 
Endometrioid 16 (32.7%) N/A 
Clear cell 8 (16.3%) N/A 
Serous papillary 20 (40.8%) N/A 
Mixed 2 (4.16%) N/A 
Carcinosarcoma
2 
2 (4.08%) 18 (38.3%) 
Leiomyosarcoma N/A 12 (25.5%) 
Rhabdomyosarcoma N/A 6 (12.8%) 
Endometrial stromal sarcoma N/A 7 (14.9%) 
Adenosarcoma N/A 4 (8.5%) 
1 
FIGO stage only applicable to primary tumors. 
2 
Only contained carcinomatous tumor portion. 
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PD-L1 expression 
The expression pattern for PD-L1 was cytoplasmic in all of the analyzed biopsies (Fig. 3).Overall, PD-
L1 is expressed in the vast majority of the currently tested samples (Fig. 4A). We found PD-L1 
expression in 81 % of normal endometria. In 4/16 of the analyzed normal endometria, PD-L1
+
 cells 
infiltrating the endometrium were seen. PD-L1 expression in tumors was found in 70 to 80 % of the 
EMCAR samples and in all of the US samples. 
 
Figure 3: PD-L1 expression in endometrial biopsies. A. endometrial carcinoma biopsy showing weak expression (intensity 
score 1, 20x enlarged). B. endometrial carcinoma expressing moderate (intensity score 2) PD-L1 levels (20x enlarged). C. 
high PD-L1 expression levels in uterine sarcoma (20x enlarged). High expression can clearly be seen on the cell membrane 
(top of picture). 
The number of analyzed samples and the corresponding percentages for each group are summarized 
in Table 3. When analyzing the expression level, we found an up-regulation in primary sarcomas in 
comparison with normal endometrium (p < 0.01). Overall, the expression level of PD-L1 was 
moderate to high. Of the patients with primary EMCAR, 72 % showed high PD-L1 expression, and for 
US, all patients were PD-L1
hi
 which shows that interference with the PD-1/PD-L1 axis could represent 
a promising new treatment option for uterine cancer patients. For EMCAR, we noticed a trend 
toward improved survival for patients with PD-L1
hi
 tumors (p = 0.084, data not shown). 
  
Part IV Immunosuppresssion 
Chapter 5 
 106 
Table 3: Immune checkpoint and IDO expression in different sample types. 
Sample IDO PD-L1 PD-L2 B7-H4 
 
N 
% 
positive 
N 
% 
positive 
N 
% 
positive 
N 
% 
positive 
nl EM 14 57% 16 81% 15 47% 15 100% 
pr 
EMCAR 
28 36% 29 83% 30 40% 30 100% 
rec 
EMCAR 
11 60% 9 67% 5 60% 11 100% 
meta 
EMCAR 
9 44% 9 100% 9 44% 10 90% 
pr US 22 14% 21 100% 19 32% 26 100% 
rec US 13 15% 11 100% 4 0% 13 92% 
meta US 13 15% 10 100% 11 27% 13 100% 
 
PD-L2 expression 
The expression of PD-L2 was different from the expression of PD-L1 (Table 3). We found that 47% of 
normal endometria expressed PD-L2. In EMCAR in general, the percentage of positive tumor samples 
varied from 40 to 70%, while in the US group, this ranged from 0 to 32 % positive tumors. In general, 
the intensity scores for all the biopsies were low to moderate, and we did not find any differences in 
expression levels between any of the analyzed groups (Fig. 4B). Next to intracytoplasmic expression 
in tumor cells, we found the presence of PD-L2
+
 cells, possibly reflecting immune cell infiltrates in 
10/30 (33 %) analyzed primary EMCAR biopsies as well as in 2/9 (22 %) of the included metastatic 
EMCAR lesions. The infiltrating cells were found intratumorally, in the tumoral stroma and in the 
tumor periphery (Fig. 5). 
Overall in primary tumors, 30 % of EMCAR patients and 16 % of US patients showed high PD-L2 
expression, thereby demonstrating the potential of PD-L2 blockade in a limited proportion of uterine 
cancer patients. 
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Figure 4: Immune checkpoints in uterine cancer. Left panels: percentage of positive tumors/normal endometrium. Right 
panels: Overall expression levels between groups. A. IHC analysis of PD-L1 expression. B. IHC analysis of PD-L2 expression. 
C. IHC analysis of B7-H4 expression. Statistical analysis was performed using the Kruskal-Wallis test in combination with the 
Dunn’s Multiple Comparison Test. 
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Figure 5: PD-L2 expression in endometrial biopsies. Endometrial carcinoma samples showing A. weak expression (20x 
enlarged) and B. moderate expression level (10x enlarged) of PD-L2. C. representative biopsy showing the presence of PD-
L2 positive cells infiltrating the tumor periphery, possibly reflecting the presence of immune cells (20x enlarged). 
 
 
Figure 6: B7-H4 expression in endometrial biopsies. Endometrial carcinoma biopsies showing A. moderate B7-H4 expression 
(20x enlarged) and B. strong expression level (20x enlarged) with in addition very clear cytoplasmic and circumferential B7-
H4 presence. 
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B7-H4 expression 
B7-H4 is expressed in the vast majority of the currently analyzed biopsies (Table 3). In-depth analysis 
of the expression levels revealed no differences between any of the groups (Fig. 4C). B7-H4 is 
expressed exclusively in the cytoplasm(Fig. 6). Due to the visual aspects of the staining, 
discrimination of infiltrating cells was not possible. 
The high expression levels of B7-H4 in both primary EMCAR (90 % of samples) and primary US 
(92 % of samples) make this an attractive candidate for uterine cancer therapy. 
Galectin-1 and galectin-3 levels 
For galectin-3, it was determined whether it is expressed on EMCAR and US cell lines (primary cell 
lines generated in our lab, kind gift from Dr. Coenegrachts) by flow cytometric analysis, and limited 
galectin-3 expression was detected on the plasma membrane, but nearly complete intracellular 
expression was found in these cell lines (Table 4). 
Table 4: Galectin-3 expression in primary cancer cell lines. 
Cell line Histology Grade FIGO stage 
% positive cells 
gal-3-M
1 
gal-3-C
2 
PC-EM-002 Endometrioid 2 II 0.54 85 
PC-EM-005 Endometrioid 3 II 3 98 
PC-EM-012 Endometrioid 2 IV 8 60 
PC-EM-018 Mixed 3 Ia 0.81 98 
PC-EM-033 Endometrioid 3 Ia 1 99 
PC-EM-046 Endometrioid 3 Ib 5 80 
PC-EM-076 Endometrioid 2 Ia 1,2 99,8 
PC-SAR-25 Embryonal 
rhabdomyosarcoma 
NA unknown 0,3 99,1 
1 
gal-3-M: membranous detection, 
2 
gal-3-C: cytoplasmic detection 
Galectin-1 and 3 presence in tumor tissue lysates was tested by ELISA in 29 EMCAR patients, 30 US 
patients, 21 normal/benign endometria and 18 normal myometria. The characteristics of the patients 
used for this study are summarized in Table 5. We found that galectin-1 is present in all of the 
different analyzed tissues, without significant differences between the entire sample groups (Fig. 7A). 
When subdividing the US group, a significant galectin-1 up-regulation was found in leiomyosarcomas 
compared to myometrium (p < 0.01), carcinosarcomas (p < 0.05) and other US subtypes (p < 0.05). 
For galectin-3 we found a significantly higher intratumoral level in EMCAR samples compared with US 
samples (p < 0.05), shown in Fig. 7B. 
To further assess which specific cell type of the tumor expresses galectins, their expression on 
fibroblasts, immune cells and tumor cells was determined in single-cell suspensions from fresh tumor 
biopsies (tumor characteristics shown in Table 6). Considerable variation in the cellular composition 
of the single-cell tumor suspensions: 1.24 – 16.16% fibroblasts, 15.19 – 75.07% immune cells and 
6.73 – 80.21% tumor cells (data not shown) was found. When gating on these different cell 
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populations, a slightly higher percentage of membranous galectin-3 positivity on tumor cells versus 
fibroblasts and immune cells was found, although this did not reach statistical significance, shown in 
Fig. 7C. With regard to intracellular galectin-3 expression, the majority of fibroblasts, immune cells 
and tumor cells expressed galectin-3. Intracellular galectin-3 expression was significantly higher in 
tumor cells versus fibroblasts (p < 0.05). 
Table 5: Clinical characteristics of tissue lysates used for galectin detection. 
Patient characteristics EMCAR patients US patients 
Total  29 30 
Age (years) 
Mean 67.1 61 
Range 48-86 29-83 
FIGO stage (2009) 
I 9 (31.0%)  
II 8 (27.6%)  
III 8 (27.6%)  
IV 4 (13.8%)  
Differentiation grade (primary tumor) 
Low 10 (34.5%)  
Moderate 6 (20.7%)  
High 13 (44.8%)  
Histologic subtype (primary tumor) 
Endometrioid 22 (75.9%)  
Clear cell 3 (10,35%)  
Serous papillary 3 (10.35%)  
Mixed 1 (3.4%)  
Carcinosarcoma  10 (33.3%) 
Leiomyosarcoma  8 (26.6%) 
Rhabdomyosarcoma  3 (10%) 
Endometrial stromal sarcoma  7 (23.3%) 
Unknown  1 (3.3%) 
Ewing sarcoma  1 (3.3%) 
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Figure 7: Galectin expression in patient plasma and uterine tissue samples. A. galectin-1 expression in uterine tissue. Left 
panel: overall galectin-1 expression. Right panel: galectin-1 expression in myometrium versus sarcoma histological 
subtypes. B. Galectin-3 expression in uterine tissue. C. Flow cytometric detection of galectin-3 on different cell populations 
within single-cell tumor suspensions. Left panel: membranous galectin-3 expression. Right panel intracellular galectin-3 
expression. Groups were analyzed statistically by one-way ANOVA followed by Tukey’s Multiple Comparison Test or the by 
Kruskal-Wallis test followed by the Dunn’s Multiple Comparison Test, depending on Gaussian distribution. 
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Table 6: Characteristics of tumors used for flow cytometric assessment of galectin-3 
ID Type FIGO stage Histology Grade Time point 
13 EMCAR IIIc serous 3 recurrence 
17 US IV leiomyosarcoma 3 primary 
18 EMCAR Ia endometrioid 1 primary 
19 EMCAR Ia endometrioid 1 primary 
22 US Ib leiomyosarcoma 3 recurrence 
24 EMCAR Ia endometrioid 2 primary 
25 EMCAR II endometrioid 1/2 primary 
26 EMCAR Ia endometrioid 1 primary 
27 EMCAR Ib endometrioid 3 primary 
 
Arginase-1 activity and MDSC infiltration 
Arginase-1 activity was measured in tissue lysates of 25 normal endometria, 39 EMCAR, 27 US and 18 
normal myometria. Clinical parameters of all patient samples are depicted in Table 7. Activity was 
significantly up-regulated in EMCAR samples compared with normal endometria (p < 0.0001). No 
difference in activity was found between normal myometria and US samples (Fig 8A). These data 
suggested a possible implication of MDSC in endometrial carcinoma and inspired us to explore 
whether MDSC infiltration can be found in EMCAR and US tumors. Therefore, single-cell suspensions 
from fresh tumor biopsies were prepared (tumor characteristics shown in Supplemental Table 6), and 
flow cytometric analysis to detect MDSC and assess their arginase-1 expression was performed. 
MDSC infiltration was indeed detected in tumor specimens, and these cells were mainly of 
granulocytic phenotype (lin
-
 HLA-DR
lo/-
 CD11b
+
 CD14
-
; Fig 8B). Tumors contained significantly more 
granulocytic compared with monocytic MDSC (p=0.0124). However, both MDSC subtypes expressed 
similar arginase-1 levels (Fig. 8C). The majority of the granulocytic MDSC were CD15
+
, with 
approximately half of them co-expressing CD33. The monocytic MDSC were mainly CD15
+
 CD33
+
 
(approximately 60 %), with an additional 24 % of CD15
+
 CD33
-
 cells (data not shown). 
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Figure 8: Arginase-1 activity in uterine tissues and MDSC infiltration in uterine tumors. A. Arginase-1 activity in uterine 
tissues. B. MDSC infiltration in uterine tumors. C. Arginase-1 expression by MDSC infiltrating uterine tumors. Data were 
analyzed statistically using the unpaired t-test or the Mann Whitney test (nl-EM vs EMCAR or nl MYOM vs US in A), 
depending on Gaussian distribution. 
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Table 7: Clinical characteristics of tissue lysates used for arginase-1 activity detection. 
Characteristics EMCAR patients US patients 
Total  39 27 
Age (years) 
Mean 67.2 61 
Range 36-86 29-83 
FIGO stage 
I 10 (25.64%)  
II 10 (25.64%)  
III 9 (23.08%)  
IV 10 (25.64%)  
Differentiation grade  
Low 8 (20.51%)  
Moderate 4 (10.26%)  
High 17 (43.59%)  
Unknown 10 (25.64%)  
Histologic subtype (primary tumor) 
Endometrioid 20 (51.3%)  
Clear cell 8 (12.8%)  
Serous papillary 11 (28.2%)  
Mixed 3 (7.7%)  
Carcinosarcoma  9 (33.3%) 
Leiomyosarcoma  8 (29.6%) 
Rhabdomyosarcoma  2 (7.4%) 
Endometrial stromal sarcoma  6 (22.2%) 
Unknown  1 (3.75%) 
Ewing sarcoma  1 (3.75%) 
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Table 8: Characteristics of tumors used for MDSC infiltration and arginase-1 expression by MDSC. 
ID Type FIGO 
stage 
Histology Grade Time point MDSC 
frequency 
MDSC 
arginase-1 
5 EMCAR Ia endometrioid 1 primary yes no 
9 EMCAR IIIa mixed serous-clear cell 3 primary yes no 
10 EMCAR Ib endometrioid 1 primary yes yes 
11 EMCAR Ia endometrioid 1 primary yes yes 
14 EMCAR Ib-II endometrioid 3 primary yes yes 
17 US IV leiomyosarcoma 3 primary no yes 
18 EMCAR Ia endometrioid 1 primary no yes 
19 EMCAR Ia endometrioid 1 primary no yes 
22 US Ib leiomyosarcoma 3 recurrence no yes 
24 EMCAR Ia endometrioid 2 primary yes yes 
25 EMCAR II endometrioid 1/2 primary yes yes 
26 EMCAR Ia endometrioid 1 primary yes yes 
27 EMCAR Ib endometrioid 3 primary yes yes 
28 US IV myxoid  primary yes yes 
 
DISCUSSION 
In the current research, we have evaluated the expression of PD-L1, PD-L2, B7-H4, IDO, galectin-1 
and galectin-3 in uterine tumors and documented the arginase-1 activity and MDSC infiltration in 
these tumors. To our knowledge, this is the first paper to describe the presence of PD-L1 and PD-L2 
in endometrial cancer as such, and we are not aware that any of the currently described molecules 
have been described in uterine sarcoma so far, except for possibly IDO [31], galectin-1 [32] and 
galectin-3 [32-34]. 
Both PD-1 ligands have previously been implicated in different types of cancer, although more is 
known about PD-L1 expression in several types of tumors, such as melanoma, brain tumors, lung 
cancer, urothelial cancer and pancreatic cancer [7, 35-38]. In soft tissue sarcomas in general, one 
study found expression of PD-L1 in 65 % of cases [9]. To date, little information is available on the 
expression of both ligands in gynecological tumors in general. Our data on PD-L1 expression show 
that it is expressed in the vast majority of both normal endometrial samples and of endometrial 
tumors, with no difference in proportion or expression level between any of the analyzed groups. In 
contrast to what we anticipated, we observed a trend toward improved overall survival in patients 
with PD-L1
hi
 tumors. However, this phenomenon has previously been described in melanoma, merkel 
cell carcinoma and MMR-proficient colorectal carcinoma [39-41]. Up-regulation of PD-L1 has been 
shown to be driven by IFNγ and CD8
+
 T cells. Hence, PD-L1 expression could be viewed as a result of 
an ongoing endogenous anti-tumor immune response and thus may represent a negative feedback 
loop dependent on an infiltrating immune response [42, 43].  
PD-L2 has long been thought to be present only on dendritic cells and macrophages. However, more 
evidence is beginning to emerge of PD-L2 presence on somatic tissues and in cancer as well. It has, 
for example, been shown to be present in cancer-associated fibroblasts (Nazareth et al. in [10]) as 
well as in esophageal [13] and hepatocellular carcinoma [11]. Most of the currently analyzed biopsies 
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were negative for PD-L2, except in the recurrent carcinoma group. Similar to our results of low 
expression in the majority of tumors, a study in ovarian cancer has shown that the majority of the 
tumors are negative for PD-L2 [12]. Both ligands have also been investigated in cervical cancer [44], 
both being present in only a minority of the investigated samples.  
B7-H4 has been shown in different tumors, summarized by He et al. [14]. Quite some data are 
available on its presence in breast cancer and ovarian cancer. It has been shown to be present 
intracellularly in ovarian tumor cells and on tumor-associated macrophages (TAM) in these tumors 
[45, 46]. B7-H4 expression levels were correlated with patient outcome [45]. Two studies report on 
B7-H4 expression in endometrial cancer [47, 48]. Both studies show B7-H4 expression in normal 
endometrium, and B7-H4 staining was shown to increase from normal to malignant endometrial 
glands. Our results are somewhat contradictory since we found high B7-H4 levels in almost all of the 
analyzed tissue samples in both benign and malignant endometrial tissues as well as in US samples. 
This observation might be due to the use of different antibodies, staining protocols and/or scoring 
protocols.  
The immune inhibitory enzyme IDO has also been shown to play an important role in cancer-induced 
immunosuppression by depriving T cells of tryptophan and thus preventing their activation [49]. 
Uyttenhove et al. described IDO in 25 different tumors [31]. IDO has previously been detected in 
ovarian [31, 50] as well as endometrial tumors [29-31, 51, 52]. We have found high IDO expression in 
21 % of primary endometrial tumors, which is in line with data reported by De Jong et al. (18,1 %), 
but lower than the results obtained by Ino et al. (46-49 %). We have also found an increased IDO 
expression level in recurrent EMCAR compared with primary EMCAR, pointing to increased 
immunosuppression in recurrent tumors. We found IDO expression only in a minority of US, in 
corroboration with Uyttenhove et al., who found IDO expression in 20% of sarcomas. However, the 
exact subtype of sarcoma is not specified any further [31]. Except for PD-L1, no correlation between 
high and low expression and patient overall survival was found (data not shown). However, the 
currently analyzed sample population is too small to perform sound survival analyses. Based on the 
current data, no definitive conclusion can be made regarding patient survival. When analyzing the 
current sample population, no differences were found regarding FIGO stage, histological subtype or 
histological grade, except for a significantly lower expression level of IDO in grade 3 tumors 
compared to grade 1 (p < 0.05; data not shown). In addition, we could not find a difference in 
expression level between type I and type II EMCAR for any of the analyzed mediators. We do, 
however, acknowledge that the current sample sizes are too small to perform adequate statistical 
analyses regarding sub-parameters, which may bias or mask possible differences in expression levels. 
Galectin-1 and galectin-3 have both been described in tumors. Galectin-1 and galectin-3 are both up-
regulated in among others bladder carcinoma [53, 54], head and neck squamous cell carcinoma 
(HNSCC) [55] and ovarian cancer [56, 57]. Several studies have been published on galectins in 
endometrial cancer, with contradictory results. Galectin-1, but not galectin-3, has been shown to be 
increased in EMCAR compared with normal endometrium [58]. Similarly, galectin-1 was found to be 
increased in endometrioid EMCAR from well differentiated to undifferentiated carcinoma [59]. 
Contradictory to the data by Van den Brule et al. [58], Brustmann et al. were able to show an 
increase in galectin-3 in EMCAR samples compared with normal endometrium samples [60]. 
However, Ege et al. reported decreased galectin-3 expression in EMCAR samples compared with 
normal endometrium [61]. We currently found no increased galectin-1 or galectin-3 expression in 
Part IV Immunosuppresssion 
Chapter 5 
 117 
tissue lysates of EMCAR or US compared with normal/benign controls. However, galectin-1 levels in 
lysates of leiomyosarcomas were significantly higher compared with myometrium, carcinosarcomas 
and other histological subtypes of US. We further showed both membranous and cytoplasmic 
expression of galectin-3 on single-cell tumor suspensions from primary tumors and on uterine cancer 
cell lines. In cancer, there is often a change in intracellular localization of galectin-3. Brustmann et al. 
found an increased nuclear expression in EMCAR [60]. Data of Mylonas et al. showed that it can be 
detected in both the cytoplasm and the nucleus [58], but exclusively cytoplasmic expression was 
associated with increased myometrial invasion of EMCAR [58]. In the current study, we used tissue 
lysates or membrane/intracellular flow cytometric analysis, and consequently, no analysis on galectin 
location could be done to corroborate these data. Weissenbacher et al. analyzed the expression of 
galectin-1 and galectin-3 in uterine leiomyosarcoma. Contradictory to what we currently found in the 
total sarcoma population for galectin-1, they found no difference in galectin-1 or galectin-3 
expression when compared with normal myometrium [34]. This discrepancy may in part be explained 
by the use of a semi-quantitative versus a quantitative analysis method in the current setting, which 
creates some difficulties for precise comparison of results. 
Myeloid-derived suppressor cells have been shown to play an important role in cancer 
immunosuppression. de Boniface et al. showed increased expression of arginase-1 on MDSC in breast 
cancer patients, which correlated with tumor grade [62]. Arginase-releasing MDSC exerting 
detrimental effects on T cells are also increased in patient blood of renal cell carcinoma (RCC) 
patients [63, 64]. We have currently analyzed the activity of arginase-1 as a surrogate for MDSC. We 
found increased arginase-1 activity in EMCAR lysates compared with normal endometrium, indicating 
a possible involvement of MDSC in EMCAR. Furthermore, we showed for the first time that both 
EMCAR and US tumors contain MDSC infiltrates that express arginase-1.  
In conclusion, we report the presence of the immune checkpoints PD-L1/PD-L2 and B7-H4 in uterine 
tumors as well as the presence of the immune inhibitory molecules IDO, arginase-1, galectin-1 and 
galectin-3 and the immunosuppressive MDSC. The current data in conjunction with positive results of 
currently ongoing clinical trials and preclinical studies with inhibitors for these molecules advocate 
for a possible future use in patients suffering from uterine tumors. In our opinion, IDO and PD-L2 are 
useful targets for immune inhibition in a minority of uterine cancer patients. Both PD-L1 and B7-H4 
could represent targets in both tumor types, considering their high expression levels. Finally, 
intervention with MDSC function offers a new treatment perspective in EMCAR patients. 
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Immune monitoring of WT1 DC vaccination in uterine and ovarian 
cancer patients 
ABSTRACT 
Ovarian cancer and endometrial cancer are the two most common gynecological malignancies. 
Ovarian cancer often presents in late stages as an aggressive tumor and tumors often recur multiple 
times. Due to its aggressive disease course and the development of resistance to current treatment 
regimens, additional treatment options are necessary. 
Endometrial cancer on the other hand, is mostly diagnosed in early stages and currently available 
treatment options for endometrial cancer are mostly curative. However, as is the case for ovarian 
cancer, treatment options are limited for far-advanced and recurrent endometrial tumors. Dendritic 
cell-based immunotherapy is a valid treatment option for both tumors. 
Eight patients suffering from recurrent ovarian or uterine tumors were vaccinated with WT1 mRNA 
loaded DC and monitored for WT1-specific immune responses and clinical response. No severe 
adverse events or toxicities were reported, further confirming the feasibility and safety of DC 
vaccination. Post-vaccination immune responses could be detected in 5/8 patients. Transient clinical 
responses were seen in 2/8 patients. 
Collectively, the currently obtained results indicate that WT1 DC vaccination in uterine cancer 
patients results in detectable immune responses with, for the current patients population, minimal 
clinical response. 
INTRODUCTION 
WT1 has been ranked as the most important tumor-associated antigen [1], making it an attractive 
target for immunotherapy. Since 2004, clinical case reports and studies have been published about 
WT1 immunotherapy. Most commonly, a modified WT1 peptide is injected with the goal of eliciting a 
WT1-specific T-cell response. Vaccination with autologous dendritic cells (DCs) loaded with WT1 
peptides is another means to establish such a response. To date, 78 cases of solid tumors, including 8 
uterine tumors [2-4] and 82 hematological malignancies have been the subject of a total of 23 
studies and case reports, with a clinical response to WT1 in 54% of cases [5]. One of the obstacles for 
the use of synthetic peptides is that patient accrual is limited to patients with the specific HLA type, 
for which the peptide is restricted. One strategy that would allow WT1-targeted immunotherapy for 
patients regardless of their HLA-type, is the transfection of WT1 mRNA into DC to achieve transient 
expression and subsequent presentation of antigenic epitopes. The in vitro work of several 
laboratories has suggested that mRNA transfection is an effective, if not superior, method of 
generating immunostimulatory DCs [6-9]. Currently, we evaluate the immunological response 
following WT1-loaded DC-based immunotherapy in a small cohort of 8 gynecological cancer patients. 
MATERIALS AND METHODS 
Study design 
This was a single-arm, pilot clinical trial (phase I/II) in patients with end-stage uterine cancer, carried 
out in a single institution (University Hospital Leuven, Belgium; EudraCT 2009-016868-37). Eight 
gynecological cancer patients, either ovarian cancer of uterine cancer were included. Specific patient 
Part V Clinical trials 
Chapter 6 
 128 
characteristics are summarized in Table 1. All of the included patients were included in the trial 
suffering from metastasized recurrent disease. All patient received multiple prior treatments. The 
total number of prior treatment regimens (pooled for both the primary tumor and the recurrence) 
are shown in Table 1. 
DCm-WT1-RNA was administered as 4 weekly intradermal injections in imiquimod-treated skin in the 
groin of the patients. Imiquimod was applied one night before and two nights after vaccination. 
Patients with disease stabilization or regression received further individually designed DC 
vaccinations with until disease progression. 
The primary end-points were to evaluate the feasibility, toxicity and tumor response rate according 
to Response Evaluation Criteria in Solid Tumors (RECIST). Secondary end-points were the assessment 
of the in vivo induced immune response and the molecular response of the tumor marker Cancer 
Antigen 125 (CA125). 
Table 1: Patient characteristics. 
 
* survival is expressed in days post WT1 DC vaccination 1  
** patient was lost from follow-up. Survival is expressed as days until last follow-up 
LMS: leiomyosarcoma, CS: carcinosarcoma, OS: ovarian sarcoma, OV: ovarian carcinoma 
 
Vaccine preparation 
For 2/8 patients, the DCm-WT1-mRNA vaccine was manufactured in culture flasks. After 
leukapheresis, monocytes were isolated via plastic adherence and cultured with rhIL-4 (1000 IU/L) 
and rhGM-CSF (1000 IU/L) in flasks in CellGro cell culture medium + 1 % autologous inactivated 
plasma. New cytokines and 10 % of medium were added at days 2, 4, and 6. For the remaining 6/8 
patients, monocytes were isolated via elutration (Elutra®; Terumo BCT, Lakewood, Colorado, USA) 
and cultured in closed culture bags (CellGenix, GmbH, Freiburg, Germany) using the same cytokine 
mixture. After seven days, immature DC (DCi) were harvested for electroporation. DCi were 
electroporated (300 V, 150 µF exponential decay pulse) to incorporate WT1-mRNA  
Part V Clinical trials 
Chapter 6 
 129 
(10 µg per 10 x 10
6
 DCi). WT1-mRNA used for 7/8 patients was manufactured by CureVac (Tübingen, 
Germany from a WT1 plasmid (pGEM4Z-WT1-A64)). For patient 8, DC were electroporated with 
WT1opt-DC.LAMP mRNA (VUB, Brussels, Belgium). Electroporated DC were cultured in the presence 
of TNF-α (1000 IU/ml) and IL-1β (2000 IU/ml). All cytokines and media were GMP-approved and were 
purchased from CellGenix (Freiburg, Germany). DCm-WT1-mRNA were frozen in liquid nitrogen until 
vaccination. Prior to vaccination, DC quality was checked by flow cytometry via the expression of 
maturation markers CD11c and CD83. 
Immune monitoring 
The immune status and response were assessed at the time of the first vaccine administration 
(baseline) and at the fourth vaccination (post V3). At these time points, PBMC were isolated by Ficoll 
density gradient centrifugation and cryopreserved in a 20 % HSA solution containing 10% DMSO. 
For HLA-A2 positive patients, T cells recognizing the WT1126-134 HLA-A*0201-restricted epitope 
(RMFPNAPYL) were measured using tetramer staining. PBMC were thawed, resuspended in T cell 
medium (IMDM + 5% human AB serum + penicillin-streptomycin + L-glutamine, all from Life 
Technologies, Ghent, Belgium, except for AB serum from Sera Laboratories International Ltd, West 
Sussex, UK) and left to recover for 1 hour at room temperature in the presence of 10 U/ml DNAse1. 
Cells were counted with trypan blue and 5 x 10
5
 to 1 x 10
6
 cells were used for tetramer staining. Cells 
were resuspended in PBS containing 0.5% BSA and 10% normal goat serum and incubated with  
PE-labeled WT1 or influenza tetramers (Glycotope Biotechnology, Heidelberg, Germany) for 45 min 
at 4°C, after which FITC-labeled anti-CD8 (BD Biosciences, San Jose, USA) and PerCp-Cy5.5-labeled 
anti-CD3 (Biolegend, San Diego, USA) were added.  
In parallel, WT1-specific T cells were detected for both HLA-A2 positive and HLA-A2 negative patients 
using the CD137 assay. In brief, PBMC were thawed as described above and counted with trypan 
blue. PBMC were resuspended in T cell medium at a concentration of 10
7
 cells/ml and incubated with 
an overlapping peptide mixture covering WT1 (PepTivator, MiltenyiBiotec, Bergisch Gladbach, 
Germany) according to manufacturer’s instructions. Cultures were incubated overnight at 37°C and 
5% CO2, after which cells were harvested and analyzed by flow cytometry using FITC-labeled anti-CD4 
(BD Biosciences), PE-labeled anti-CD137 (BD Biosciences), PerCp-Cy5.5-labeled anti-CD3 (Biolegend) 
and APC-H7-labeled anti-CD8 (BD Biosciences). Results are expressed as fold increase after 
stimulation with the specified antigen (overlapping peptide pool) compared to mock stimulation.  
A two-fold increase is considered to be positive. The culture supernatant was stored at -20°C for 
cytokine quantification. Production of IFN-γ, TNF-α, IL-2, IL-4, IL-5, IL-10 was quantified using the BD 
Cytometric Bead Array (CBA, BD Biosciences) according to manufacturer’s instructions and analyzed 
on a FACSCantoII flow cytometer using FCAP Array software (BD Biosciences). In addition, natural 
killer (NK) cells were measured using PE-conjugated anti-CD161 (Biolegend), PerCp-Cy5.5 conjugated 
anti-CD16 (BD Biosciences) and PE-Cy7 conjugated anti-CD56 (Biolegend). Abs were added and 
incubated for another 30 min at 4°C. Subsequently, cells were washed in PBS containing 0.5% BSA 
and a minimum of 10
5
 cells was analyzed by flow cytometry using a FACSort or FACSCanto II flow 
cytometer (BD Biosciences). Data were analyzed using FlowJo software (Treestar Inc, Ashland, USA). 
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RESULTS 
Toxicities 
No toxicities were reported, evaluated according to the Common Terminology Criteria for Adverse 
Events (CTCAE), except for local redness of the skin at the injection site. One patient mounted an 
allergic reaction to the imiquimod cream. For this patient, PGE2 was added to the DC culture to 
achieve full DC maturation. 
Clinical response 
In 2/8 patients, a clinical response could be observed after 4 vaccines. Vaccination resulted in disease 
stabilization in one patient and a mixed response was seen in one other patient. These 2 patients 
received additional boost vaccines. No clinical improvement could be seen in any of the 6 other 
patients (Table 1). 
Immune monitoring 
In the current cohort, applying the commonly upheld threshold of > 2-fold increase, an immune 
response was seen in 5/8 patients. 
With regard to WT1-specific T cells, tetramer analysis showed a clear WT1-specific T cell response in 
1/5 analyzed HLA-A2 positive patients (2.8-fold increase, Table 2). One other patient showed a minor 
WT1-specific response, yet not reaching the threshold (1.7-fold increase). That same patient also 
showed an increased CD8
+
CD137
+
 T cell frequency following in vitro stimulation with WT1 peptides, 
further supported by an increased IL-2 secretion. This indicates that patient 7 has an increased 
frequency of WT1-specific T cells after 4 vaccinations, but these are still in a non-activated state in 
vivo. 
Table 2: Immune monitoring. 
 
NA: not applicable; ND: not detectable; -: not analyzed. 
All values are calculated as V4/V1 ratio (fold change of V4 compared to V1)  
Values above commonly applied threshold of > 2-fold increase at V4 compared to at V1 are indicated in bold. 
In patient 5, a 2.8 fold increase in activated NK cells was seen after 3 vaccinations and patient 6 
showed an increased state of in vitro immune activation, following stimulation, exemplified by 
increased secretion of IL-2 and the pleiotropic immune activator TNF-α. The latter was also increased 
in patient 8, as well as IL-10 and IFN-γ. This patient also showed increased levels of  
CD4
+
CD137
+
 T cells, indicating a possible presence of an increased frequency of WT1-specific Th1 
cells. 
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DISCUSSION 
We present the first series of eight patients with ovarian or uterine cancer treated with autologous 
DC loaded with WT1 mRNA. This approach was feasible and well tolerated. No side-effects were 
reported, apart from local redness of the skin at the injection site in all patients and an allergic 
reaction to the imiquimod cream in one patient. An immunological response was detected in 5/8 
patients and 2 patients showed a transient clinical response according to the RECIST criteria.  
HLA-A2-negative patients did not show an oncological or immunological response. For comparison, 
Ohno et al. reported two uterine cancer patients receiving WT1 peptide immunotherapy, both 
showing progressive disease [4]. Miyatake et al. recently reported five patients with uterine sarcoma 
receiving WT1 peptide immunotherapy, showing disease stabilization in one patient [3]. In these 
studies, immune monitoring was limited to a test for delayed-type hypersensitivity (DTH) reaction 
specific to the WT1 peptide used for vaccination. No match between immunological and clinical 
response was found. Taking together all published series and case reports, in 54.5% of cases, the 
immunological response matched the clinical response [5]. 
The limited clinical responses in our study can partly be explained by the condition of the patients 
included. A large tumor burden, present in four patients, creates an immunosuppressive 
environment, which hampers the efficacy of immunotherapy. Moreover, the immune system was 
heavily challenged in nearly all patients because of prior chemotherapy and surgery. Therefore, the 
immune system may not have fully recovered prior to the immunotherapy regimen. 
As in our trial, Miyatake et al. recorded longer survival because of the addition of WT1 
immunotherapy [3]. Comparing the survival of the first HLA-A2-positive patient with that of 
comparable historical controls in University Hospital Leuven shows a striking difference in survival 
from the moment palliation was declared: 11 months versus 67 days. The same was true for the 
second HLA-A2-positive patient with end-stage disease. Four comparable historical cases were 
available in our database. In this small group, two patients died of progression during chemotherapy, 
one patient before chemotherapy could be initiated, but one patient had a similar cancer history as 
our patient. She died five months after she was put on palliative care, whereas our patient survived 
for 10 months. From these observations, it seems that a combination of immunotherapy and 
chemotherapy might be beneficial, as shown by others [10]. Doxorubicin, for example, results in 
apoptotic tumor cell death, which increases the antigen uptake by the antigen-presenting cells, 
leading to in situ immunization against tumor antigens. Chemotherapy might also lead to direct 
activation of DC, previously demonstrated for doxorubicin and paclitaxel, or their effector 
mechanisms [11]. Lower doses of chemotherapy, e.g. cyclophosphamide, have been shown to be 
synergistic with immunotherapy in mice, by depleting regulatory T-cells and retaining memory T-cells 
[12]. In our study population, there was a clear discrepancy between HLA-A2-positive and -negative 
patients. HLA type is a known prognostic factor in some types of cancer. However, to our knowledge, 
nothing has been demonstrated about the HLA type and the response to immunotherapy, nor of a 
possible dominance of the A2 epitope of WT1. Larger studies are needed to clarify this. 
In conclusion, this study presents promising results of the first eight patients with ovarian or uterine 
cancer to be treated with autologous DC loaded with WT1 mRNA. The technique is feasible and safe. 
In addition, an immune response following vaccination could be seen in 5/8 patients either in vivo or 
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following in vitro activation. In addition, a transient clinical response after 4 vaccinations, was seen in 
2/8 patients. 
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Variability in CRP, regulatory T cells and effector T cells over time in 
gynecological cancer patients: a study of potential oscillatory 
behavior and correlations 
ABSTRACT 
The inflammatory marker, C-reactive protein has been proposed to also be a biomarker for adaptive 
immune responses in cancer patients with a possible application in time based chemotherapy. Fluxes 
in serum C-reactive protein levels were suggested to be indicative of a cyclical process in which, 
immune activation is followed by auto-regulating immune suppression. The applicability of C-reactive 
protein as a biomarker for regulatory or effector T cells was therefore investigated in a cohort of 
patients with gynecological malignancies, as well as the ability of low dose cyclophosphamide to 
influence the frequencies of both these cell types. 
Peripheral blood samples were obtained from a cohort of patients at 7 time points over a period of 
12 days before treatment and at 3 time points after each cycle of cyclophosphamide. Serum and 
mononuclear cells were isolated and C-reactive protein levels in serum were detected using ELISA 
while regulatory and effector T cell frequencies were assessed using flow cytometry. To test 
periodicity, periodogram analysis of data was employed while Pearson correlation and the Wilcoxon 
signed rank test were used to determine correlations. 
The statistical analysis used showed no evidence of periodic oscillation in either serum C-reactive 
protein concentrations or frequencies. Furthermore, there was no apparent correlation between 
serum CRP concentrations and the corresponding frequencies of regulatory T cells or effector T cells. 
Relative to healthy individuals, the disease state in the patients neither significantly affected the 
mean frequency of regulatory T cells nor the mean coefficient of variation within the regulatory T cell 
population over time. However, both effector T cell mean frequency and mean coefficient of 
variation were significantly reduced in patients. No effects of cyclophosphamide treatment on Treg 
frequencies could be observed. 
Using our methods we were unable to detect C-reactive protein oscillations that could be used as a 
consistent serial biomarker for time based chemotherapy.  
INTRODUCTION 
The link between inflammation and tumor development has been widely reported and recently, in an 
update to their seminal paper on the hallmarks of cancer, Hanahan and Weinberg refer to 
inflammation as an “enabling characteristic” for tumor development [1]. This link is well illustrated in 
gynecological malignancies. The processes of ovulation and menstruation are associated with 
inflammation of the ovarian surface and endometrial epithelia [2, 3]. During ovulation there is an 
increase in the macrophage population in the perifollicular stroma of pre-ovulatory follicles [4, 5]. 
These macrophages produce pro-inflammatory cytokines interleukin (IL)-6, IL-1β and tumor necrosis 
factor (TNF), [2]. Estrogen in the endometrium also induces the up-regulation of these pro-
inflammatory cytokines [6]. Over time, the cyclical process of epithelial damage and repair, involving 
inflammation, predisposes to neoplastic growth. Not only does inflammation play a role in 
tumorigenesis, it also facilitates disease progression. The tumor microenvironment is rich in 
inflammatory mediators produced by tumor cells and infiltrating leukocytes [7-9]. Specifically, IL-6 
Part V Clinical trials 
Chapter 7 
 136 
triggers tumor cells to produce matrix metalloproteinase (MMP)-9 that promotes tumor growth by 
initiating angiogenesis [10]. 
C-reactive protein (CRP), an acute phase protein produced by hepatocytes is the most widely used 
indicator of inflammation. The transcription of CRP is induced by IL-6 alone while the presence of 
either IL-1β or TNF augments its production [11, 12]. Gynecological cancer patients exhibit elevated 
levels of CRP, however these levels are not static. In a preliminary study of melanoma and ovarian 
cancer patients, serum CRP levels oscillated around a certain mean value with a periodicity (λ) of 7 
days [13]. The dynamic state of inflammation could indicate an underlying persistent but regulated 
antitumor immune response in the cancer patients, which is characterised by a cyclical repeating 
process of endogenous auto-vaccination, preceding suppression by regulatory cells. 
In the past few decades the role of the adaptive immune system in driving antitumor immunity has 
been highlighted. Studies have shown a positive correlation between the number of tumor-
infiltrating effector T cells and patient survival, as well as a negative correlation with 
Foxp3
+
CD25
Hi
CD4
+
 regulatory T cells [14, 15]. Inflammatory cytokines and chemokines such as TNF 
and CCL22 facilitate the infiltration of T cells into the tumor microenvironment. When activated, 
effector T cells up-regulate CD25 and transiently express FoxP3 [16]. This enables them to expand 
and secrete pro-inflammatory cytokines. FoxP3
+
CD25
Hi
CD4
+
 regulatory T cells, which express high 
levels of the CCL22 receptor CCR4, also infiltrate tumor sites where they expand in response to TNF 
and IL-2 produced by effector T cells, and subsequently inhibit the immune response [17-19]. 
Commonly used chemotherapy has been shown to have immunomodulating effects. Thus, the use of 
these compounds may have a beneficial effect on tumor immune escape. Cyclophosphamide, for 
example, has been shown to influence the frequency and functional properties of regulatory T cells. 
Both the presence of immune-oscillation patterns of CRP, regulatory and effector T cells was 
evaluated in this study, as well as the influence of oral low-dose CY intake on the frequency and 
functional capacities of these cell types. 
METHODS 
Trial design and patient details 
In total, 19 patients with gynecological tumors were included in this bicentric phase II trial. The 
patients had end stage treatment-refractory gynecological tumors, i.e. ovarian cancer (n=5), papillary 
serous cystadenocarcinoma (n=9), adenocarcinoma (n=1), serous cystadenocarcinoma (n=1), 
endometrial carcinoma (n=1), peritoneal tumor, (n=1) or malignant mixed müllerian tumors (n=1) 
and were recruited from the Royal Women’s Hospital, Melbourne, Australia (n=12) and the 
University Hospital Leuven, Belgium (n=7). Patient age ranged from 43-82 years. The relative 
institution’s research and ethics committees approved the study. From the time of recruitment, 
written consent was obtained from patients and 7 blood collections were performed over 12 days 
with daily and second daily bleeds, to assess the presence of a CRP cycle. Blood was collected in the 
morning on days 1, 3, 5, 6, 8, 10 and 12 with one exception who had blood collected on days 1, 2, 4, 
5, 6, 8, 12. Following collection, the blood samples were immediately transported to the laboratory 
for processing with a maximum of 12 hours between blood collection and freezing of plasma. Based 
on predicted CRP cycling patterns [13], patients went on to receive treatment with low-dose 
cyclophosphamide, 50 mg administered p.o. twice daily for 3 consecutive days. Blood was also 
collected from 7 healthy volunteers at the Alfred Hospital, Melbourne, Australia. Ethical approval was 
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obtained from the institution’s research board and written consent was also obtained from the 
volunteers. The blood collection protocol for the healthy volunteers was similar to that of the cancer 
patients. Specific characteristics of the all patients are summarized in Table 1. 
Table 1: Patient characteristics. 
Patient ID Age Tumor type Prior Treatment Disease status at inclusion 
BLV 01 74 Ovarian carcinoma Surgery, 3 lines 
chemo 
PD with newly formed hepatic lesion, hepatogastric, 
lymph node, peritoneal and mesenteric lesions present 
BLV 02 80 Ovarian carcinoma Surgery, 3 lines 
chemo, provera 
PD with increase of peritoneal metastases with ascites 
formation 
BLV 03 73 Ovarian carcinoma 3x surgery, 4 
lines chemo 
PD with increase and new formation of abdominal 
metastases and possible lymph node metastases 
BLV 04 64 Peritoneal tumor Surgery, 6 lines 
chemo, avastin 
PD with peritoneal, omental, vertebral, hepatic and 
possible gastric metastases 
BLV 05 62 Endometrial carcinoma 2x surgery, 1 line 
chemo, 
radiotherapy 
PD with increase of hepatic metastases and possible 
renal metastases, as well as brain metastases 
 
BLV 06 74 Malignant mixed 
Müllerian tumor 
(MMMT) 
Surgery, 1 line 
chemo 
PD with increase of known retroperitoneal lesions and 
occurence of a new lesion 
BLV 07 82 Ovarian carcinoma 2x surgery, 5 
lines chemo, 
provera 
PD with increase of LN metastases in upper abdomen, 
metastases in mediastinum and formation of lung 
metastases 
IRS 01 43 Adenocarcinoma Surgery, 1 line 
chemo, 
radiotherapy and 
EGFR inhibitor 
PD with recurrence in supraclavicular fossa lymph node 
 
IRS 02 45 Ovarian carcinoma Surgery, 3 lines 
chemo, 
radiotherapy 
PD with hepatic involvement 
 
IRS 03 54 Papillary serous 
cystadenocarcinoma 
Surgery, 2 lines 
chemo, 
radiotherapy 
PD with rising CA-125 marker 
 
IRS 04 63 
 
Papillary serous 
cystadenocarcinoma 
Surgery, 5 lines 
chemo, hormone 
therapy 
PD with rising CA-125 marker 
 
IRS 05 68 Serous 
cystadenocarcinoma 
2 x Surgery, 1 
line chemo, 
hormone 
therapy 
 
PD with rising CA-125 marker 
 
IRS 06 74 Papillary serous 
cystadenocarcinoma 
Surgery, 2 lines 
chemo 
PD rising CA-125 marker , PAN and adrenal gland 
involvement 
IRS 07 66 Papillary serous 
cystadenocarcinoma 
Surgery, 3 line 
chemo, 
radiotherapy, 1 x 
EGFR inhibitor 
PD with rising CA125 
 
IRS 08 63 Papillary serous 
cystadenocarcinoma 
Surgery, 2 lines 
chemo 
PD with rising CA125 level 
 
IRS 09 63 Papillary serous 
cystadenocarcinoma 
Surgery, 5 lines 
chemo 
PD with omental mass increased in size 
IRS 11 70 Papillary serous 
cystadenocarcinoma 
Surgery, 2 lines 
chemo 
Progessive disease (PD)  with rising CA125 
IRS 12 79 Papillary serous 
cystadenocarcinoma 
Surgery, 2 lines 
chemo 
PD with progressive nodal abnormalities above and 
below diaphragm and new peritoneal abdo/pelvic 
disease 
IRS 13 69 Papillary serous 
cystadenocarcinoma 
Surgery, 2 lines 
chemo 
PD with short bowel syndrome  
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hsCRP plasma level measurements 
Plasma was isolated from whole blood collected either in EDTA-coated tubes (Belgian patients) or in 
serum separation tubes (Australian patients) by centrifugation. After removing cellular and protein 
debris, plasma was aliquoted and stored at -80°C for later use. HsCRP levels were determined by 
ELISA (Human High Sensitivity C-Reactive Protein ELISA kit; Cusabio Biotech Co., LTD, China) 
according to manufacturer’s instructions. For each treatment cycle, batch analysis was performed on 
all the necessary samples. To increase experimental precision, all samples were analyzed in duplicate. 
Peripheral blood mononuclear cell isolation 
Mononuclear cells were obtained from peripheral whole blood collected in EDTA-coated tubes via 
Ficoll (Amersham Pharmacia Biotech, Sweden) density gradient centrifugation. The isolated PBMCs 
were cryopreserved using a freeze mixture containing 10% DMSO (Sigma-Aldrich, Australia) and 
either 90% Fetal Calf Serum (Australian samples, JRH Bioscience) or human AB serum (Belgian 
samples, Sera Laboratories International) and stored in freezing containers (Nalgene) and finally in 
liquid nitrogen until use. For use, cells were thawed in a 37°C water-bath and quickly re-suspended 
using AIM-V medium (Invitrogen) with 5% human serum (Sigma). PBMC samples were available at all 
time points from 10 patients in total. 
Flow cytometric analysis 
(7/10 analyzed patients are included at University Hospital Leuven) 
To determine the frequency and phenotype of T cell populations in PBMC of patients with 
gynecological malignancies and age-matched female, healthy volunteers, multicolor flow cytometric 
analysis was performed using the following surface antibodies: anti-CD3 Q655 (Invitrogen), 
 anti-CD4 AF700 (BD Pharmingen), anti-CD25 PE (BD Pharmingen), and anti-CD127 Biotin (BD 
Pharmingen). Following primary staining, a fixable dead cell dye (Invitrogen) was also used to 
distinguish between dead and live cells. Intracellular levels of FoxP3 were determined following 
fixation and permeabilization using a fixation/permeabilization buffer kit (eBioscience) then staining 
with anti-FoxP3 PercpCy5.5 (eBioscience). Flow cytometry data were acquired on a Becton Dickinson 
LSR II using FACSDiva software, collecting a minimum of 100 000 events per sample. Fluorescence 
minus one (FMO) and isotype-matched antibodies were used as controls with all samples. Data were 
analyzed using Flowjo software (TreeStar). Samples were analyzed applying a gating strategy as 
follows: first, live PBMC were selected. From live PBMC, CD3
+
 T cells were gated, after which CD4
+
 
and CD8
+
 cells were separately selected. Within the CD4
+
 cell population, CD25
HI
 and CD25
int
 cells 
were identified. FoxP3 expression was analyzed on CD4
+
CD25
HI
 cells 
FOXP3 PCR 
(all patients are included at University Hospital Leuven) 
Genomic DNA (gDNA) was isolated from PBMC pellets using the Purelink™ Genomic DNA Mini kit 
(Invitrogen). In order to discriminate the methylated and non-methylated form of FOXP3 a bisulfite 
reconversion was subsequently performed using the Epitect® Plus DNA Bisulfite kit (Qiagen). Analysis 
was performed using primers and probes specific for (un)methylated FOXP3 (Eurogentec) according 
to the following program: 10’ at 95°C followed by 45 cycles of 15’’ at 95°C and 1’ at 64°C. The exact 
primer and probe sequences for both forms of FOXP3 are given in Table 2. Results are analyzed as 
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follows: total copy number of both methylated and demethylated sequences were calculated based 
on a plasmid standard curve multiplied with a correction factor of 1 for methylated and 0.3 for 
demethylated FOXP3. Final results are expressed as % demethylated sequences out of the total 
number of sequences, corrected for the number of chromosomes. In this case a correction factor of 2 
was used since the gene encoding FOXP3 is located on the X chromosomes and the entire patient 
population is female. 
Table 2: Primer/probe sequences for the detection of methylated and demethylated FOXP3 
sequences. 
 
Methylation pattern sequence 
LNA modified 
bases 
Probe methylated AAACCCGACGCATCCGAC 3 
FW primer methylated CTCTTCTCTTCCTCCGTAATATCG  
RV primer methylated GTTATTGACGTTATGGCGGTC  
Probe demethylated AAACCCAACACATCCAACCA 5 
FW primer demethylated TCTACCCTCTTCTCTTCCTCCA  
RV primer demethylated GATTTTTTTGTTATTGATGTTATGGT  
All LNA modified bases are underlined and indicated in bold. 
Statistics 
To determine the respective periodicity of serum CRP concentration, and Teff and Treg frequencies 
periodogram analysis was used. The null hypothesis was that there was no consistent period to the 
measurements, which implies no peaks in the mean periodogram beyond noise. Individual subjects' 
periodograms were calculated and standardized to have sum of squares equal to 1, then averaged 
pointwise. Under the null hypothesis, the population pointwise mean periodogram is a horizontal 
line at 1. The pointwise, lower one-sided 95% confidence bound for the mean periodogram was 
calculated by the bias-corrected bootstrap method. This lower confidence bound was then compared 
to the null mark at 1. Exceeding 1 at a peak would be necessary to suggest a significant peak. 
The Pearson correlation coefficient between Teff first differences and CRP first differences was 
estimated for each subject, and the Wilcoxon signed rank test was used to test whether the mean 
correlation coefficient was non-zero. The same procedure was performed to test for a relationship 
between Treg and CRP, Tregs and Teffs, and CRP and IL-6. The first difference is defined as the 
change in value from one time point to the next. 
Coefficients of variation in the frequencies of Tregs and Teffs among 7 time points over a period of 12 
days were determined by initially calculating the standard deviation, which was then expressed as 
percentages of the mean frequency of the respective population over the 7 time points. Statistical 
significances between mean values of Treg and Teff frequencies as well as coefficients of variation for 
both populations were calculated using non-parametric (Wilcoxon Mann Whitney) tests. P values < 
0.05 were considered significant. All mean values were presented ± the standard error of the mean 
(SEM). 
Statistical significance was determined by performing 2 tailed, unpaired students’ t-Tests for 
comparison of healthy and cancer patient samples. Two tailed, paired Students t-Tests were 
performed for comparison of patients’ pre-treatment and post-treatment samples. P<0.05 was 
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considered to be significant. The software used for statistical analysis was GraphPad Prism. Data was 
always shown as mean ± Standard Error from the Mean (SEM). 
RESULTS 
Oscillation patterns of CRP 
In the individual patients serum hsCRP concentrations appeared to fluctuate over time (Fig 1A). 
However, when a mean standard periodogram analysis was carried out for the pooled patient cohort 
at every time point, while small peaks were apparent in the periodograms at 3.6 days and 4.6 days, 
neither was significant (Fig 1B). In a smaller cohort of 10 patients from whom PBMCs were collected, 
the periodicity of peripheral blood Treg and Teff frequencies was also investigated. Tregs were 
defined as expressing high levels of CD25 and FoxP3, which we confirmed expressed low levels of 
CD127, while Teffs were defined as expressing intermediate levels of CD25 as per previous studies 
[20, 21]. Similar to serum CRP concentration, both frequencies appeared to fluctuate over time, in 
some individual patients (data not shown). In the pooled cohort, mean standard periodogram 
analysis revealed small peaks for Treg frequencies at 4.8 days and for Teff frequencies at 3.6 and 4.6 
days, but none was significant (data not shown). 
 
Figure 1: CRP cycle analysis. A. hsCRP analysis. B. Periodogram analysis. 
Effect of cyclophosphamide treatment on T cell distribution 
We investigated the effect of treatment with repeated cycles of low dose cyclophosphamide (CY) on 
the distribution of T cells in peripheral blood of 10 end-stage gynecological cancer patients and 
further used 11 healthy, age-matched, female donors as controls. In 8/10 patients, samples were 
available following the second line of CY treatment. There was no significant effect of treatment on 
the overall frequencies of CD3
+
 T cells within peripheral blood of patients, nor in the frequencies of 
CD4
+
 and CD8
+
 T cells (Fig. 2A, B). Compared to pre-treatment levels in cancer patients, there was a 
significant increase in the mean frequency of CD4
+
CD25
+
 cells (both CD25
Hi
 and CD25
Int
) following the 
first cycle of treatment (p < 0.05; Fig. 2C). Furthermore, the mean frequency of CD25
+
FoxP3
+
 cells as 
well as FoxP3 expression within the CD25
Hi
CD4
+
 T cell population was significantly higher in patients 
than in healthy donors prior to treatment as well as following CY treatment. However, the 
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frequencies of FoxP3
+
CD25
Hi
 regulatory T cells (Tregs) within CD4
+
 T cells were not significantly 
different between healthy donors and cancer patients following either treatment cycle (Fig 2D). 
 
Figure 2: A. CD3
+
 T cell frequencies in peripheral blood. B. CD4
+
 and CD8
+
 T cell frequencies. C. CD25 expression within the 
CD4
+
 T cell population. D. FoxP3 analysis. All cycles were compared with healthy controls using the student’s t test. 
Correlation between FoxP3
+
 T cell frequencies and FOXP3 mRNA transcripts 
In conjunction with the frequency of Treg in peripheral blood, the level of demethylated FOXP3 in 
PBMC were analyzed. As shown in Fig. 3, although the Treg frequencies were different with both 
methods, the fluctuation pattern was similar using both assays. However, we did notice that the 
fluctuation pattern of both parameters did not occur simultaneously across the entire period of 
analysis (Fig. 3). 
Effect of cyclophosphamide treatment on T cell effector functions 
To additionally investigate whether treatment may enhance antitumor immunity by increasing CD8
+
 
T cell cytotoxic function, PBMC collected from 7 healthy donors and 6 cancer patients, prior to 
treatment, and after cycles 1 and 2 of treatment were stimulated with PMA /Ionomycin. Contrary to 
expectation, compared to healthy donors, cancer patients had a slightly elevated mean frequency of 
CD8
+
IFN-γ
+
T cells and this was significantly higher following the second cycle of treatment 
(20.3%±4.06% compared to, 39.7%±7.81% p = 0.04; Fig. 4A). Considering the cancer patients  
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pre-treatment, there were no significant differences in the frequencies of CD8
+
IFN-γ
+
 T cells following 
either cycle of treatment (Fig 4B). Conversely, the frequency of CD107a
+
 cells remained constant 
between healthy donors and cancer patients, and was not affected by treatment (Fig 4B). 
 
Figure 3: Treg frequencies by flow cytometry and FoxP3 mRNA levels in PBMC. 
 
Figure 4: Effect of cyclophosphamide treatment on T cell effector functions. A. IFN-γ secretion. B. CD107a expression. All 
cycles were compared with healthy controls using the student’s t test. 
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Low-dose cyclophosphamide and treatment response 
Prior to treatment and after each treatment cycle, CA125 measurements were done and a CT scan 
was performed for clinical evaluation of the low-dose cyclophosphamide treatment every 3 cycles. 
Although all patients eventually progressed (Table 3), 7/19 (36.8 %) patients received multiple cycles 
of cyclophosphamide, indicating transient clinical responses. 
Table 3: Clinical response data. 
Patient ID Disease state at 
inclusion 
Total number 
of cycles 
received 
CA125 
evolution 
Target-related 
adverse events 
IRS001 PD 15 Transient 
decrease 
- 
IRS002 PD 3 Increase - 
IRS003 PD 2 Increase - 
IRS004 PD 9 Stable after 3 
cycles 
- 
IRS005 PD 1 - - 
IRS006 PD 6 Fluctuating - 
IRS007 PD 3 Increase - 
IRS008 PD 5 Transient 
stabilization 
- 
IRS009 PD 2 Increase - 
IRS011 PD 2 Increase - 
IRS012 PD 2 Increase - 
IRS013* PD 6 Fluctuating - 
BLV01 PD 3 Increase - 
BLV02 PD 3 Increase - 
BLV03* PD 3 Increase - 
BLV04 PD 2 Increase - 
BLV05 PD 9 Transient 
decrease 
- 
BLV06 PD 6 Stable until CY6 - 
BLV07* PD 2 Increase - 
* dropped out of the study at patients’ own request 
DISCUSSION 
The dynamic nature of the adaptive immune response has been described in two ways. Firstly, there 
are diurnal fluctuations, regulated by the circadian clock exemplified in CD4
+
 T cells by the rhythmic 
expression of genes that control cytokine secretion and cell function [22]. Secondly,  
antigen dependent fluctuations occur during acute infections and the kinetics of the immune 
response are controlled by a system of positive and negative feedback mechanisms designed to limit 
the immune response when pathogenic insults are resolved. In chronic diseases such as cancer, 
antigenic clearance does not occur and the persistent antigen exposure results in a constant state of 
immune activation. The tumor, however, limits immune activation by secreting immune inhibitory 
cytokines such as IL-10, and tumor growth factor (TGF)-β as well as inducing regulatory cell 
populations including myeloid derived suppressor cells (MDSCs) and regulatory T cells [18, 23-25]. 
Although intratumoral immune cells are skewed towards immune inhibition, there may still exist a 
homeostatic balance that needs to be maintained in the periphery of cancer patients in which an 
Part V Clinical trials 
Chapter 7 
 144 
oscillating sequence of immune activation is followed by negative feedback immune suppression 
[13]. The current study however, showed that CRP concentrations in all the patients did not appear 
to oscillate periodically nor did the concentration of CRP correlate significantly with Treg or Teff 
frequencies. Therefore, CRP may not be a practical useful surrogate marker for either cell population. 
In a study of 12 patients with melanoma, less than 50% showed possible time dependent CRP 
concentration profiles [26]. The two data sets available therefore suggest that inflammation in 
cancer patients may not consistently follow an oscillatory, sinusoidal (or other mathematical) pattern 
with a constant period or amplitude. This may be because any such model oversimplifies the 
inflammatory process, and correlations are easily disrupted by a number of potential additional in 
vivo co-parameters or process variations. Multiple factors influence the levels of cytokines that 
regulate inflammation. One such factor is the tumor growth. In patients with papillary thyroid cancer 
CD4
+
 T cell frequencies correlate with tumor size while Treg frequencies correlate with lymph node 
metastasis [27]. Such variables may hence significantly influence the magnitude of T cell effector and 
suppressor frequency and function. 
Although changes in the frequencies of conventional Treg and Teff did not correlate with 
inflammation (data not shown), it is still possible that minor subsets within each phenotype (Treg or 
Teff) or their specific function over time, may correlate. Indeed, effector and regulatory T cells are 
heterogeneous populations of cells. Further breaking down these populations based on phenotype 
and function may also show greater variation between patients and healthy donors. For example, 
Treg populations with enhanced suppressive function due to elevated expression of inhibitory 
receptors such as glucocorticoid induced tumor necrosis factor receptor (GITR) and cytotoxic T-
lymphocyte antigen (CTLA)-4 as well as increased production of suppressive factors such as 
adenosine and cytokines TGF-β and IL-10, have been reported to be elevated in cancer patients [28-
30]. Similarly, effector T cells can be broken down into different functional phenotypes such as IL-17 
secreting and type-1 interferon secreting Teffs. Type-1 interferon secreting Teffs promote 
proliferation of cytotoxic CD8
+
 T cells, which contribute toward an antitumor effect [31-34]. It cannot 
therefore be excluded that the frequencies of some of these functional subsets, as well as CD8
+
 T 
cells, may be subject to regulation by inflammatory factors, even when the results presented show 
that total Treg and Teff populations are not correlated to inflammatory status, as reflected by CRP 
levels in blood. Mathematical models that aim to predict the balance that exists between immune 
activation and regulation within accessible blood samples, will therefore benefit from additionally 
taking into account the following variables: 1) the effect of diurnal variation 2) the tumor growth rate 
3) the heterogeneity present within both regulatory and effector T cell populations. 
Cyclophosphamide (CY) administration has been shown to result in immunomodulatory effects 
including selective depletion of regulatory T cells as well as increased effector T cell function [35-38]. 
However, these effects are not seen in all studies. de Vries et al. evaluated the effect of several 
possible Treg-depleting agents, among which cyclophosphamide. In this study, none of the agents 
could induce a 50 % reduction in peripheral blood frequencies in the majority of the patients tested 
[39]. In our analysis, partly corroborating these results, no effect of cyclophosphamide on Treg 
depletion could be seen. However, in the current analysis, again, no discrimination was made for the 
different types of Treg, e.g. inducible and natural Treg. In addition, we were not able to show an 
increased effector cell function after cyclophosphamide treatment. 
In conclusion, in our cohort of patients with gynecological malignancies, CRP concentrations do not 
oscillate in a consistent predictable manner, and do not correlate either positively or negatively with 
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conventional Treg or Teff subsets. Therefore, there is no evidence to suggest that CRP can reliably be 
used across cancer patients as a surrogate, time-sensitive and most importantly, predictive marker, 
to reflect circulating effector or regulatory T cell frequencies, as previously suggested [13].  
Time-based therapy founded on modelling a consistent cyclical pattern of inflammation using serum 
CRP concentration as a predictive marker of regulatory T cell expansion may not be possible. 
However, we cannot exclude that further investigating the kinetics of inflammation in cancer 
patients, perhaps by taking more frequent blood samples or else by taking into consideration 
multiple inflammatory and immune-regulatory parameters, the progressive nature of immune 
suppression, as well as the heterogeneity of effector and regulatory T cell populations could all help 
in modelling more complex, and potentially predictive, equations. Metronomic treatment with  
low-dose cyclophosphamide did not result in selective Treg depletion nor were any durable clinical 
responses noticed. 
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General discussion 
The current treatment of uterine tumors comprises surgery as the cornerstone of the first-line 
treatment, possibly followed by adjuvant treatments, such as chemotherapy, radiotherapy or 
hormonal therapy [1]. In case of far-advanced tumors or recurrent tumors, however, tumors often 
become treatment refractory and further treatment options are limited. Immunotherapy may 
provide an additional treatment option for these patients. 
A major advantage of immunotherapy is that it is often accompanied by only minor non-toxic  
side-effects such as fatigue and only local reactions of the skin at the injection site. Recently used 
specific targeted treatments, such as ipilimumab, however, are accompanied with more severe side 
effects, which can be managed with the use of corticosteroids, administered simultaneously with 
ipilimumab in case of moderate side-effects [2]. In addition, a fairly large proportion of uterine tumor 
patients are elderly women, which advocates for the use of less toxic treatment options. 
The main goal of the current project is the development of a dendritic cell-based vaccine for uterine 
tumors. Many different modalities can be applied for the composition of a dendritic cell vaccine, as 
described in the general introduction of this thesis, such as peptide-loaded DC, RNA-loaded DC or 
tumor lysate-loaded DC. We opted for the use of autologous monocyte-derived mRNA-
electroporated DC. This technique offers several advantages. First of all, monocytes as an initial 
source for the generation of DC can easily be obtained via leukapheresis, followed by monocyte 
enrichment via plastic adherence or elutriation. 
In addition, by using mRNA, patient selection for DC vaccination is no longer confined to patients 
with a certain HLA type. Antigens are processed by the DC’s machinery into several peptides, each 
with its own MHC restriction. A certain peptide can only bind one specific type of MHC molecule, 
which results from the presence of the concomitant genetic HLA type. Thus, when using a certain 
peptide to load DC, only patients positive for the HLA type to which this peptide is restricted are 
eligible for vaccination. When using mRNA which encodes for the entire TAA, all possible peptides 
encoded by this antigen can be processed. Consequently, one is no longer bound to a patient’s 
specific HLA subtype. In addition, mRNA that is used for electroporation can be artificially improved 
to obtain better results. The mRNA that was currently used was cloned into the pST1 vector, which 
was described to have better translational properties by Holtkamp [3]. In addition, the cDNA 
sequence was codon-optimized in order to obtain a more accurate transcription of the mRNA. Lastly, 
the cDNA sequence was coupled to a DC-LAMP sequence in order to ensure peptide presentation in 
both MHC I and MHC II context, ensuring the activation of helper T cells [4]. 
The development of this vaccine was subdivided in 2 objectives: 
Obj. 1: Target antigen selection 
 
An important lag in immunotherapy trials is the lack of a consistent correlation between an 
immunological response and a clinical response. An important reason that may explain this 
discrepancy is the presence of immunosuppressive mediators. Tumors often express 
immunosuppressive molecules on their surface, which can interact with immune cells in the tumor 
micro-environment and subsequently silence possible antitumor immune responses. In addition, 
uterine tumors, like all other tumor types, are often infiltrated with immune cells, further elaborated 
on in chapter 2, which can also contain immune cells with suppressive capacity, such as regulatory T 
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cells and myeloid-derived suppressor cells. This led us to the incorporation of the second objective in 
the project: 
Obj. 2: Identification of immunosuppressive mechanisms 
One other possible reason for a lack of immunological-clinical correlate is the evaluation criteria that 
are being used for the evaluation of the clinical response. This will be explained in further detail in 
the section with future directions. 
OBJ. 1: TAA VALIDATION 
The ideal tumor-associated antigen would be a highly specific, oncogenic antigen, with multiple 
epitopes ensuring the ability to bind most MHC molecules. It should be expressed by most tumor 
cells as well as cancer stem cells and by most tumors of a certain subtype. Additionally, the tumor 
antigen should be capable of eliciting a definite immune response and have proven therapeutic 
efficacy in clinical trials [5]. 
In the first part of this thesis, we validated the presence of arbitrarily chosen tumor-associated 
antigens (TAA). Based on the prioritization of cancer antigens, published in 2009 by Cheever et al. [5] 
as well as previously published data concerning TAA in uterine tumors and immunotherapeutic 
applications in other tumors, six different TAA were initially selected: BORIS, MUC1, survivin, 
MAGE-A3, Sp17 and hTERT (chapter 3 and 4). Sp17, BORIS and MAGE-A3 pose as interesting targets 
to investigate, due to their restricted expression in normal adult tissues. These molecules are 
members of the cancer testis antigen family and have an important function during development, 
but are restricted to expression in the male germ line in adult life. These antigens have been shown 
to re-emerge in cancer. Therefore, by targeting these antigens, one would be targeting the tumor 
specifically, while leaving normal surrounding tissues unharmed. The cancer testis antigens were 
found to be over-expressed in only a small fraction of the analyzed tumor samples, except for BORIS, 
which was expressed in 62% of uterine sarcomas. 
Direct targeting of tumor survival is an important mode of action for anticancer therapies. Therefore, 
the antigens hTERT and survivin were selected additionally. These antigens are valid candidates for 
two main reasons. First, these antigens play a role in cell proliferation and survival during 
development. In normal, terminally differentiated adult cells and organs these antigens are virtually 
absent. In case of a growing tumor, these antigens are expressed in order to facilitate cell 
proliferation. Like for the cancer testis antigens, targeting these antigens is aimed at directly 
targeting the proliferating cancer cells, while not affecting normal non-proliferating cells. In addition, 
by directly targeting cell proliferation, tumor survival is affected. In the current analyses, we found 
expression of both these antigens in the majority of tumors. We also found high expression of MUC1 
in EMCAR, and as expected in a substantially lower amount of US samples. MUC1 as a tumor antigen, 
however, cannot be implemented as an RNA construct. This is due to the fact that the TAA form of 
this antigen differs from the wild-type by a post-translational hypoglycosylation pattern, which 
cannot be incorporated in RNA encoding for MUC1. 
Based on the expression profiles of these selected antigens, survivin and hTERT were further 
evaluated in DC. The quality of the DC that are used in the vaccine is of critical importance. The DC 
must be sufficiently capable of inducing a functional immune response. Electroporation with a 
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certain antigen may have an unfavorable effect on these capacities in terms of dendritic cell 
phenotype or function. Therefore, the effect of electroporation with survivin and hTERT was 
examined (unpublished results). Electroporation with hTERT proved unsuccessful, most likely due to 
the large size of the RNA construct for the molecule. Using 3 buffy coats from healthy donors 
(obtained from the Belgian Red Cross), we found that electroporation with survivin mRNA (obtained 
from the lab of molecular and cellular therapy, VUB , Brussels) did not result in a negative effect on 
DC phenotype, nor on its viability or functional capacity, as shown by their ability to elicit T cell 
proliferation in an allogeneic mixed leukocyte reaction (allo-MLR) (data not shown). 
Based on the expression data and the effects on in vitro generated DC, in conjunction with the 
presence of spontaneous T cell responses in patient blood, it was decided to select survivin as a 
target antigen for further preclinical experiments for the development of the DC vaccine. Survivin 
was expressed in the vast majority of uterine tumor samples, and we detected spontaneous  
survivin-specific T cell responses in 22 % of endometrial cancer patients (4/18) and in 10 % (1/10) of 
uterine sarcoma patients. 
OBJ. 2: IMMUNOSUPRESSIVE ENVIRONMENT 
An important issue hampering the efficacy of immunotherapy is that of immunosuppression. This can 
be the result of either the intratumoral immune infiltrate, which may contain suppressive cells such 
as MDSC and macrophages, or Treg, or the presence of immune mediators on tumor cells or in the 
tumor microenvironment. On the contrary to ovarian cancer, little information is currently available 
concerning the immunosuppressive environment in endometrial cancer (Part I, chapter 2). 
We have explored the presence of several important immunosuppressive mediators (Part III, chapter 
1) in uterine tumors. We found expression of several members of the B7 family. We have currently 
analyzed the presence of PD-L1 (B7-H1), PD-L2 (B7-DC), and B7-H4, as well as IDO, galectin-1 and 
galectin-3 and the presence of intratumoral MDSC and MDSC activity. 
We identified the PD-1/PD-L1 axis as well as B7-H4 as possible targets for therapeutic intervention, 
since PD-L1 and B7-H4 were expressed in vast majority of the current tumor sample population. In 
addition, in a small portion of both endometrial cancer and uterine sarcoma, IDO presented as a valid 
option. 
The current data are, to our knowledge, the first data describing the presence of MDSC in uterine 
tumors. We found both monocytic and granulocytic MDSC infiltration in uterine tumors. In addition, 
Arginase-1 activity was measured at increased levels in endometrial tumors compared to normal 
endometrial tissues, indicating that the MDSC are most likely functionally active. Thus, mediation of 
MDSC function can be exploited in the treatment of endometrial cancer. 
CLINICAL APPLICATION AND SITUATION IN CURRENT LANDSCAPE OF IMMUNOTHERAPY FOR 
UTERINE TUMORS 
Although having been applied in many different cancer types, immunotherapy in uterine tumors has 
not been explored to much extent so far. To our knowledge, less than 15 clinical studies have been 
published to date (Table 1). As shown in Table 1, current studies in uterine tumors result in no or 
transient clinical responses, indicating that there are still many hurdles to overcome to increase the 
efficacy of immunotherapy in uterine tumors, as is the case in other tumor types. 
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Most studies have been done using peptides (6/13). Only 3 studies and 1 case report using DC 
therapy were found. To our knowledge, the current setup of mRNA-based DC therapy is so far only 
pursued in uterine tumors by our own research group. 
The current results are in any case a step forward in the research by our own research group [5, 6]. 
Our results have identified survivin as a novel antigenic target to include in the vaccine, beside the 
previously validated WT1. This will further strengthen the DC vaccine, since now 2 separate antigens 
are targeted instead of a single antigen, and it is aimed at directly targeting the survival of the tumor, 
since survivin is actively involved in tumor cell proliferation and survival. In addition, the RNA 
constructs that were validated preclinically are transcribed from codon-optimized cDNA, ensuring 
transcription of the optimal cDNA sequence of the target antigen and thus provides an optimal 
starting point for successful protein translation of the desired antigen. In addition, the mRNA was 
coupled to the DC-LAMP signal, which ensures antigen presentation in both MHC I and MHC II 
context [4]. This set-up was already applied for 1 patient in the first cohort in our own study [5]. In 
addition, the current results using TriMix for DC maturation have shown that this maturation cocktail 
results in DC of good phenotypic quality. TriMix DC have been used previously in clinical trials in 
melanoma patients [7-9]. In 71.4 % of tested patients, TAA-reactive T cells could be found both in 
blood and in a skin biopsy taken at the site of vaccine injection [7]. Another study showed that using 
a mixture of TriMix DC loaded with four different antigens, in combination with IFN-α-2b, durable 
clinical responses could be measured in 35 % of patients. In 1/17 patients, partial disease remission 
was seen and in 5 other patients, stable disease lasting more than 6 months was seen [9]. 
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Table 1: Immunotherapy trials in uterine tumors (adapted from [10]). 
Author Tumor type Trial 
phase 
Set-up Number of 
patients 
Outcome 
Steis et al. 
[11] 
Endometrial 
carcinoma 
Phase I ACT of activated killer 
cells + interperitoneal IL-
2 
1 PD 
Hersh et al. 
[12] 
Endometrial 
carcinoma 
Phase II Injection with TNF-α 2 Not specified 
Santin et al. 
[13] 
Endometrial 
carcinoma 
Case 
report 
T cells stimulated in vitro 
with tumor lysate-
loaded DC 
 Tumor marker 
stabilization, 
intratumoral T cell 
infiltration 
Santin et al. 
[14] 
Endometrial 
carcinoma 
Phase I DC loaded with whole 
tumor lysate 
3 Induction of CD8
+
 T 
cells with in vitro 
killing capacity 
Tsuda et al. 
[15] 
Endometrial 
carcinoma 
Phase I Injection of up to 4 
different peptides 
1 PD 2 months after 
start of therapy 
Kaumaya et 
al. [16] 
Endometrial 
carcinoma  
Phase I Injection of B cell 
epitopes fused to a 
promiscuous T cell 
epitope 
2 ½ patients in 
partial remission 
for 4 years 
Ohno et al. 
[17] 
Endometrial 
cancer 
Phase I Injection with a modified 
WT1 peptide 
1 PD 3 months after 
start of therapy 
Coosemans 
et al. [6] 
Endometrial 
carcinoma 
Case 
report 
WT1 mRNA-loaded DC  Tetramer-positive T 
cells post 
vaccination 
Coosemans 
et al. [5] 
Endometrial 
carcinoma/uterine 
sarcoma 
Phase I/II WT1 mRNA-loaded DC 6 Immunological 
response in 3/6 
patients. Transient 
clinical responses 
in 2/6 patients 
Miyatake et 
al. [18] 
Uterine sarcoma Phase II WT1 peptide vaccination 5 Not specified 
Hernando 
et al. [19] 
Uterine sarcoma Phase I DC loaded with tumor 
lysate and KLH 
2 PD after 3 months 
in 1 patient and 6 
months in patient 2 
Tsuda et al. 
[15] 
Uterine sarcoma Phase I Injection of up to 4 
peptides 
1 PD after 5 months 
Ohno et al. 
[17] 
Uterine sarcoma Phase I WT1 peptide 1 PD after 3 months 
The current data will be implemented in a clinical trial, using TriMix DC. Initial proof of concept data 
have shown that 48h after electroporation, DC obtain a mature phenotype, with expression of CD54, 
CD80, CD83, CD86, and CCR7 [20]. 
As research progresses, gradually more and more mechanisms of immunosuppression are being 
unraveled, raising awareness of the importance of these mechanisms. This results in more and more 
efforts being done to combine active immunotherapy and targeting of immunosuppression. The 
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current results provide important information on which targets to be used in future combination 
therapies in uterine tumors. 
For these targets, several inhibitors are currently being tested in clinical settings, as elaborated on in 
the discussion to Part III, chapter 1 and Part I, chapter 1. 
FUTURE DIRECTIONS 
The current work is the expansion of previous research regarding WT1 as an immunotherapeutic 
target in uterine cancer [6, 21-23]. We have currently selected an additional antigen to include in the 
vaccine. The currently validated targets were arbitrarily chosen, mainly based on literature. However, 
these are not the only valid targets. Future expansion of the current findings may be accomplished by 
further validation of additional targets or screening for new tumor-associated antigens. 
In addition to using a (combination of) single, defined antigens, total tumor RNA presents as another 
option for antigen loading. With this technique, all tumor-associated antigens are included, including 
the tumor driver genes. In addition, tumor-specific epitopes that differ slightly from the natural 
counterparts, due to genetic mutations in a specific tumor can also be presented to the immune 
system (mutatopes). The latter provides the benefit that no tolerance exists against mutatopes, since 
many conventional TAA are in fact auto-antigens and thus subject to tolerogenic mechanisms. 
One factor contributing to the occurrence of recurrent tumors, is that of cancer stem cells. 
Vaccination with moDC loaded with total tumor RNA from glioma cancer stem cells was recently 
shown to result in progression-free survival that was 2.9 times as high as that of normal controls [24]. 
Evidently, when using total tumor mRNA, mRNA originating from cancer stem cells is included, which 
may consequently contribute to targeting of cancer stem cells. 
A downside of using whole tumor mRNA is that electroporation will result in antigen presentation in 
MHC I context only. In addition, whole tumor mRNA presents with some difficulties regarding 
immune monitoring. In case of whole tumor mRNA antigen-specific immune monitoring is not 
feasible since the target antigen that can be used for monitoring cannot be readily identified. This 
can be overcome by adding mRNA encoding for a defined TAA coupled to the DC-LAMP signal. This 
will ensure both presentation in MHC I and MHC II context of the defined TAA and thus provide CD4
+
 
T cell help. 
Some studies have been performed using total tumor mRNA. A preclinical study using total mRNA 
from a mouse gastric cancer cell line to load dendritic cells together with 4-1BBL, has shown that it 
induces a stronger T cell proliferation than DC alone, as well as an increased secretion of IL-12 and 
increased killing capacity towards MFC target cells [25]. In addition, autologous DC transfected with 
total tumor RNA could induce antigen-specific T cell responses in vivo in patients [26], indicating that 
this approach holds promise for future clinical applications. 
In current clinical trials, there is often an important lack of a clinical correlate with a detected 
immune response. The immunosuppressive environment is an important factor influencing this 
parameter, although the reported lack may also be explained in part at a different level. The 
immunological outcome is highly dependent on the immunological parameters that are being 
assessed. The immune system has a complex role in cancer, including several players, which can have 
both anti-tumor and pro-tumor functions. Using the proper targets for monitoring can improve the 
effectiveness of the monitoring and may clarify the correlation between a clinical and immunological 
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response. In addition, next to the parameters that are included in the immunological monitoring, the 
site at which the monitoring is performed is of importance. Many immune monitoring assays are 
being performed in peripheral blood. However, this may generate a certain bias since the site of 
action for the immune system is the tumor site. By comparing intratumoral factors or immune 
factors in the tumor microenvironment prior to and after immunotherapy, a more adequate analysis 
can be obtained [27]. 
Clinical responses are currently evaluated using the commonly applied and validated RECIST criteria. 
However, these criteria may potentially not suffice for the evaluation of a clinical anti-tumor 
response. Immunotherapy can results in an initial increase in tumoral lesions, followed by a 
subsequent decline after a certain amount of time. Consequently, an increase in existing lesions or 
the occurrence of new lesions is considered to be a part of the tumor burden and does not 
necessarily indicate progressive disease (PD) according to immune-related criteria [28]. A comparison 
between the WHO, RECIST and immune-related response criteria (irRC) is given in Table 2 [29]. 
Table 2: Comparison between WHO, RECIST and irRC (adapted from [29]. 
 WHO RECIST irRC 
CR No lesion detected for at least 4 weeks Disappearance of all 
target lesions or lymph 
nodes <10 mm in the 
short axis 
Disappearance of all lesions 
(including non-index 
lesions) at two consecutive 
observations ≥ 4 weeks 
apart, no new 
nonmeasurable disease 
PR ≥ 50% decrease in SPD (confirmed at 4 
weeks) 
> 30% decrease in SLD 
of target lesions 
50 % decrease in tumor 
burden (confirmed at 4 
weeks) 
PD ≥ 25% increase in SPD in one or more 
lesions; new lesions 
> 20% increase in SLD 
of target lesions with 
an absolute increase 
of 5 mm; new lesions 
25% increase in tumor 
burden (confirmed at 4 
weeks), new measurable 
lesions included within 
tumor burden 
SD  None of the above None of the above None of the above 
SPD: sum of perpendicular diameters. SLD: sum of longest diameters. 
As stated above, more efforts are being put in the development of combination therapies to target 
cancer, often involving the immune system. To this end, many options can be pursued. 
A preclinical study using a combination therapy of a DC vaccine loaded with tumor lysate originating 
from breast cancer cell lines and anti PD-L1 antibody in mice showed that the combination of the DC 
vaccine and anti PD-L1 slowed tumor growth and survival of the mice compared to the untreated 
group. Interestingly, the results were even more profound when anti PD-L1 was used during the 
maturation of DC as well as in combination with a vaccine using these DC [30]. Currently (May 2014), 
353 clinical trials evaluating combination immunotherapy in cancer are listed at clinicaltrials.gov. 
These trials include trials combining active immunotherapy and targeted therapy, immunotherapy 
and chemotherapy, whether or not in combination with immune checkpoint inhibitors, and 
combinations of immunogenic chemotherapy. 
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Beside targeted treatments or known cytotoxic anticancer therapies, some food supplements may 
also have anticancer effects and can also be used in immunotherapeutic strategies. Several groups of 
nutrient components have been shown to have antitumor effects, reviewed by González-Vallinas et 
al. [31]. The most familiar of these nutrients are flavonoids, mainly found in fruit and green tea,  
β-carotene present in carrots and curcuminoids, found in the spice turmeric [31]. 
These supplements together with for example nutrients to fortify the patients’ immune system may 
also be incorporated in future immunotherapy-related trials. 
Collectively, the current research builds on and further extends previous research by our own 
research group on WT1 as an immunotherapeutic target and provides the basis for a subsequent 
clinical study. However, immunotherapy in uterine tumors is still in its early days and much is still left 
to be explored. With the current data, we have increased the, as of yet still quite narrow, insights in 
the immune system in uterine tumors, providing another up-step for future exploratory and 
treatment-directed research in uterine cancer. 
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Summary 
Although current treatments are often curative for uterine cancer when it is diagnosed in an early 
stage, with a 5-year survival rate of around 80 %, these treatments are often no longer effective in 
case of far-advanced disease. The mean survival rate for stage III uterine tumors is 57.8 %, while for 
stage IV, this number decreases even further to a mere 22.8 %. Consequently, additional treatments 
are needed. 
The main focus of the current project was to further develop an autologous dendritic cell-based 
vaccine for uterine tumors. The initial vaccine, using WT1 mRNA loaded monocyte-derived DC, 
showed an immunological response in 5/8 patients and a transient clinical response in 2/8 patients 
(chapter 6). In the current study, the vaccine was further improved and extended. 
The first objective was to identify additional antigenic targets to include in the vaccine. We selected 6 
different antigens, MAGE-A3, BORIS, MUC1, Sp17, hTERT and survivin, for validation using 
immunohistochemistry as well as qRT-PCR. In addition, to verify the immunogenicity of these 
antigens, spontaneous ex vivo T cell responses to these antigens were analyzed. From these analyses, 
we found that survivin was the best suitable target to proceed with (Chapter 3 and 4). 
In addition to adding a new target antigen to the DC vaccine, we aimed to further improve the 
functional characteristics of the DC used in the vaccine. To this end, an optimal protocol for the 
generation of monocyte-derived DC was established using an IL-4/GM-CSF/TriMix maturation 
cocktail. As shown in previously published data this improves the maturity profile of the DC and 
improves the T cell stimulatory capacity. 
Tumor-induced immunosuppression is an important factor hampering the efficacy of 
immunotherapy. More and more awareness is being raised for this issue. We aimed to map some of 
the immunosuppressive mechanisms in uterine tumors. To this end, 3 members of the B7 family,  
B7-H1 (PD-L1), B7-DC (PD-L2) and B7-H4 were analyzed as well as IDO, galectin-1 and galectin-3 as 
well as the presence and activity of myeloid-derived suppressor cells in uterine tumors (chapter 5). 
IHC analysis showed that the PD-1:PD-L1 axis and B7-H4 are promising targets in the vast majority of 
tumors and IDO in a minority of cases. Flow cytometric analysis showed that MDSC do infiltrate 
uterine tumors and are likely functionally active, thus presenting another route at which tumor 
immune escape may be interrupted. 
Beside using active immunotherapeutic regimens or direct intervention of immunosuppression, 
substances that are used for current anti-cancer treatment may also be averted in a different dosage 
to modulate the immune system. Low-dose cyclophosphamide, for example, has been shown to have 
immunomodulatory effects. We verified the effect of oral administration of low-dose 
cyclophosphamide on the Treg population in order to determine whether or not this modality could 
be applied for uterine tumors. However, we could not confirm the suppressive effect of 
cyclophosphamide on Treg (chapter 7). Consequently, this method is, according to our results, not 
applicable in uterine tumors. 
Taken together, the current research is the next step in the identification of the role the immune 
system plays in uterine tumors and provides novel indications for its use and its modulation in the  
treatment of uterine cancer. 
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Samenvatting 
De huidige behandeling voor uteriene tumoren is in de meerderheid van de gevallen een curatieve 
behandeling wanneer de tumor gediagnosticeerd is in een vroeg stadium. De overlevingskans na 5 
jaar bedraagt hier 80 %. In een vergevorderd stadium daarentegen, zijn de huidige behandelingen 
echter niet meer effectief. De 5 jaar overleving bedraagt 57.8 % voor stadium III tumoren en slechts 
22.8 % voor stadium IV tumoren. Bijgevolg is er een hoge nood aan bijkomende behandeling. 
De voornaamste focus van het huidige project is de ontwikkeling van een autoloog dendritische 
cel-gebaseerd vaccin voor uteriene tumoren. Het initiële vaccin ontwikkeld door onze 
onderzoeksgroep, waarbij er gebruik gemaakt werd van DC afgeleid van monocyten (moDC), 
opgeladen met mRNA coderend voor WT1, resulteerde na behandeling in een immunologische 
respons in 5/8 patiënten en een transiënte klinische respons in 2/8 patiënten (hoofdstuk 6 ). In de 
huidige studie werd dit vaccin verder uitgebreid en verbeterd. 
Het eerste objectief van de studie behandelde de identificatie en de validatie van bijkomende 
antigen doelwitten om te includeren in het vaccin. Zes antigenen werden geselecteerd, MAGE-A3, 
BORIS, MUC1, Sp17, hTERT en survivine, voor validatie door middel van IHC en qRT-PCR. Bijkomend 
werden de ex vivo spontane T cel responsen gericht tegen deze antigenen nagegaan. Uit deze 
resultaten werd survivine geïdentificeerd als bijkomend doelwitantigen voor het vaccin  
(hoofdstuk 3 en 4). 
Bijkomend aan het toevoegen van een doelwitantigen, beoogden we tevens de functionele 
karakteristieken van het bestaande vaccin verder te verbeteren. Hiervoor werd een optimaal 
protocol ontwikkeld voor de generatie van moDC, volledig gematureerd met een IL-4/GM-CSF/TriMix 
cocktail. Eerder gepubliceerde data toonden aan dat met deze cocktail een verbeterd 
maturiteitsprofiel en een verhoogde T cel stimulatie kan bereikt worden. 
Tumor-geïnduceerde immuun suppressie is een belangrijke factor in de belemmering van 
immunotherapeutische behandelingen. Dit probleem wordt steeds meer onder de aandacht 
gebracht. Een volgend doel in het project was om een deel van deze immuunmodulerende factoren 
in uteriene tumoren in kaart te brengen. Drie componenten van de B7 familie, B7-H1 (PD-L1), B7-DC 
(PD-L2) en B7-H4 werden geanalyseerd, naast IDO, galectine-1 en galectine-3. De aanwezigheid en 
functionele activiteit van MDSC in uteriene tumoren werd eveneens bepaald (hoofdstuk 5). IHC 
analyse toonde aan dat de PD-1:PD-L1 as en B7-H4 veelbelovende doelwitten zijn in de meerderheid 
van de tumoren en IDO in een minderheid van de gevallen. Een andere mogelijke route voor 
therapeutische interventie is deze van de MDSC, aangezien deze functioneel actief aangetoond 
worden in uteriene tumoren. 
Naast actieve immunotherapeutische strategieën of directe interventie van immuun suppressieve 
mechanismen, kunnen therapeutica die momenteel gebruikt worden in de standaard 
kankerbehandeling in een aangepaste dosis aangewend worden om het immuunsysteem te 
moduleren. Voor cyclofosfamide is er reeds eerder aangetoond dat er in lage dosis gunstige effecten 
op het immuunsysteem zijn, met name de depletie en functionele onderdrukking van Treg. Deze 
effecten konden echter niet bevestigd worden in patiënten met gynaecologische tumoren 
(hoofdstuk 7). 
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Het huidige onderzoek vormt de volgende stap in het ontrafelen van de rol die het immuun systeem 
speelt in uteriene tumoren en toont nieuwe indicaties aan voor het aanwenden en het moduleren 
van het immuun systeem in de behandeling van uteriene tumoren. 
Professional career 
 
 169 
Professional career 
Birth: Hasselt, September 25th 1986 
High school education: Latin-mathematics.  
 1998 – 2004. Sint-Aloysius Instituut, Zepperen 
Higher education: Biomedical sciences, subspeciality clinical molecular lifesciences 
 Hasselt University. 2004 – 2009 
Current degree: Master of Science in biomedical sciences 
SCIENTIFIC ABSTRACTS 
 Vanderstraeten A. et al. CD4
+
CD28
NULL
 T cells in autoimmune disease. Culprits or bystanders? 
Maastricht Medical Students Research Conference. 2009, Maastricht, the Netherlands. 
 
 Vanderstraeten A. et al. The role of CD4
+
CD28
NULL
 T cells in the pathogenesis of multiple sclerosis 
and rheumatoid arthritis. 
International Life Sciences Master students Research Conference, 2009. Maastricht, the 
Netherlands. 
 
 Anke Vanderstraeten, Sandra Tuyaerts, Catherine Luyten, Rieta Van Bree, Lieve Verbist, Carlo 
Heirman, Kris Thielemans, Frédéric Amant. Tumor-associated antigen validation in uterine 
tumors. 
Oncoforum, 2012. Leuven, Belgium. 
 
 Sandra Tuyaerts, Anke Vanderstraeten, Catherina Luyten, Rieta Van Bree, Godelieve Verbist, 
Frederic Amant. Validation of tumour antigens for immunotherapy of uterine cancer. 
Cancer Research Institute conference, 2012. New York, U.SA. 
 
 Sandra Tuyaerts, An Coosemans, Anke Vanderstraeten, Zwi N Berneman, Vigor FI Van Tendeloo, 
Ignace Vergote, Stefaan W Van Gool, Frederic Amant. WT1-specific dendritic cell vaccination in 
uterine cancer 
Cancer Research Institute conference, 2012, New York, U.SA. 
 
 Anke Vanderstraeten, Sandra Tuyaerts, Catherine Luyten, Rieta Van Bree, Lieve Verbist, Carlo 
Heirman, Kris Thielemans, Frederic Amant. Tumor-associated antigen validation in uterine 
tumors. 
European Association for Cancer Research conference, 2012. Barcelona, Spain. 
 
 Sandra Tuyaerts, An MT Van Nuffel, Anke Vanderstraeten, Tina Everaert, Carlo Heirman, Kris 
Thielemans and Frederic Amant Effect of rapamycin and curcumin on TriMix DC. 
Association for cancer immunotherapy conference, 2013. Mainz, Germany. 
Oncoforum, 2013. Leuven, Belgium. 
Professional career 
 
 170 
 Sandra Tuyaerts, Anke Vanderstraeten, Godelieve Verbist, Rieta Van Bree,Tina Everaert  and 
Frederic Amant. Tumor-infiltrating immune cell profiling in uterine tumors –implications for 
immune therapy.  
Cancer Immunology and Immunotherapy conference, 2013. Krakow, Poland. 
Oncoforum, 2013. Leuven, Belgium. 
 
 Sandra Tuyaerts, Anke Vanderstraeten, Tina Everaert, Godelieve Verbist, Rieta Van Bree, 
Frederic Amant. Phenotypic characterization of the immune infiltrate in gynecological tumors. 
Cancer research Institute conference, 2013. New York, USA. 
 
 Sandra Tuyaerts, Anke Vanderstraeten, Tina Everaert, Frederic Amant. Phenotypic 
characterization of the immune infiltrate in gynaecological tumours. 
Association for cancer immunotherapy conference, 2014. Mainz, Germany. 
Oncoforum, 2014. Leuven, Belgium. 
 
 Sandra Tuyaerts, An Coosemans, Kim Morias, Tina Everaert, Anke Vanderstraeten, Stefaan W. 
Van Gool, Frederic Amant. Exploring dendritic cell (DC) vaccines targeting Wilms’ tumour gene 1 
(WT1) and survivin for uterine cancer. 
Association for cancer immunotherapy conference, 2014. Mainz, Germany. 
Oncoforum, 2014. Leuven, Belgium. 
Publications 
 
 171 
Publications 
PUBLICATIONS 
Non-peer reviewed book chapter 
Coosemans, A., S. Tuyaerts, A. Vanderstraeten, and F. Amant. 2012. Immunotherapy in uterine 
cancers. In Textbook of gynecological oncology, 2 ed. A. Ayhan, N. Reed, M. Gultekin, and P. Dursun, 
eds. Günes Publishing, Ankara, Turkey. 809-816. 
Peer-reviewed journal papers, related to PhD 
Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman Z, et al. 
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma 
and carcinosarcoma. Anticancer res. 2013;33(9):3855-9. 
Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, et al. Wilms' 
Tumor Gene 1 (WT1)-loaded dendritic cell immunotherapy in patients with uterine tumors: a phase 
I/II clinical trial. Anticancer res. 2013;33(12):5495-500. 
Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S, Amant F. Mapping the immunosuppressive 
environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother. 
2014;63(6):545-57. 
Madondo MT, Tuyaerts S, Turnbull BB, Vanderstraeten A, Kohrt H, Narasimhan B, Amant F, Quinn M, 
Plebanski M. Variability in CRP, regulatory T cells and effector T cells over time in gynaecological 
cancer patients: a study of potential oscillatory behaviour and correlations. J Transl Med. 2014; 
23;12(1):179. 
Peer-reviewed journal papers, not related to PhD 
Coosemans A, Tuyaerts S, Vanderstraeten A, Vergote I, Amant F, Van Gool SW. Dendritic cell 
immunotherapy in uterine cancer. Hum vaccin immunother. 2014;10(7). 
SUBMITTED MANUSCRIPTS/MANUSCRIPTS IN PREPARATION 
Vanderstraeten A, Tuyaerts S and Amant F. The immune system in the normal uterus and its 
implication in endometrial cancer development. Submitted to J Reprod Immunol. 
Vanderstraeten A, Tuyaerts S, Everaert T, Van Bree R, Verbist G, Luyten C and Amant F. Validation of 
tumor antigens as immunotherapeutic targets in uterine cancer. Manuscript in preparation. 
Vanderstraeten A, Tuyaerts S, Everaert T, Van Bree R, Verbist G, Luyten C and Amant F. Preclinical 
evaluation of survivin as target tumor-associated antigen for immunotherapy in uterine cancer. 
Submitted to J Immunoth. 
